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ABSTRACT  
Malaria poses the greatest threat of all parasites to human life.  Current vaccines and efficacious 
drugs are available however their use is limited due to toxicity, emergence of drug resistance, and 
cost.  The discovery of an alternative pathway of isoprenoid biosynthesis, the non-mevalonate 
pathway, within the malarial parasite has resulted in development of novel anti-malarial drugs.  1-
Deoxy-D-xylulose-5-phosphate (DOXP) reductoisomerase, the second enzyme in this pathway, is 
responsible for the synthesis of 2-C-methyl-D-erythritol 4-phosphate (MEP) in an intramolecular 
rearrangement step followed by a reduction process involving NADPH as a hydrogen donor and 
divalent cations as co-factors.  Fosmidomycin and FR900098 have been identified as inhibitors of 
DOXP reductoisomerase. However, they lack clinical efficacy.  In this investigation recombinant 
DOXP reductoisomerase from Escherichia coli (EcDXR) and Plasmodium falciparum (pfDXR) 
were biochemically characterized as potential targets for inhibition.  (His)6-EcDXR was 
successfully purified using nickel-chelate affinity chromatography with a specific activity of 1.77 
μmoles/min/mg and Km value 282 μM.  Utilizing multiple sequence alignment, previous structural 
data predictions and homology modeling approaches, critical active site amino acid residues were 
identified and their role in the catalytic activity investigated utilizing site-directed mutagenesis 
techniques.  We have shown evidence that suggests that Trp212 and Met214 interact to maintain the 
active site architecture and hydrophobic interactions necessary for substrate binding, cofactor 
binding and enzyme activity.  Replacement of Trp212 with Tyr, Phe, and Leu reduced specific 
activity relative to EcDXR.  EcDXR(W212F) and EcDXR(W212Y) had an increased Km relative to 
EcDXR indicative of loss in affinity toward DOXP, whereas EcDXR(W212L) had a lower Km of 
~8 μM indicative of increased affinity for DOXP.  The W212L substitution possibly removed 
contacts necessary for full catalytic activity, but could be considered a non-disruptive substitution in 
that it maintained active site architecture sufficient for DOXP reductoisomerase activity.  
EcDXR(M214I) had 36-fold reduced enzyme activity relative to EcDXR, while its Km
 
 (~8 μM) was 
found to be lower than that of EcDXR.  This suggested that the M214I substitution had maintained 
(perhaps improved) substrate and active site architecture, but may have perturbed interactions with 
NADPH.  Rational drug design strategies and docking methods have been utilized in the 
development of furan derivatives as DOXP reductoisomerase inhibitors, and the synthesis of 
phosphorylated derivatives (5) and (6) has been achieved.  Future inhibitor studies using these novel 
potential DOXP reductoisomerase inhibitors may lead to the development of effective anti-malarial 
drug candidates. 
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CHAPTER 1 : LITERATURE REVIEW 
  2 
1 INTRODUCTION 
Malaria is one of the worlds most infectious and fatal tropical diseases resulting in approximately 
1.5-3 million deaths annually (Shi et al., 1999).  The majority (greater than 90 %) of these 
fatalities occur in Sub-Saharan Africa affecting mainly pregnant woman and children (Shi et al., 
1999).  Fatal cases of malaria are often the result of infection from Plasmodium falciparum (P. 
falciparum). Currently malaria poses a health risk to over 90 countries of which 40% of the 
global population inhabit (Beier, 1998).  Not only does malaria pose a health risk but it also 
accounts for the loss of gross domestic product.  In Sub-Saharan Africa this loss was estimated 
between 1-4%, which amounts to roughly 12 billion dollars (Beier, 1998).  With no vaccine or 
cure against the disease, and many of the traditional anti-malarial drugs are failing due to 
growing drug resistance in P. falciparum.  With the prevalence of malaria on the increase and the 
compounding problem of multiple drug resistance there is an urgent demand for new anti-
malarial drugs.   
 
With the discovery of the alternative pathway of isoprenoid synthesis within malaria parasites, 
and the validation of the 1-deoxy-2-xyulose-5-phosphate (DOXP) pathway has come the 
realization of the importance of this pathway in the fight against malaria, and the development of 
new anti-malarial drugs.  Consequently, the development of inhibitors of the alternative pathway 
for isoprenoid biosynthesis in the respective pathogen will allow one to target and thus kill the 
pathogen with no subsequent side effects for the human host, which lacks the DOXP pathway.   
 
In this research, the DOXP reductoisomerase enzyme, of the alternative mevalonate pathway, 
will be biochemically characterized as a target site for inhibition.  Inhibition of this enzyme will 
hopefully lead to the development of novel anti-malarial drugs for the future fight against 
malaria.    
 
1.1 Malaria  
 
Sir Patrick Manson first discovered that malaria was being transmitted via the female mosquito in 
1876 (http://www.  Malaria.freewire.co.uk/malaria.html; date accessed 04/2002).  The malaria 
parasite is a member of the protozoan parasites belonging to the genus Plasmodium as well as a 
  3 
group of one-celled organisms referred to as apicomplexans (Foley and Tilley, 1997; Ridley, 
1999).  Four species of Plasmodium are responsible for human malaria: P. falciparum, P. vivax, 
P. ovale, and P. malariae, the most fatal of these being P. falciparum (Foley and Tilley, 1999; 
Beier, 1998; Phillips, 2001).   
 
In the past, many attempts to eradicate malaria have been unsuccessful.  This has resulted in 
malaria still being one of the world’s most prominent diseases with approximately 300 to 500 
million infections and approximately one million deaths from the disease annually, meaning a 
death every 30 seconds as a result of malaria (Gardner et al., 1998; Greenwood and Mutabingwa, 
2002).  Malaria therefore remains a public health threat for more than 90 countries, which 
comprise 40% of the global population (Beier, 1998).  A large percentage of fatalities due to 
malaria occur within Africa.  However malaria is endemic through most of South East Asia, the 
Indian sub-continent and the South Pacific region (Foley and Tilley, 1997).  The disease is 
endemic to the tropical regions, with extensions into the subtropics.  However, due to the 
ignorance of travelers toward prophylactic drugs there has been an increase in deaths due to 
malaria in non-malarious regions.  Thus, there is a drastically deteriorating situation with the 
disease returning to areas where the disease had been eradicated and the spread of the disease into 
new areas such as Eastern Europe and Central Asia (Beier, 1998).  Additionally, due to the 
increase in resistant strains of the parasite there has been a resurgence of malaria including within 
areas that were previously eradicated of the disease. 
 
1.2 The Biology and Life Cycle of Plasmodium parasites 
 
All the members of the phylum Apicomplexa, generally referred to as sporozoans, are parasites of 
mammals (Campbell, 1996).  However, Apicomplexa and Plasmodium parasites are not exclusive 
parasites of mammals or man, respectively.  The female Anopheles mosquito transmits malaria, 
although out of the 380 species of this mosquito only 60 are vectors for malaria (Beier, 1998).  
The reason that not all mosquitoes are vectors of malaria lies in the presence of a toxin to 
Plasmodium within their cells preventing them from being suitable vectors (http:www-
micro.msb.le.ac.uk/ 224/ Bradley /Biology.html).  In 1998 malariologists celebrated the 
centenary of the demonstration that the female mosquito transmits malaria.  It was the British GP, 
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Dr Ronald Ross, that demonstrated the biology behind the disease in August 1897 and was 
awarded the Nobel Prize for his research (reviewed in Phillips, 2001). 
 
The majority of Apicomplexans have intricate life cycles in which there is both a sexual and 
asexual stage with the requirement of at least two hosts for the completion of the cycle 
(Campbell, 1996).  As seen in Figure 1.1 of the life cycle of the Plasmodium species in 
mammals, the malaria parasite disseminates into minute infectious thread-like cells known as 
sporozoites.  These sporozoites are produced within the female mosquito salivary gland and are 
subsequently injected into the human blood stream as the mosquito must inject anticoagulant 
saliva to ensure an “even-flowing” meal.  Once the sporozoite has gained access to the 
bloodstream its first destination is the liver whereupon it infiltrates the hepatocytes utilizing a 
complex group of organelles concentrated within the apex of the sporozoite specialized for the 
purpose of penetrating host cells and tissues.  The sporozoite then remains within the hepatocytes 
for a period of 6 to 15 days, depending on the species, for the sole purpose of multiplication 
(Phillips, 2001). 
 
Upon the rupture of the hepatocyte, due to the effects of multiplication of the sporozoite, the 
parasite is once again released into the blood stream in the form of a merozoite.  At this point the 
pathogen begins to target the hosts red blood cells where they devour haemoglobin and either 
produce new merozoites through shizogony (asexual division) or the sexual micro and 
macrogametocytes.  Normally several cycles of shizogony occurs prior to the production of any 
gametocytes (Phillips, 2001).   
 
The new merozoites penetrate additional red blood cells repeatedly rupturing the erythrocytes at 
intervals of 48 to 72 hours depending on the species of parasite.  At this stage of infection the 
host will begin to take affects of what is occurring within his/hers body, the symptoms being 
periodic chills, fever and sweating (Campbell, 1996).   
 
The micro and macrogametocytes, which were produced from merozoites, have no further role to 
play within the human host and are therefore transmitted to the next mosquito that happens to 
feed upon the infected hosts blood.  Upon transmission to the mosquito the gametocytes increase 
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in volume resulting in the rupture of the erythrocyte within the mosquito.  After which, they 
travel toward the gut where exflagellation of the microgametocytes occurs and fertilization of the 
macrogametocytes takes place resulting in an ookinete.  The ookinete will then infiltrate the 
midgut wall of the mosquito where it will develop into an oocyst.  The oocyst is then responsible 
for the production of sporoblasts from which sporozoites will bud off.  The sporozoites travel to 
and penetrate the salivary gland cells where they lie in vacuoles for 59 days.  During this period 
of time the sporozoites develop and become a 1000 fold more infectious and more antigenic.  A 
biting mosquito will then transfer at least 10% of the infectious sporozoite load into the 
capillaries or perivascular tissue of the human host.  At this point the sporozoites will begin to 
evade the hosts immune response on their passage towards the liver.  All sporozoites will have 
left the peripheral circulation within 45 minutes of being transmitted (as reviewed in Phillips, 
2001; Bannister and Mitchell, 2003).   
 
Throughout this complicated life cycle the parasite is able to take advantage of several different 
biological environments (Bannister and Mitchell, 2003).  Within the human host the parasite 
masks its invasion by remaining within host cells and avoiding contact with the hosts circulating 
antibodies.  Additionally, immune attack on vulnerable parasites is avoided through the alteration 
in the expression of parasitic genes (Bannister and Mitchell, 2003).  Another key feature to the 
survival of the parasite is its ability to adhere to the linings of the blood vessel walls thus 
hindering tissue perfusion (Bannister and Mitchell, 2003; Miller et al., 2002).   
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Figure 1.1: The life cycle of the malaria parasite in man and mosquito 
The phases of the life cycle in the liver and erythrocytes of the human host, and in the mid-gut and salivary glands of 
the Anopheles mosquito are shown (taken from Bannister and Mitchell, 2003).   
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1.3 Prevention and Treatment of Malaria 
 
Chemotherapy and prophylaxis are the principal means of combating malaria in the human host.  
In the past 75 years, during which there was an introduction of synthetic anti-malarials, only a 
small minority of these compounds have been proven useful in clinical trials and this limited 
protection against malaria is diminishing with the emergence of drug resistance parasite strains 
(Hyde, 2002).   
 
Prevention may be implemented through the interruption of the transmission of the disease from 
the vector to the host.  This involves the use of insecticides, bed nets etc. to contain the mass 
populations of mosquitoes in any particular area.  This in itself presents several problems and has 
declined as a preventative method over the last few years due to the consequences of the 
dichloro-diphenyl- trichloroethane (DDT) catastrophe, lack of personnel, inefficient insecticide 
usage and mass population dynamics (Phillips, 2001).  However, since many of the techniques 
for genetically manipulating the mosquito are readily available, another approach has been to 
genetically manipulate the vector itself to render it unable to transmit the parasite (Ito et al., 
2002).  Ito et al. (2002) demonstrated hampered malarial transmission by utilizing a transgenic 
approach, which allowed for the expression of anti-parasitic genes within the midgut epithelium 
of culicine and anopheline mosquitoes.  Though their preliminary results were successful, one of 
the main disadvantages to implementing transgenic mosquitoes as a means for combating malaria 
is the dispersion of foreign genes amongst other mosquito populations.  Another option is the 
most common preventative measure, and involves the use of prophylactic drugs.  The current 
anti-malarial drugs target the various stages of the parasite life cycle with the majority being 
specific for the intra-erythrocytic stages (Olliaro, 2001).   
 
Most people suffering from malaria in the tropics are treated as outpatients with treatment mainly 
involving antipyretics (paracetamol and aspirin) and oral anti-parasitics which target the asexual 
blood stages of the diseases.  However, there are a limited number of anti-malarial drugs for 
widespread use and a lack of affordable new ones.  Some common anti-malarial drugs are shown 
in Figure 1.2 (Winstanley, 2000).    
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Treatment of malaria is becoming an ever-increasing problem due to the rise in drug resistant 
species of malaria; this is especially the case with P. falciparum.  With the exception of 
artemisinin and its derivatives, all other anti-malarial drugs have been shown to elicit drug 
resistance within the parasite.  This has consequently spurred much research into the mechanism 
of drug resistance (Phillips, 2001).  The knowledge of the mode of action of anti-malarial drugs, 
and the mechanism of drug resistance is vital information that will lead to the discovery of novel 
therapeutics and anti-malarial drugs for the future.   
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Figure 1.2: The chemical structures of common drugs utilized for malaria treatment 
 
Resistance to several anti-malarial drugs emerged due to their widespread use.  This problem was 
compounded due to multiple drug resistance also being reported due to the use of several closely 
related anti-malarial compounds (Phillips, 2001).  Furthermore, the rapid development of 
resistance, as well as cross-resistance, also resulted due to the drugs not being administered in 
high enough doses to ensure a cure to the infection.  Selective pressure under such conditions 
results in the development of increased drug resistance.  For this reason, drugs with longer half-
lives will exert a larger selection pressure for resistance due to the drug being able to linger in the 
body at levels which are not suitable to ensure eradication of the infection (Phillips, 2001).  
Additionally, a further aspect for consideration is whether the parasite was able to undergo 
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biological modifications due to the effects of acquiring drug resistance.  This may allow for 
certain advantages, or disadvantages, for the parasite regarding survival within the host as well as 
upon transmission from one host to the other.  Studies involving these aspects have already 
indicated that the resistant parasites are not as effectively transmitted as the non-resistant 
(reviewed within Phillips, 2001).  Table 1 illustrates the mode of action and resistance for some 
common anti-malarial drugs (Olliaro, 2001).    
 
Various in vivo and in vitro techniques can be employed to assess drug efficacy but mainly in 
vitro techniques are currently used to detect drug sensitivity of malarial parasites due to the low 
risk to patients.  Several novel in vitro techniques have been developed namely the WHO 
schizont maturation assay, isotopic and colourimetric assays based on the parasitic protein lactate 
dehydrogenase (pLDH) and the histidine-rich protein 2 (HRP-2) and are reviewed within Noedl 
et al. (2003).   
 
1.3.1 The Antifolates 
 
A large proportion of anti-malarial drugs fall into this class of nucleic acid inhibitors, even 
though their role in combating malaria is now diminished due to the emergence of drug resistance 
under drug pressure (Olliaro, 2001).  In contrast to other anti-malarials the primary targets for the 
antifolates has been established with a large degree of research in understanding the mechanism 
of drug resistance towards these drugs being emphasized upon (Hyde, 2002).    
 
Malarial parasites attain their folate requirements via de novo synthesis.  The purpose of 
antifolate drugs is to inhibit two main enzymes within this pathway namely dihydrofolate 
reductase (DHFR) and dihydropteroate synthase.  Pyrimethamine and proguanil target plasmodial 
DHFR while the sulfur drugs target dihydropteroate synthase, hence their synergistic activity 
when used in combination therapies (Phillips, 2001).  Consequent inhibition of the enzymes of 
the folate pathway results in decreased pyrimidine synthesis, as well as reduced DNA, serine and 
methionine formation (Olliaro, 2001).     
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Table 1: Mechanism of action and resistance for the main classes of anti-malarial drugs  
Drug Class Stage of life Cycle 
affected 
Pathway Target and mode of 
Action 
Resistance Status 
Antifolates  
 
 
 
Type-1 
 
 
 
 
Type-2 
 
 
 
 
 
 
 
 
Atovaquone 
Pre-erythrocytic 
cycle and the asexual 
intra-erythrocytic 
cycle 
Folate synthesis  
 
 
 
Inhibit DHPS 
through mimicking 
the substrate PABA 
 
 
Inhibit DHFR by 
mimicking the 
substrate 
dihydrofolate 
 
 
 
 
 
Affects 
mitochondrial 
electron transport 
and inhibits 
DHODase 
 
 
 
 
Mutations in the 
active site of DHPS 
reduce binding of the 
drug 
 
Mutations at the 
active site reduce 
binding of drug.  
Introduction of 
bulky amino acids 
cause steric 
hindrance for rigid 
drug molecules. 
 
Mutations in 
cytochrome b 
include T431C, 
G399A, and G850T. 
Quinolines Asexual and intra-
erythrocytic cycle 
Haem detoxification and 
disposal 
Haem crystallization 
and food vacuole 
functioning 
Point mutations in 
the pfmdr1 gene as 
well as other genes 
result in proteins that 
confer resistance 
Artemisinin Asexual and intra-
erythrocytic cycle 
Questionable but may be 
linked to oxidative stress 
Reductive cleavage 
of endoperoxides 
No known cases of 
resistance 
       (adapted from Rastelli et al., 2000; Olliaro, 2001; Hyde , 2002) 
 
The DHFR inhibitors mode of action is to mimic the pteridine ring of the natural substrate DHF 
and as a result compete with it for the active site upon the enzyme (Olliaro, 2001).  The enzyme 
DHFR plays a vital role within the folate pathway maintaining a constant supply of folate 
cofactors that are essential in allowing for the single carbon transfer reactions of which only the 
fully reduced (tetrahydro) forms are functional (Hyde, 2002).  These reactions are vital for the 
provision of nucleotides for DNA synthesis and in the metabolism of certain amino acids (Hyde, 
2002).  Pyrimethamine (PYR), proguanil (PG), the sulfonamides, such as sulfadoxine (SDX) and 
dapsone are the most commonly used antifolate drugs.   
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Resistance towards the DHFR and DHPS inhibitors is conferred via single mutations of the gene 
encoding for the respective enzyme, and consequently resulting in the substitutions in the 
respective amino acid chain.   Isolates that have failed to respond to such drugs have resulted in 
the identification of the corresponding mutations within these genes that confer resistance 
(reviewed in Olliaro, 2001).  Currently seven point mutations, occurring within the DHFR gene, 
have been identified as being linked with reduced drug binding capacity in resistant DHFR 
strains of P. falciparum (reviewed in Phillips, 2001; Sirawaraporn et al., 1997).  In addition, 
DHFR and DHPS mutations seem to occur in a progressive stepwise fashion i.e. resistance 
slowly increases by the accumulation of mutations under drug pressure (Olliaro, 2001).  
Pyrimethamine resistance, for example, has been associated with a point mutation of Serine 108 
to Asparagine 108.  This mutation has been considered as the essential precursor to additional 
mutations that confer resistance and in due course lead to treatment failure (as reviewed in 
Olliaro, 2001).  It has been proposed that by introducing bulkier amino acids at the site of action, 
especially the serine 108 position, steric hindrance results and as a consequence specific drugs, in 
particular those with a characteristically rigid structure such as pyrimethamine, are hampered 
from fitting within the active site (Olliaro, 2001).  Rastelli et al. (2000) have demonstrated that 
this may indeed be the case using a homology model of the P. falciparum dihydrofolate reductase 
(pfDHFR) enzyme.  The homology models of the wild-type and various mutant proteins 
associated with cycloguanil resistance were used to assess binding of pyrimethamine, 
cycloguanil, and WR99210 to the pfDHFR active site.  Their data supports the steric constraint 
predictions previously mentioned and sheds light upon the basis of cycloguanil-resistant and 
pyrimethamine-sensitive strains.  In addition the binding of WR99210, a drug structurally similar 
to cycloguanil, is not affected by steric mutations within the active site that confer cycloguanil 
resistance and therefore WR99210 is still effective against both resistant and pyrimethamine 
sensitive strains.  This data may aid in the development of novel anti-malarial drugs. 
 
1.3.1.1 Atovaquone 
 
Atovaquone is also regarded as a hydroxynaphthoquinone and is utilised as a drug in both the 
prevention and treatment of malaria.  It is vital to consider that it is only administered as a 
combination drug together with proguanil, an antifolate classed anti-malarial drug.  Even though 
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it is known to target the mitochondrial functionality its mode of action, especially in combination 
with proguanil, is not fully elucidated.  The general dogma underlies the ability of atovaquone to 
affect the mitochondrial electron transfer mechanism, although in recent studies and reviews it 
has been reported that its activity and synergy with proguanil has an impact on the mitochondrial 
membrane potential.  These two processes are in fact related as the mitochondrial electron 
transfer chain serves to generate and maintain the membrane potential (reviewed within Olliaro, 
2001). 
 
Dihydroorotate dehydrogenase (DHODase), a critical enzyme within the mitochondrial electron 
transport chain, has been proposed as a potential site for atovaquones activity.  This enzyme 
catalyzes the reaction where-upon dihydroorotate is oxidised to orotate.  Additionally, it is 
considered the link between pyrimidine de novo synthesis and the mitochondrial electron 
transport system as it serves as the vital source of electrons.  The consequent inhibition of 
DHODase results not only in the interference of the mitochondrial electron transport chain but 
additionally it blocks pyrimidine synthesis (Olliaro, 2001).   
 
Fry and Pudney (1992) indicated that atovaquone indeed inhibits the respiratory mechanisms of 
the malarial mitochondria at the cytochrome bc1
 
 complex through its ability to mimic the natural 
substrate, ubiquinone.   The result is the consequent depolarisation of the malarial mitochondria 
and the hampering of electron flow from ubiquinone to cytochrome c. 
Despite the novel mode of action that atovaquone possesses, resistance is still apparent upon the 
utilization of atovaquone independently.   For this reason it is no longer administered alone but in 
fixed-ratio combination therapies along with proguanil, as mentioned previously.  The 
pharmacokinetics surrounding this drug may explain why monotherapy failed due to parasite 
resistance.  Due to atovaquones slow uptake and high lipophilicity the parasite again is exposed 
to relatively low levels of the drug over extended periods of time, consequently leading to 
resistance.  The mechanism of resistance was associated with single point mutations within the 
cytochrome b gene itself.  This concurrently resulted in amino acid changes in the binding sites 
of ubiquinone (coenzyme Q).  Three such mutations have been identified within the genome of P. 
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berghei, namely T431C, G399A and G850T, with the resulting amino acid mutations in the 
putative cytochrome b products at the residues 133, 144 and 284 (as reviewed in Olliaro, 2001). 
 
1.3.2 The Quinolines 
 
The first treatment to reach the Western world came with the discovery of the medicinal 
properties of quinine.  Quinine, a quinolinemethanol, is an alkaloid type compound isolated from 
the bark of the cinchona tree, which is indigenous to specific areas of South America (Raynes, 
1999).  This anti-malarial is no longer used for prophylaxis or routine treatment as it is 
considered far too toxic however it still remains an option to treat severe cases of malaria (Foley 
and Tilley, 1997).  The quinoline anti-malarials include the cinchona alkaloids, quinine and 
quinidine and the aminoalcohol quinine analogues commonly referred to as mefloquine and 
halofantrine (Phillips, 2001).  In addition to these are the 8-aminoquinoline primaquine and the 4-
aminoquinolines, chloroquine and amodiaquine (Phillips, 2001).  These anti-malarials are 
categorised as blood schizontocides meaning that they act on the intra-erythrocytic (asexual and 
to an extent also sexual) parasites (Olliaro, 2001).   
 
Despite the utilization of these anti-malarials for many years, as well as their widespread usage, 
fairly little is known regarding their mode of action.  Some of the proposed mechanisms include 
inhibition of protein synthesis, inhibition of the food vacuole lipase, aspartic proteinase and 
inhibition of DNA and RNA synthesis.  These mechanisms have been refuted, as they would 
require higher drug concentrations than those that can be achieved in vivo (Olliaro, 2001).  
Studies regarding the effects of quinoline anti-malarials upon P. falciparum indicated the 
swelling of the food vacuole (FV) or digestive organelle, vesiculation and the accumulation of 
undigested haemoglobin.  From these reported morphological changes within the parasite, it was 
suggested that the action of these drugs may involve the inhibition of the functioning of the FV, 
specifically targeting haem disposal, a process whereby intra-erythrocytic-stage malaria parasites 
detoxify heamoglobin in the FV (as reviewed in Raynes, 1999; Olliaro, 2001).  Most theories 
regarding this statement concur only on two points.  Firstly, that chloroquine selectively affects 
stages of the parasite life cycle after haemoglobin is digested and secondly that chloroquine 
selectively accumulates within the FV (Olliaro, 2001). 
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1.3.2.1 Mechanism of Action of Chloroquine 
 
Chloroquine, a diprotic weak base, is only effective against the blood stages of the parasite and 
only against those stages in which the parasite is actively degrading haemoglobin (Foley and 
Tilley, 1997).  In its unprotonated form, choloroquine is able to pass through the membranes of 
the parasitised erythrocyte, and by means of the pH gradient, accumulates within the acidic food 
vacuole (pH5) (Foley and Tiley, 1997).  At this point, chloroquine becomes protonated and is 
now membrane-impermeable and therefore trapped within the FV (Raynes, 1999).  The FV of the 
parasite is responsible for the degradation of host haemoglobin, which in turn provides a valuable 
source of amino acids vital for growth (Raynes, 1999).  From this observation it is thought that 
chloroquine affects the metabolic processes involved in the endocytosis and digestion of 
haemoglobin.  Chloroquine is considered capable of inhibiting endocytosis through disrupting the 
recycling of receptors, which are potentially necessary for the uptake of lysosomal enzymes, 
leading to the inhibition of lysosomal function and haemoglobin degradation ultimately resulting 
in parasite starvation (Raynes, 1999).   
 
Additionally, during this metabolic pathway there are several enzymes, which have been 
considered as potential drug targets.  However, recent evidence supports the hypothesis that 
detoxification of haem is the most probable site of action (Foley and Tilley, 1997; Raynes, 1999).  
During catabolism of host haemoglobin, a toxic by-product namely ferriprotoporphyrin IX (FP) 
is produced (as reviewed in Raynes, 1999; Foley and Tilley, 1997).  The plasmodia cannot 
degrade these potentially lytic and extremely toxic haem molecules and therefore polymerize the 
haem into harmless crystals referred to as haemozoin (also known as malarial pigment).  
Regardless of the nature of catalysis that occurs, chloroquine is thought to interrupt the 
polymerization process and as a result there is a toxic accumulation of haem molecules within the 
FV leading to the ultimate poisoning of the parasite (as reviewed in Foley and Tilley, 1997).  A 
key point to keep in mind however is that it is still not clear whether this mechanism of 
chloroquine action can apply to the other forms of quinoline anti-malarials. 
 
Resistance towards the quinoline anti-malarials is thought to result as the direct consequence of 
decreased drug accumulation within the FV and is probably conferred by multiple gene mutations 
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(Raynes, 1999).  Theories surrounding the possible mechanisms of drug resistance generally fall 
into two main categories.  The first being that there is an altered accumulation/exclusion 
mechanism ultimately resulting in the diminished drug levels within the digestive organelle, and 
secondly that transport mechanisms at the cytoplamsic and/or FV membrane have been affected 
directly impacting on the drug uptake/efflux processes (Raynes, 1999).   
 
Initially the evolution of parasites, which have a considerably higher pH in their FV than 
chloroquine sensitive strains were analysed (Ginsburg and Stein, 1991).  It was found that the 
chloroquine resistant isolates did indeed have a diminished or weakened proton pump on the 
vacuolar membrane, which resulted in the decrease in the concentration of the drug within the 
FV.  From this initial point of discovery it was found that this condition of resistance could be 
‘reversed’ in vitro utilizing drugs that reverse drug resistance in tumor cells (reviewed in 
Winstanley, 2000).  Within tumor cells, p-glycoprotein pumps are encoded via multi-drug 
resistant genes and are responsible for the expulsion of drugs from the cell.  Similar genes, 
namely pfmdr1 and pfmdr2, were identified in P. falciparum however it proved unlikely that such 
genes were indeed responsible for conferring full resistance toward chloroquine.  Alternatively, 
some studies revealed that a point mutation of the pfmdr1 gene (Tyr 86) could be connected with 
chloroquine resistance of field isolates in vitro.  Su et al. (1997) initiated a genetic cross 
experiment whereby neither gene was connected to resistance but alternatively the chloroquine 
phenotype was mapped to a 36-kb segment of chromosome 7.  Additionally, fine-scale analysis 
of this segment resulted in the identification of multiple potential genes that (together with 
pfmdr1) might encode for proteins that play a role within chloroquine resistance. 
 
1.3.3 Artemisinin-type Compounds 
 
This class of anti-malarials include either the natural extract artemisinin itself or alternatively the 
semi-synthetic derivatives which include: dihydroartemisinin, artesunate, artemether and 
arteether (Olliaro, 2001).  Artemisinin compounds are active throughout the phases of the asexual 
and intra-erythrocytic schizogonic cycle of the parasite as well as having the ability to affect the 
young gametocytes.  In addition, these drugs are particularly favoured as they are capable of 
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reaching higher reduction rates than any of the other anti-malarials known to date, and are 
therefore utilized within the treatment of uncomplicated as well as severe malaria (Olliaro, 2001). 
 
The mode of action of these anti-malarials is also not completely understood.  The current 
hypothesis is that reductive cleavage of peroxide via ferroheme ferrous-protoporphyrin IX 
(Fe(II)PPIX) produces carbon-centered radicals, which ultimately would alkylate biomolecules 
and result in the death of the parasite (reviewed in Olliaro, 2001).  This hypothesis is commonly 
referred to as the “carbon-centered radical theory” and several arguments regarding its validity 
exist.  It is doubted whether the formation of the carbon centered radicals is indeed common in 
the reductive cleavage of endoperoxides at all, and even if this is the case it is still questionable 
whether this process can be linked appreciably with anti-malarial activity.  In addition, there is 
the concern as to whether the putative adducts of this process are likely to survive long enough to 
even have any bearing on biomolecules (Haynes et al., 1999; reviewed in Olliaro, 2001).  Upon 
consideration of these arguments a further suggestion is that it is the 1,2,4-trioxane 
pharmacophore within artemisinin that confers anti-malarial activity, and in so doing provides the 
source of hydroperoxide through the generation of an oxo-stabilised cation upon heterolysis of 
the C3-O2 bond.   From the reductive cleavage with exogenous iron (II) or other reducing agents 
the electrophilic oxygenating species/hydroxyl/alkoxyl radicals which are responsible for 
hydroxylating biomolecules or removing hydrogen atoms are thought to be produced (Olliaro et 
al., 2001).  Additionally Ecktein-Ludwig et al. (2003) have demonstrated that artemisinin could 
also specifically and selectively inhibit the sarco/endoplasmic reticulum Ca2+ -ATPase (SERCA) 
of P. falciparum.  Furthermore, their results confirm the Fe2+
 
 dependent activation and 
consequent antimalarial activity of artemisinins being independent of haem binding.   
An additional benefit for these anti-malarials so far is that there are no known cases of resistance, 
nor have there been any reported therapeutic failures as a result of decreased parasitic sensitivity 
(Olliaro, 2001). 
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1.4 Vaccines Against Malaria 
 
Acquired immunity plays a vital role in malaria involving both the humural and cellular immune 
response (Phillips, 2001).  The mechanism of naturally acquired immunity relies on the antibody 
response toward the parasitic proteins, which are expressed on the surfaces of infected red blood 
cells, merozoites and within the apical organelle of the merozoite (reviewed in Doolan and 
Hoffman, 2001).  It was from the observation of acquired immunity that the initial idea of 
developing a vaccination against malaria originated.   
 
The complex life cycle of the parasite and its intricate relationship with the vector and host as 
well as allelic diversity and antigenic variations makes the development and implementation of 
effective malaria control problematic (Phillips, 2001).  However vaccination towards malaria, if 
successful, would be one of the most efficient and vital prophylactic methods against malarial 
infection.  In comparison to several viral vaccines, malarial vaccines would have to be subunit 
vaccines due to the impracticalities of growing any stage of the malarial parasite life cycle on a 
mass scale to produce enough antigenic material to produce a whole-parasite vaccine (Phillips, 
2001; de Roode and Read, 2003).  Subunit vaccines are defined as those containing one or more 
pure or semi-pure antigens.  In order to develop such a vaccine, it is vital to identify the 
individual components out of a myriad of proteins and glycoproteins of the pathogen that play a 
role in inducing protection.  This allows for an additional difficulty when developing the malarial 
vaccine.   
 
Effective vaccines elicit immune responses that destroy infectious agent or the host cells in which 
they reside, or inhibit a function that is vital for the parasites survival.  The complex life cycle of 
the malarial parasite allows for several areas as potential targets for vaccination.  There are 
currently three main categories in which malarial vaccine development lies.  These include the 
pre-erythrocytic stage, the asexual stage, and the sexual as well as the transmission stages of the 
parasites life cycle (Doolan and Hoffman, 2001; Carter, 2001).  The best candidates for malaria 
vaccines are those proteins required for parasitic survival, those with a low mutation rate and 
conserved epitopes.  Due to these proteins playing essential roles within the multiple or 
alternative steps during the invasion process, they should be the targets against which a protective 
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immune response should be elicited (refer to Table 2; Phillips, 2001; Doolan and Hoffman, 
2001).  In order to increase the efficiency of any malarial vaccines under investigation, a 
combination of specific antigens, and/or epitopes from various stages in the life cycle are 
required and both a humoral as well as cellular immunity stimulation are required for optimal 
results.    
 
1.4.1 Pre-erythrocytic Vaccines 
 
Sporozoites are the first stage of the parasites life cycle that comes into contact with the human 
host.  The pre-erythrocytic vaccine is engineered to either prevent sporozoites from invading the 
hepatocytes or alternatively to prevent liver-stage parasites from developing to maturity and 
subsequently producing and releasing infective merozoites, or both (Doolan and Hoffman, 1997).  
Ultimately, by targeting the sporozoites circulating in the blood stream, prior to their invasion 
into the hepatocytes, a preventative vaccine against malaria would be obtained (Phillips, 2001).   
 
The anti-sporozoite vaccine, designed to prevent infection, was first effective upon using 
radiation-attenuated sporozoites (as reviewed in Philips, 2001).  The immunity gained from such 
a vaccination was shown to be species specific and independent of parasite strain.  However, it 
carried the severe disadvantage of requiring vast quantities of infected mosquitoes for each 
individual immunized (reviewed in Phillips, 2001).  The main target in recent anti-sporozoite 
vaccine development has been revolving around the CSP or circumsporozoite protein. 
 
CSP is the dominant protein located on the surface of the sporozoite and was shown to have 
substantial antigenic properties and was thus considered as a possible candidate for vaccine-
induced immunity (Nussenweig and Nussenweig, 1989).  Initial clinical studies were performed 
using both the recombinant protein as well as synthetic peptides based upon the repetitive 
immunodominant sequence NANP (Asn-Ala-Asn-Pro) within the CSP protein amino acid 
sequence (reviewed in Anders and Saul, 2000 and Phillips, 2001).  Unfortunately, from the 
vaccination trials of both the synthetic and recombinant vaccine, it was found that only one out of 
three vaccinees were protective against exposure to P. falciparum sporozoites.   
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However, promising results have been reported recently utilizing a recombinant hepatitis B 
surface antigen vaccine, known as the RTS,S vaccine developed by GlaxoSmithKline, 
incorporating the repeat and non-repeat CSP sequences in adjuvant where-upon six out of seven 
vaccinees were protected in introductory trials (reviewed in Anders and Saul, 2000, Doolan and 
Hoffman, 1997 and de Roode and Read, 2003).   
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Table 2: Malaria vaccines and their antigenic targets 
Stage of P. 
falciparum life 
cycle 
Features Antigenic Target and Vaccine 
Description 
Evaluation 
LIVER STAGE 
Pre-erythrocytic Stage or species specific; 
antibody inhibits infection of 
liver; large dosage required; 
can terminate an infection 
Irradiated sporozoites;  
Circumsporozoite protein (CSP) or 
peptides 
CS protein RTS,S (incorporating 
Hepatitus B antigen) 
CS protein (NANP) (synthetic 
sporozoite conjugated vaccine) 
PfCSP(DNA) (VCL-2510 DNA 
plasmid containing genes for P. 
falciparum CSP expression) 
Liver Stage Antigens –1 (LSA-1)  
Protection 
Protection 
 
Short-term 
protection 
No protection 
 
Cytotoxic and IFN-
γ-producing Tcells 
present 
BLOOD STAGE 
Merozoite and 
Erythrocytes 
Species as well as stage 
specific; cannot terminate an 
infection; inhibits invasion of 
erythrocytes, therefore 
reducing severity of infection 
Erythrocyte Binding Antigen (EBA-
175),  
Merozoite Surface Protein MSP19kd 
(19kDa C-terminal fragment of 
MSP1) 
Merozoite Surface Antigen 1&2 
(MSA-1&2);  
Ring Infected Erythrocytic Surface 
Antigen (RESA);  
Serine Repeat Antigen (SERA);  
Rhoptry Associated Protein (RAP); 
Histidine Rich Protein (HRP);  
Apical Membrane Antigen-1(APM-1) 
 
 
Atibody and Tcell 
production 
 
 
 
 
SEXUAL STAGE 
Gametocytes & 
gametes 
Prevents infection of 
mosquitoes; antibody to this 
and antigen inhibits 
fertilization and maturation 
of gametocytes, zygotes or 
ookinetes; available in 
endemic areas but not suited 
for travelers; antibody blocks 
transmission cycle 
Pfs 25, 48/45k, Pfs 230  
MULTI-STAGE 
Combined vaccine 
(cocktail) 
Incorporation of expressed 
antigens from various life 
cycle stages into one vaccine 
to produce an immune 
response, blocking all stages 
of the parasite development. 
SPf 66 (incorporates pre-erythrocytic 
and asexual blood stage proteins of P. 
falciparum conjugated to alum) 
No protection 
 Multi-stage vaccine with 
multiantigenic variants, 
highly attenuated vaccinia 
virus 
NYVAC-Pf7  Tcells and 
antibodies 
(adapted form Doolan and Hoffman, 2001; Plebanski et al., 2002) 
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1.4.2 Asexual Blood-Stage Vaccines 
 
Animal models for crude-blood stage vaccines have successfully resulted in a strong induced 
resistance against the malarial parasite.  Research now lies in the identification of those antigens, 
present within the crude extracts, which are responsible for the induction of protection (Phillips, 
2001).  From monoclonal antibody studies against the rodent and human malarial parasites 
several antigenic molecules have been identified (Holder and Freeman, 1981).  The two most 
promising antigenic candidates are the merozoite surface protein 1 (MSP-1) and apical membrane 
antigen 1 (AMA-1) (as reviewed in Phillips, 2001 and Anders and Saul, 2000).  Both of these 
antigens are present within all four of the malarial species and due to their homologues in both 
the rodent and simian parasites the vaccine potentials of these two candidates has been tested 
utilising numerous animal models (Anders and Saul, 2000).     
 
The MSP-1 protein is the major surface protein of the merozoite, with its 19 kDa carboxy 
terminal portion remaining on the surface of the merozoite even after infection of the hosts red 
blood cells has occurred (Holder and Freeman, 1981).  As discussed in Phillips (2001) the 19-
kDa fragment of the protein is conserved amongst all MSP-1 proteins and consists of two 
cysteine-rich epidermal growth factor domains (EGFD), which are possibly essential for the 
parasite to invade the erythrocytes of the host.  The first EGF domain has been shown to be the 
target of monoclonal antibodies directed against P. falciparum proteins, which are responsible for 
hindering the development of the parasite, in vitro (Chapel and Holder, 1993).  From 
immunization studies the recombinant proteins from the MSP-1 of P. yoelii and P. falciparum 
were shown to be effective due to the induction of protective antibody (Phillips, 2001). 
 
The AMA-1 antigen is located in the rhoptry organelles, which are responsible for the invasion of 
the erythrocytes.  Other antigens, which are currently being studied as potential vaccine 
candidates, involved in this organelles task include the erythrocyte-binding antigen (EBA-175) 
and the serine-rich antigen (SERA) (as reviewed within Phillips, 2001).  Immunization studies 
involving the recombinant forms of AMA-1 have been successful against both P. fragile and P. 
chabaudi with current studies involving the AMA-1 of P. falciparum (Phillips, 2001).   
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1.4.3 Transmission – Blocking Vaccines 
 
Several efforts have been attempted in the identification of existing, as well as potential, 
antigenic targets for the development of a Transmission-blocking vaccine (TBV).  Currently, 
these studies have led to the identification of proteins such as chitinase, which occurs on the 
surface of the malarial ookinete and are vital for the penetration of the mosquito mid-gut, as well 
as other surface proteins of the extracellular male and female gametes, zygote and ookinete as 
potential antigenic targets (as reviewed in Carter, 2001).   
 
TBV`s are targeted against the sexual stages of the life cycle of the parasite, including the stages 
within the mosquito mid-gut, and essentially prevent the parasite from infecting the mosquito 
vector.  Due to the vaccines role in reducing or abolishing the transmission of the disease they 
were named transmission blocking vaccines or TBV`s (Carter, 2001).  There are three main 
categories in which transmission blocking vaccines currently lie.  The first involves the pre-
fertilization antigens - which are expressed either entirely or predominantly in the gametocytes, 
the second involves the post-fertilization antigens which are expressed completely or 
predominantly on the zygotes or ookinetes, and the third category includes the late-mid-gut 
antigens which are essential for the ookinete to penetrate the peritrophic membrane (Phillips, 
2001). 
 
Numerous efforts in development of pre-fertilization target antigen identification resulted in the 
production of monoclonal antibodies namely: Pf230, Pf48/45, and Pf11.1.  These antibodies have 
shown considerable transmission-blocking activity in vitro, however validation of whether these 
antibodies occur naturally has not yet been manageable (reviewed within Phillips, 2001). 
 
Post-fertilization antigens are antigens that are not expressed by the parasite in the host and thus 
they have the undesirability of serving as potential vaccine targets due to the antibody response 
failing to be stimulated after natural infection.  However, these antigens are still considered 
possible targets due to the lack of exposure they have had toward the immune response and thus 
their lack of exposure toward selection of immune evasion mechanisms (Phillips, 2001).  
Currently two potential post-fertilization antigenic targets are being investigated, namely P25 (or 
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Pfs25 in P. falciparum) and P28 (or Pfs28 in P. falciparum) (Barr et al., 1991; Duffy et al., 
1993).  Pfs25 was the first sexual-stage antigen to be cloned and is minimally expressed in 
maturing gametocytes, and mainly expressed after the dispersal of the gametes and formation of 
the zygote.  It is the main surface protein on the zygote and ookinete, whereupon it is always 
expressed (Barr et al., 1991).  Pfs25 has been shown to have antigenic diversity and the 
recombinant form has been expressed within mammalian expression vectors, as well as yeast 
expression systems, and has been reported to have transmission-blocking activity and induce the 
respective antibodies in both mice and monkeys (Barr et al., 1991; as reviewed in Phillips, 2001).  
From this initial success, Pfs25 is currently in Phase I trials.  Pfs28, in comparison, has only been 
shown to have transmission-blocking activity in P. gallinaceum (Duffy et al., 1993). 
 
Shortcomings surrounding vaccine development against malaria begin with the inability to grow 
the parasite in large quantities and range from difficulties of evaluation to the fact that there are 
multiple antigens, which are species as well as stage specific.  Further problems include antigenic 
diversity and immune evasion.  This is especially the case regarding the blood-stage vaccines as 
they are polymorphic and the antigenic diversity resulting form these polymorphisms is thought 
to limit the effectiveness of the malarial vaccine.  Additionally there are multiple problems within 
conducting clinical and field trials.  Several researchers have hypothesized that a vaccine for a 
specific spectrum of antigens is unlikely to be protective due to the variation in the target for the 
immune response at different stages of the parasitic life cycle.  An additional aspect to consider is 
that immunizing against a specific group of antigens may result in the parasite changing its 
“identity” due to the chances of mutation amongst the parasite itself also being a possibility. 
 
1.5 Genomics, Proteomics and Malaria 
 
The release of the genome sequence of the anopheles mosquito has allowed for the development 
of new tools for the control of malaria with regard to vector-related strategies.  In addition, 
several organizations collaborated their efforts in order to sequence the P. falciparum genome, 
some of which included The Institute for Genomic Research and the Naval Medical Research 
Center (TIGR/NMRC), the Sanger Institute and Stanford University.  The whole-chromosome 
shotgun strategy was chosen for the task of sequencing the 22.8-Mb genome, which is comprised 
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of 14 chromosomes, encoding 5300 genes, and the mitochondrial and apicoplast genome 
sequences (Gardner et al., 2002).  The publication of the P. falciparum genome sequence in 
Nature during October 2002, has allowed for new hope in the battle against malaria.  The 
identification of potential leads for anti-malarial drugs and targets for vaccine development have 
already been assisted through the availability of genome sequence data in the past (Roberts et al., 
1998; Surolia and Surolia, 2001; and Jomaa et al., 1999).  Now, with the genome sequence in 
hand researchers are looking for novel vaccine and drug targets amongst the 5 279 predicted 
proteins however it will still be several years before any success is envisaged.  In the case of 
vaccine development this is not due to a lack of vaccine candidates but due to their effectiveness 
to stimulate an immune response as even though irradiated parasites can illicit a protective 
immune response several proteins on their own cannot (reviewed in de Roode and Read, 2003). 
 
1.5.1 Target and Lead Identification for drugs based on genome sequence data 
 
Through homology modeling strategies between P. falciparum chromosome 2 sequence data, and 
known genes of plants and algae, researchers have already identified several lipid biosynthesis 
genes within P. falciparum and have demonstrated the characteristic targeting toward the 
apicolast of these gene products (Waller et al., 1998).  The proteins of these genes are critical 
drug targets as they are vital for the survival and viability of the parasite and also due to the 
absence of the type II fatty acid biosynthesis pathway in humans.  An enzyme of this pathway, 
namely enoyl-acyl-carrier protein (enoyl-ACP) reductase (FabI), was identified from sequence 
data and subsequent inhibition of this enzyme was shown to have an in vitro affect against P. 
falciparum activity (Surolia and Surolia, 2001).   
 
The additional identification of the enzymes 1-deoxy-D-xylulose 5-phophate (DOXP) synthase 
and reductoisomerase, from the sequence data of chromosome 14, has supplied the evidence that 
can now link P. falciparum with the alternative DOXP pathway for isoprenoid biosynthesis, 
which is essential for parasitic survival (Jomaa et al., 1999).  Furthermore, there was no 
indication within the genome of the mevalonate pathway for isoprenoid synthesis common within 
eukaryotes thus making this pathway an ideal target for anti-malarial drugs (Gardner et al., 2002).  
The two DOXP reductoisomerase inhibitory drugs, fosmidomycin and its derivative FR-900089, 
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have been demonstrated as being successful against P. falciparum, as well as multi-drug resistant 
P. falciparum, activity in vitro and in vivo against P. vinckei in mice (Jomaa et al., 1999).   
 
More recently however, researchers have managed to identify a metal-dependent RNA 
triphosphate protein family as a novel target for drug design within the parasite P. falciparum 
(Ho and Shuman, 2001).  This family of proteins are vital for mRNA cap formation and therefore 
eukaryotic gene expression.  The structure of the active site and catalytic mechanisms of these 
proteins are similar amongst fungi and P. falciparum however differ from the RNA triphosphate 
domain found in metazoan capping enzymes.  For this reason genomic and structural similarities 
between these enzymes amongst fungi and P. falciparum offer the opportunity to generate 
antifungal as well as anti-malarial activity amongst a single class of mechanism-based inhibitors 
(Ho and Shuman, 2001; as reviewed in Hoffman et al., 2002).  Additional protein families within 
P. falciparum, which are considered as potential targets for drug design, include the cysteine and 
aspartyl proteases, with special interest focusing on the metacaspase of the family of cysteine 
proteases. 
 
1.5.2 Target identification for vaccines based on genome sequence data 
 
Potential vaccine targets are those that are often present on the surface of the infected erythrocyte 
or merozoites and parasitic proteins essential for erythrocytic invasion.  Several such protein 
targets have been identified from genomic sequence data and their potential as vaccine targets are 
being investigated (Duffy et al., 2001; reviewed in Hoffman, 2002; Gardner et al., 2002).  The 
availability of genomic sequence data has not only allowed the identification of such targets but 
also revealed clues as to how these genes are regulated.  One such example is with the P. 
falciparum erythrocytic membrane protein (PfEMP) gene family (Deitsch, et al., 2001).  Many 
proteins, which can be considered as potential vaccine targets, are those responsible for initiating 
infection within the host and stimulating the immune response.  However, for there to be any 
success in the incorporation of genome sequence data into the development of a malaria vaccine, 
development of high-throughput immunological assays as well as techniques for ensuring the 
stability of a protective immune response is needed (Gardner et al., 2002).   
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1.6 Novel Approaches and Strategies in Combating Malaria 
 
1.6.1 Targeting Metabolic Pathways of the Parasite 
 
Several novel strategies for targeting malaria have involved the possibilities of inhibiting the 
metabolic pathways of the parasite.  Utilizing a combination of inhibitors, which target metabolic 
pathways that converge to produce a final product, has been proposed as being far more effective 
and beneficial in the struggle against malaria than merely the utilization of a single inhibitor 
(Macreadie et al., 2000).  These studies are hopeful in deterring the evolution of drug resistance 
however, such studies are promising but still at preliminary stages and examples of such 
approaches are limited.   
 
The discovery of the apicoplast or apicoplexan plastid within the malarial parasite is an exciting 
prospect for novel drug development against malaria.  The apicoplast contains a circular, 35 kb, 
extrachromosomal strand of DNA that comprises genes of only 30 proteins.  Gardner et al. 
(2002) also identified 551 nuclear-encoded proteins that are destined to the apicoplast, and 
together with the apicoplast encoded proteins may be promising drug target candidates (Vial, 
2000; Gardner et al., 2002).  This non-photosynthetic plastid is protected by four membranes and 
possesses a genome that is homologous amongst algae and plants.  Due to the evolutionary status 
of this organelle in all parasites it is essential for the survival of the parasite.  Exactly how the 
organelle ensures the survival of the parasite however, remains a mystery (Vial, 2000).  The 
apicoplast is known to house several metabolic pathways namely those of fatty acid (Gardner et 
al., 1998b; Waller et al., 1998), isoprenoid (Jomaa et al., 1999) and haem synthesis (Sato and 
Wilson, 2002).  Jomaa et al., (1999) have identified the mevalonate-independent pathway of 
isoprenoid biosynthesis in P. falciparum as a potential source for drug inhibition.  This pathway 
is thought to occur in the apicoplast and operates via a different mechanism to that in humans.  
Through the identification of the enzymes within this pathway a new target for anti-malarial 
chemotherapy has originated (Jomaa et al., 1999).  The alternative pathway for isoprenoid 
synthesis will also allow for immunotherapeautic drug development, as many pathogens rely on 
the alternative pathway of isoprenoid synthesis to produce toxic compounds that interfere with 
the hosts immune system (www.jomaa-pharmaka.com; dates accessed 01/2002-12/2003).  By 
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utilizing the inhibitor compounds therapeutically, diverse immune reactions common in disorders 
such as multiple sclerosis and several allergies may be corrected and pathology prevented 
(www.jomaa-pharmaka.com).   
 
The shikimate pathway (also known as the aromatic biosynthesis pathway), responsible for the 
synthesis of aromatic compounds comprises a sequence of seven enzymatic steps in which the 
starting materials (generated via carbohydrate metabolism) phosphoenolpyruvate and erythrose-
4-phosphate are converted to chorismate.  This pathway exists in prokaryotes, fungi and the 
plastids of plants but is absent in mammals, which rely solely upon exogenous folates (Hermann 
and Weaver, 1999).  In plants the shikimate pathway enzymes are targeted to the plastid via an 
amino-terminal leader sequence (Waller et al., 1998).  However, the apicomplexan pathway is 
thought to occur within the cytosol due to the lack of the leader sequence within any of the 
shikimate pathway proteins (Keeling et al., 1999).  Apart from this, the shikimate pathway is still 
a valid target for novel anti-parasitic drugs especially due to the absence of the pathway within 
mammals.  Roberts et al. (1998) demonstrated the presence of this pathway within P. falciparum 
together with other parasites and in addition have shown its inhibition by the herbicide 
glyphosate, a known shikimate pathway inhibitor.  Glyophosate inhibits the enzyme 5-
enolpyruvyl shikimate 3-phosphate synthase and administering p-aminobenzoate can reverse its 
inhibitory affects.  The discovery of the apicomplexan shikimate pathway is therefore a 
promising metabolic pathway for drug targeting and harbours possibilities for a broad-spectrum 
drug in the future (Roberts et al., 1998).   
 
1.6.2 Rational Drug Design 
 
Another leading field that has not yet been fully explored is that of rational drug design supported 
by the existing structural information of malarial protein targets (Macreadie et al., 2000).  Great 
hopes have been pinned upon the computational methods for structure based ligand design and 
some success has been reported within other areas of research, especially in cases regarding water 
soluble targets, with 3-D structures having been accurately determined via the technique of X-ray 
crystallography and NMR studies.  The main requirement of these methods is knowledge 
pertaining to the 3D topology of the targets ligand-binding pocket, with the ligand docked in 
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place (Farber, 1999).  The identification of lead compounds from library compounds has also 
been explored.  Wiesner et al. (2001) have shown the identification of a novel lead compound, 
namely 2,5-bis-acylaminobenzophenone, from a library of 61 compounds through inhibitory 
assays against a resistant strain of malaria. 
 
In order for rational drug design to be a success, over-expression of the gene of interest is 
essential to provide sufficient levels/quantities of recombinant protein for biophysical studies; 
these include techniques such as X-Ray crystallography and NMR.  The over-expression of 
parasitic genes, especially P. falciparum, in Escherichia coli (E. coli) has been difficult due to the 
codon-bias of these organisms.  The P. falciparum genome in particular is extremely AT-rich 
which has added to the problem of heterologous protein expression and production within 
bacteria (Saul and Battistutta, 1988).  With the construction of the RIG plasmid researchers are 
now able to overcome the potential problems of codon-bias apparent in the P. falciparum and 
other parasitic genes  (Baca and Hol, 2000).  This plasmid is engineered to encode for the three 
tRNA`s, namely Arg, Ile and Gly, which recognize codons that are found frequently within 
parasitic genes but are rare within highly expressed genes in E. coli. 
 
Another interesting field is that of serial analysis of gene expression (SAGE) which in tandem 
with the malaria genome project will allow for the identification of novel drug targets.  The 
technology available will allow one to identify genes, or gene clusters, which have 
characteristically high expression levels under normal conditions, however, when treated with a 
particular drug have affected expression levels (i.e. considerably lower).  Additionally this 
technology will further allow for researchers to monitor the effects of any particular drug on the 
parasite (Macreadie et al., 2000). 
 
Inherent to all approaches in combating malaria, discussed in the sections above, is the ultimate 
need to achieve a reasonable level of progress for malaria control.  Intensive measures have been 
made in malaria control in the dispensation and administration of several chemotherapeutic 
therapies, as well as physical and chemical strategies to control the vector i.e. the mosquito.  
Despite these efforts the disease is still on the increase, with P. falciparum now ranking amongst 
the top four infectious disease killers worldwide (de Koning-Ward et al., 2000). 
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The parasites complex relationship with the vector, as well as the host, poses a challenge towards 
medical research in the field of novel drug development.  However, through the utilization of 
genetic tools, such as transfection, a deeper understanding of the parasites biology will hopefully 
serve as a catalyst for a more rational approach toward both vaccine and anti-malarial drug 
development (de Koning-Ward et al., 2000).  Advances in proteomics will additionally aid the 
battle against malaria, allowing for the identification of differentially expressed proteins, which 
along with comparative genomic analysis and the utilization of protein interaction maps and the 
knowledge of the mechanisms of metabolic pathways, will aid the development of therapeutic 
intervention. 
 
1.7  The Mevalonate/Non-Mevalonate Pathways for Isoprenoid Biosynthesis 
 
Isoprenoids are a heterogenous collection of biomolecules that are paramount for the survival of 
all organisms, with representatives in all taxonomic groups.  Of the 23 000 known isoprenoids 
some common examples include cholesterol, steroid hormones, and ubiquinones in animals, 
carotenoids, plastoquinones, and the phytyl side chains of chlorophyll in plants, and hopanoids 
and undecaprenylpyrophosphate in bacteria.  Isoprenoids are involved in several cellular 
processes such as electron transport within respiration and photosynthesis, hormone-based 
signaling, control of transcription, post-translational processes in lipid biosynthesis, meiosis, 
apoptosis, protein cleavage and degradation. 
 
In all organisms isoprenoid biosynthesis relies on the condensation of varying numbers of 
isopentenyl diphosphate units (IPP).  Initially it was accepted that all organisms produced IPP via 
the mevalonate pathway.  Within this pathway IPP is synthesized from three molecules of acetyl-
CoA with the intermediate being mevalonate (MVA).  However, it was discovered after 1993 that 
several bacteria, green algae and the chloroplasts of higher plants generate IPP via the non-
mevalonate or 1-deoxy-D-xylulose 5-phosphate/2-C-methyl-D-erythritol 4-phosphate 
(DOXP/MEP) pathway (reviewed in Lichtenhaler, 1999 and Rohmer, 1999).   
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This DOXP/MEP pathway or non-mevalonate isoprenoid pathway has also been shown to exist 
in the malaria parasite as well as several other potentially pathogenic bacteria however, it is 
absent in humans and other mammals (Jomaa et al., 1999; Lichtenhaler et al., 2000).  The 
discovery that the alternative pathway is also present in the malaria parasite has allowed for the 
discovery of a completely novel therapeutic concept for malaria treatment.  For this reason it 
promises the development of novel drug candidates, which would have no adverse affects upon 
humans and other mammals.  Additionally, the lack of the mevalonate pathway within the 
parasite makes it impossible for this pathway to rescue any inhibition of the alternative pathway. 
 
The discovery of the apicoplast in the phylum apicomplexa, and its indispensability within the 
Toxoplasma and Plasmodium parasites, resulted in much curiosity regarding the origin and 
metabolic importance of this plastidic organelle (Waller et al., 1998).  In comparison to other 
organisms the production of IPP in plants was found to occur via both pathways, with the 
mevalonate pathway residing in the cytosol and the alternative pathway in the plastid.  For this 
reason, it has been thought that the plastids developed evolutionary from prokaryotes due to a 
secondary endosymbiotic event (Palmer and Delwiche, 1996).  Additionally, two genes of the 
alternative non-mevalonate pathway of isoprenoid biosynthesis have been identified in the 
apicoplast of P. falciparum, thus directly linking the DOXP/MEP pathway with this organelle 
(Jomaa et al., 1999). 
 
Evidence for the existence of an alternative isoprenoid biosynthesis pathway emerged from the 
independent incorporation studies in the research groups of Rohmer and Arigoni who found that 
the isotopic labeling patterns observed within their studies could not be explained via the 
mevalonate pathway (reviewed within Eisenreich et al., 1998; Lichtenhaler, 1999 and Rohmer, 
1999).  Not much information regarding the reaction mechanisms of this novel pathway has yet 
been confirmed, especially regarding the last steps leading to release of IPP.  However, it is 
currently expected that the following outline of the reactions steps is common amongst all species 
harbouring the DOXP/MEP pathway.   
 
The initial step of this novel pathway involves the condensation of pyruvate and glyceraldehyde-
3-phosphate.  1-deoxy-D-xyulose-5-phosphate (DOXP) synthase catalyses this initial step, which 
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results in the production of 1-deoxy-D-xyulose-5-phosphate (refer to Figure 1.3; Part A).  DOXP 
reductoisomerase then synthesizes 2-C-methyl-D-erythritol 4-phosphate (MEP) in an 
intramolecular rearrangement step followed by a reduction process using NADPH as a hydrogen 
donor (Vial, 2000; Proteau et al., 1999; Reuter et al., 2002)(Figure 1.3 Part B).  Divalent cations 
such as Mn 2+, Co 2+ and Mg 2+ are also required as co-factors for this reaction, with Mn 2+
Figure 1.3
 being 
the most effective (Reuter et al., 2002).  From here, MEP is cytidylated via 4-(cytidine 5΄-
diphospho)-2-C-methyl-D-erythritol (CDP-ME) synthetase with the release of pyrophosphate and 
subsequently phosphorylated by the CDP-ME kinase to result in the production of 4-
diphosphocytidyl-2-C-methyl-D-erythritol-2-phosphate (CDP-ME-2-phosphate)( ; Part 
C and D).  CDP-ME-2-phosphate is then cyclised by the enzyme MECDP synthase resulting in 
the release of CMP and the production of 2-C-methyl-D-erythritol-2,4-cyclodiphosphate 
(MECDP)(Figure 1.3; Part D).  The terminal reaction steps are, however, still not fully elucidated 
(reviewed within Rohmer, 1999; Reuter et al., 2002)(Figure 1.3; Part E). 
 
Additionally, this pathway has been reported as synthesizing other intermediates other than those 
of IPP in bacteria, for example thiamine (vitamin B1) and pyridoxol (vitamin B6) (Takahashi et 
al., 1998).  Importantly, the novel pathway for IPP biosynthesis is presently not fully understood 
especially regarding the terminal reaction steps, which lead to the production of IPP itself.   
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Figure 1.3: The mevalonate & alternative pathway for the biosynthesis of isoprenoid units   
The mevalonate (left) and the alternative (right) pathway of isoprenoid synthesis.  The terminal steps are still not 
fully elucidated (adapted from www.jomaa-pharmaka.com).   
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1.8  1-Deoxy-D-xylulose-5-phosphate Reductoisomerase 
 
Enzymes within the alternative pathway of isoprenoid synthesis have become promising targets 
for novel drug development against several bacteria and pathogens including malaria.  This lies 
within the importance of the production of isoprenoids to ensure survival of the respective 
pathogen.  The enzyme, which is responsible for the second step of the alternative pathway, 
namely 1-deoxy-D-xyulose-5-phosphate reductoisomerase (DOXP reductoisomerase or DXP 
reductoisomerase) has attracted much interest within this field as a potential drug target.  
Additionally, both the DOXP synthase and DOXP reductoisomerase genes have been cloned, and 
the expression of these genes in the erythrocytic stages of P. falciparum has been confirmed by 
Jomaa et al, 1999 utilizing reverse transcriptase- polymerase chain reaction (Jomaa et al., 1999; 
Reuter et al., 2002; Sprenger et al., 1997; Takahashi et al., 1998).  The manipulation of the non-
mevalonate pathway that exists in E. coli has shown that the over-expression of DOXP synthase 
can be correlated with the increase in levels of carotenoid and ubiquinone synthesis (Harker and 
Bramley, 1999).  Additional studies regarding the expression levels of these enzymes, was 
demonstrated within Arabidopsis, however the roles of these enzymes and the reductase isoforms 
in regulating the non-mevalonate pathway are still unclear (Estèvez et al., 2000).  Recently, 
DOXP reductoisomerase proteins were also cloned from Mentha x piperita (Lange and Croteau, 
1999), Arabidopsis thaliana (Schwender et al., 1999), Synechocytis sp. (Proteau et al., 1999), 
Synechococcus leopoliensis (Miller et al., 2000), Zymomonas mobilis (Charon et al., 1999, Grolle 
et al., 2000) and Pseudomonas aeruginosa (Altincicek et al., 2000).   
 
Reuter et al. (2002) were the first group to have determined the crystal structure of the E. coli 
DOXP reductoisomerase to within 2.5 Å.  DOXP reductoisomerase was previously reported as 
being a homotetramer via gel filtration and native polyacrylamide gel electrophoresis (PAGE).  
However, from the crystal structure the enzyme was shown to be present as a homodimer with 
each monomer forming a V-shaped molecule, where DOXP reductoisomerase was concluded as 
having a molecular mass of 86 kDa (each monomer being 43.5 kDa) (Reuter et al., 2002).   
 
The three dimensional structure of the enzyme was shown to consist of three domains, which 
ultimately form the overall V-shape.  Thus each monomer is comprised of an amino-terminal 
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dinucleotide binding domain, a connective domain, and a carboxy-terminal domain.  The amino-
terminal domain stretches from residues 1 to 150 and forms one arm of the V.  It represents the 
dinucleotide binding domain responsible for binding NADP(H).  The connective/catalytic 
domain (residues 150-285) is accountable for the dimerization of the enzyme as well as 
containing the majority of the active site of the enzyme.  In addition, the DOXP reductoisomerase 
enzyme has been shown to have high intrinsic flexibility within the connective domain.  The 
carboxy-terminal domain spans residues 312 to 398 and is present as a four-helix bundle and 
consequently forms the second arm of the V (Reuter et al., 2002).   
 
The apical region of the DOXP reductoisomerase enzyme is mostly comprised of the connective 
α/β domain.  This region forms a deep cleft in which the substrate binding and catalytic site are 
situated.  Within the connective domain several highly conserved acidic residues are clustered at 
the active site and are thought to be responsible for the binding of the divalent cations essential 
for enzyme activity.  These residues include Asp150, Glu 152, Glu 231, and Glu 234
 
 (Reuter et al., 
2002). 
In addition, Yajima et al. (2002) have obtained the crystal structure of E. coli DOXP 
reductoisomerase in complex with the co-factors NADPH and a sulphate ion from E. coli at 2.2 
Å.  The structure obtained was also reported as being in a homodimer conformation with the 
monomer consisting of the three domains reported by Reuter et al. (2002).  However, they 
initially reported and identified the third domain present within DOXP reductoisomerase that 
seems to be absent amongst other NADPH-dependent oxidoreductases.  This flexible loop region 
covers the substrate-binding domain and is therefore thought to be critical in the enzymatic 
reaction and the determination of substrate specificity.  Additionally, they propose that this loop 
may act as a “hatch” that seals the active site once the substrate has entered the catalytic pocket.  
From the analysis of the crystal structure and subsequent mutational analysis of DOXP 
reductoisomerase, Yajima et al. (2002) demonstrated that the four amino acid residues His153, 
His209, Glu231, and His253
 
, present within the central domain with their side chains protruding into 
the binding pocket, are essential for enzyme catalysis.   
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Steinbacher et al. (2003) have released the most recent crystal structure, which is in complex with 
NADPH and the metal ion cofactor as well as the inhibitor fosmidomycin (see Figure 1.4).  They 
report the protein structure as a homodimer both within the crystal and in the solution state with 
the presence of a groove within each monomer that is protected via a flexible hatch region that 
was previously reported by Yajima et al. (2002).  The monomer was reported as containing the 3 
domains reported previously by Reuter et al. (2002) and Yajima et al. (2002).  Additionally, they 
describe the presence of the binding sites for the divalent cation, the phosphate moiety of the 
substrate DOXP, and the catalytic loop within the connective/catalytic domain (residues 150-285) 
of the protein structure with the carboxy terminal maintaining the structural integrity of the active 
site pocket.  Binding of the metal cation was found to be in an octahedral co-ordination sphere 
with three water molecules and the residues Asp150, Glu152 and Glu231
 
.   
 
Figure 1.4: Ribbon representation of the DOXP reductoisomerase monomer in complex 
with the inhibitor fosmidomycin 
This figure was generated using Molscript (Kraulis, 1991) using the crystal structure data generated via Steinbacher 
et al. (2003) (Protein Data Bank accession codes 1ONN and 1ONP).  (A) The enzyme comprises three domains, 
which form the overall V-shape of the molecule.  The N-terminal NADPH binding domain is shown in violet.  The 
central connective/catalytic domain shown in crimson binds the divalent cation (magnesium, manganese or cobalt) 
and the phosphate moiety of the substrate.  The carboxy terminal provides structural integrity for the active site 
pocket and is shown in turqouise.  (B) Fosmidomycin is shown bound to the active site in ball and stick 
configuration.   
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1.9 Stereochemistry of the Reduction Step Mediated via 1-Deoxy-D-xylulose 
5-Phosphate Reductoisomerase 
 
DOXP reductoisomerase is the second enzyme of the methylerythritol (MEP) pathway and is 
involved in the conversion of DOXP to MEP by catalyzing the rearrangement of the carbon 
backbone as well as the nucleotide adenosine diphosphate hydrogen (NADPH)-dependent 
reduction of the carbon 1 position of the putative intermediate 2-C-methylerythrose 4-phosphate 
(Proteau et al., 1999).  Proteau et al., (1999) originally elucidated the stereochemistry of this 
reductive step of the MEP pathway (see Figure 1.5).  Through the utilization of the Synechocystis 
sp. protein, which has a 42% identity to the E. coli DOXP reductoisomerase sequence, they 
addressed the following stereochemical issues surrounding the reaction this enzyme catalyses: “1) 
which hydrogen at the carbon 1 position of the 2-C-methyl-erythritol phosphate originates from 
the carbon 3 of DOXP and which from NADPH? 2) delivery of the hydride from NADPH occurs 
on which face of the intermediate aldehyde – re or si? and 3) which hydride from NADPH is 
delivered in the reduction (class A or class B dehydrogenase)”. 
 
Utilizing [3-2H]DOXP the H′ NMR spectrum indicated that the pro-S proton/hydrogen of MEP 
resonates at 4.156 ppm and is derived from the carbon 3 position of deoxyxylulose whereas the 
pro-R proton/hydrogen at the carbon 1 position of MEP, is derived from NADPH and resonates 
at 3.90 ppm.  In addition this result further established that the hydride delivery occurred at the re 
face of the proposed intermediate (Proteau et al., 1999).  Additionally, from incubation 
experiment studies involving [1-2
 
H] glucose in cyanobacterium Synechocystis sp.  Proteau et al., 
(1999) have proposed that the 4 S-hydride of NADPH is delivered, this therefore classifies 
DOXP reductoisomerase as a class B dehydrogenase.   
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Figure 1.5: Stereochemical view of the reaction catalysed by DOXP reductoisomerase  
The manganese metal cation is anchored by the catalytic residues Asp150, Glu152 and Glu231.  1-deoxy-D-xylulose-5-
phosphate is converted into 2-C-methyl-D-erythritol 4-phosphate via the aldose intermediate 2-C-methyl-erythrose 
4-phosphate.  The hydride of NADPH and C4 group of DOXP attack opposite sides of the C3 and C2
 
 respectively.  
The asterisk represents the hydride that is transferred via the cofactor NADPH (adapted from Steinbacher et al., 
2003). 
1.10 Inhibitors of the DOXP synthase and DOXP reductoisomerase enzymes 
of the Non-Mevalonate Pathway 
 
Tools for the discovery of potential inhibitors of DOXP reductoisomerase as well as DOXP 
synthase have been investigated as potential drug candidates for malaria.  In order to identify 
possible inhibitors towards the DOXP pathway, initial database searches to identify antibiotics 
that were active against E. coli and Bacillus subtilis, harboring the non-mevalonate pathway and 
inactive against Staphylococcus aureus possessing the mevalonate pathway were undertaken in 
the hope that such inhibitors may already have been reported as antibacterial drugs (Kuzuyama et 
al., 1998).  It was from such searches that the inhibitor fosmidomycin (FR-31564) was identified 
as being a potential inhibitor of the DOXP pathway.  Fosmidomycin (3-(N-formyl-N-
hydroxyamino)propylphosphonic acid) (FOSM) has been reported as having a powerful 
antibacterial activity against the majority of Gram-negative bacteria and some Gram-positive 
bacteria.  From the identification that this inhibitor had a direct impact upon the biosynthesis of 
menaquinone and carotenoids in Micrococcus luteus it was proposed that this inhibitors 
mechanism of action could be linked with the biosynthetic pathway of isoprenoid and terpenoid 
synthesis and thus a useful inhibitor towards the nonmevalonate pathway (reviewed within 
Kuzuyama et al., 1998).   
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Altincicek et al. (2000) investigated this approach utilizing enzymes from the pathogenic 
bacterium Pseudomonas aeruginosa.  From their research it was found that the recombinant 
enzymes, of both DOXP synthase and DOXP reductoisomerase, expressed within Escherichia 
coli were inhibited by submicromolar concentrations of fosmidomycin and its derivative FR-
900098 (Figure 1.; Jomaa et al., 1999; Reichenberg, 2001).  In addition, it has been demonstrated 
that these antibiotics are efficient inhibitors toward DOXP reductoisomerase from both P. 
falciparum as well as E. coli  (Jomaa et al., 1999).  These results were additionally confirmed 
through the demonstration of the anti-malarial activity of both these antibiotics in vitro and in 
vivo.   
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Figure 1.6: Structures of the antibiotic fosmidomycin and its derivative FR-900098 
Binding of the inhibitors has been demonstrated within the crystal structure generated via 
Steinbacher et al. (2003).  Fosmidomycin binds to the active site through its (N-formyl-N-
hydroxy) amino head group by displacing two water molecules present in the octahedral sphere 
of the metal cation.  The phosphate moiety is then secured within the active site through 
hydrogen bonding with residues Ser186, Ser222, Asn227 and Lys228 with the N-formyl oxygen 
placed trans to Glu231 and the N-hydroxyl oxygen placed trans to Asp150.  Additionally, Trp212 
and His257 are proposed to form a stacking role, which is maintained by Pro274 
 
within the catalytic 
hatch region only in the presence of NADPH.  NADPH is essential for this role to be fulfilled, as 
it seems to orchestrate the conformation of the active site. 
Due to the low oral efficacy of fosmidomycin and its derivatives, prodrugs of the fosmidomycin 
derivative FR-900098 were then investigated for increased anti-malarial activity (Reichenberg et 
al, 2001).  Utilizing FR-900098 as the lead molecule, because of its characteristic 2-fold greater 
anti-malarial activity, the charged phosphonate moiety was altered into phosphodiaryl esters.  
  39 
This transformation was chosen as it was expected, and demonstrated, that bioavailabilty would 
be enhanced through the hydrolysis of the phosphodiaryl esters via non-specific plasma esterases 
(Reichenberg et al., 2001).   
 
Unfortunately, no other inhibitors against additional enzymes of the nonmevalonate pathway 
have been reported and due to the short half-life of fosmidomycin and its derivatives there has 
been a diminished impact upon the clinical application of these drugs.  The advantage of 
fosmidomycin and its derivatives is their low toxicity and therefore they may be potential starting 
points from which lead molecules may be designed in order to identify new anti-malarial drugs 
(Zubrzycki and Blatch, 2001).   
 
Zubrzycki and Blatch (2001) have investigated the electrostatic properties of the substrate DOXP 
and the inhibitors FOSM and FR-900098 through Density Functional Theory (DFT) studies.  To 
assess the possible regions of hard and soft nucleophilic and electrophilic attack, analysis of the 
charge distribution as well as highest occupied molecular orbital (HOMO) and lowest unoccupied 
molecular orbital (LUMO) analyses were performed on both the substrate and inhibitor 
molecules.  From the stick conformations of FOSM and FR-900098 it was determined that the 
positive charges were concentrated at the head while in the natural substrate, DOXP, there was a 
negative charge, with the similarity amongst the substrate and inhibitors being the negative 
charges upon the tail groups.  It was concluded that the inhibiting properties of FOSM and FR-
900098 were due to the physical properties of these tail groups.  From the electrostatic analysis 
the nitrogen atom, within FOSM and FR-900098, was found to possess a high electronegativity, 
as well as an increased charge density, with its introduction being directly linked towards the 
inhibitory properties of the molecule.  It was additionally confirmed upon comparison of the 
charge upon the nitrogen atom within FOSM and FR-900098, with the charge upon the carbon at 
position 3 in DOXP.  The nitrogen atoms within the inhibitory molecules FOSM and FR-900098 
were reported as having the charges –0.149 and 0.195 respectively, whereas the carbon atom 
within DOXP was found to be almost neutral with the charge –0.011 (Zubrzycki and Blatch, 
2001).   
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From the DFT studies of Zubrzycki and Blatch, (2001) it was confirmed that the introduction of 
the nitrogen atom, carrying a significant negative charge as compared to the carbon atom within 
DOXP, influences the molecular environment of the active residues in the active centre of the 
enzyme.  This charge was reported to possibly alter the three dimensional microstructure of the 
active pocket of the enzyme and competitively bind to the active site.   
 
1.11 Hypothesis Statement: 
 
DOXP reductoisomerase is a potential target for inhibition within the mevalonate-
independent pathway and serves as a potential site for novel drug design against malaria. 
 
1.12 Approach 
 
Within this investigation E. coli and P. falciparum DOXP reductosiomerase will be 
biochemically characterized as a potential target for inhibition.  In particular, this will involve the 
biochemical characterization of the active site (in specific the catalytic hatch region) of E. coli 
and P. falciparum DOXP reductoisomerase by rational amino acid analysis.  Rational drug 
design and in silico docking strategies will be used to identify novel DOXP reductoisomerase 
inhibitors for organic synthesis and inhibitor assays.   
 
1.13 Aims and Objectives 
 
For the biochemical characterization of both E. coli and P. falciparum DOXP reductoisomerase 
the respective recombinant proteins were to be produced as (His)6
 
 fusion proteins within the 
heterologous expression system E. coli and purified to homogeneity, such that the protein can be 
utilized in further functional and inhibitor analysis, via nickel-chelate affinity chromatography.   
Homology modeling of the P. falciparum DOXP reductoisomerase, using the E. coli DOXP 
reductoisomerase structure as a template, were performed to generate a model of the 3-D 
predicted structure for P. falciparum DOXP reductoisomerase.  From this potentially critical 
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amino acids that are involved in the catalytic mechanism of the P. falciparum DOXP 
reductoisomerase activity were identified. 
 
Protein engineering studies upon E. coli and P. falciparum DOXP reductoisomerase proteins 
were then performed to assess their involvement in DOXP reductoisomerase activity.  Since there 
is only ~56.5 % amino acid variation between the E. coli and P. falciparum DOXP 
reductoisomerase amino acid sequences, the E. coli DOXP reductoisomerase could be used as a 
model system on which functional predictions could be made and tested that should reflect the 
parasitic system as well.  Ultimately, all functional predictions should be verified through 
analysis with the recombinant P. falciparum DOXP reductoisomerase protein. 
 
Optimization of the NADPH DOXP reductoisomerase coupled enzyme assay for the 
determination of DOXP reductoisomerase activity was performed to allow for the biochemical 
characterization of the E. coli and P. falciparum DOXP reductoisomerase proteins and their 
derivatives.   
 
For the identification of novel DOXP reductoisomerase inhibitors a rational drug design approach 
utilizing the natural substrate (DOXP) and the inhibitors fosmidomycin and FR900098 as lead 
molecules were performed.  Ligand docking methods, with the lead compounds and novel drugs, 
allowed for the analysis of potential inhibitors and their identification for organic synthesis.  The 
synthesized drugs were to be assessed for their inhibitory affect in vitro using the NADPH DOXP 
reductoisomerase coupled enzyme assay with the purified recombinant DOXP reductoisomerase 
protein. 
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CHAPTER 2: HETEROLOGOUS PROTEIN PRODUCTION, PURIFICATION 
AND CHARACTERIZATION OF DOXP REDUCTOISOMERASE  
 
  43 
2 HETEROLOGOUS PROTEIN PRODUCTION AND PURIFICATION OF 
DOXP REDUCTOISOMERASE 
2.1 Introduction 
A major requirement of biochemical research is to purify large quantities of pure protein for 
further analysis and research.  The production of proteins from their natural source often does not 
fulfill these requirements as well as such cases often being problematic due to scarcity or 
pathogenicity.  The production of proteins in recombinant expression systems has therefore 
become an established field in both biochemical and biotechnological research.  Typical 
expression systems utilize the protein production machinery of well-characterized organisms 
such as Saccharomyces cerevisiae, E. coli and Baculovirus infected insect cells (Higgins and 
Hames, 1999).   
 
2.1.1 Heterologous Production of Recombinant Proteins 
 
E. coli specifically has often been the host system of choice to many researchers due to its 
relatively simple genetics and rapid growth rate.  Considerable genetic and biochemical 
knowledge has accumulated on E. coli making it a desirable host for the production of large 
quantities of heterologous proteins and as a consequence many E. coli host systems for direct 
expression, fusion protein expression, and secretion have been developed and optimized.  Fusion 
protein strategies ensure favourable translation initiation and avoid instability problems regarding 
small peptides.  Within this strategy the fusion partner encodes an affinity tag to facilitate 
purification.  The coding region of interest is introduced into an expression vector 3’ to a 
sequence encoding for the amino terminus or whole length of a highly expressed protein, referred 
to as a carrier protein (Studier et al., 1990).  Within this approach two separate concepts are 
addressed, the carrier protein facilitates solubility and high-level expression whereas the affinity 
tag allows for purification. 
 
However, there are several problems in expressing proteins of eukaryotic origin in prokaryotic 
host expression systems.  One such disadvantage in utilizing E. coli to heterologously over-
express proteins is that the proteins are often expressed as insoluble aggregated folding 
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intermediates, known as “inclusion bodies”.  Several techniques are employed to overcome such 
difficulties in protein folding.  Aggregation can often be prevented by altering the growth 
parameters such as lowering the growth temperature, thus decreasing the rate of transcription and 
translation resulting in higher levels of native recombinant protein (Lilie et al., 1998; Schein and 
Noteborn, 1988).  In addition, one can also recover an active protein expressed within inclusion 
bodies by initially solubilizing the ‘insoluble’ protein using denaturants such as urea and 
guanidine hydrochloride and then exposing the solubilized protein to refolding strategies.  
However, the level of recombinant protein obtained in such cases is often low and hampered by 
the optimization of the refolding conditions to that specific target protein. 
 
Another emerging technique for increasing heterologous protein production in the native form 
has been to co-express molecular chaperones, which aid in protein folding.  This often requires 
several experiments to match the target protein to its specific molecular chaperone (Weickert et 
al., 1996). 
 
Codon usage is a further difficulty that can be encountered when utilizing E. coli as the host 
expression system.  The problem arises due to the protein coding region containing rare codons 
that are not common in the host expression system.  In such cases the translation product is often 
truncated and the resulting protein unstable.  Such expression problems can be combated by 
altering growth conditions of the host cell to lower transcription levels prior to induction of the 
protein of interest or “codon optimizing” the gene of interest to that of the host (Kurland and 
Gallant, 1996).   
 
Bacillus subtilis, a gram-positive bacteria, is another bacterial expression system that is often 
considered.  This organism, although its cloning and gene characterization are not as well known 
as E. coli, has the advantages of being non-pathogenic, lacks endotoxin production, and secretes 
the protein into the surrounding medium (Madigan et al., 1997).  The B. subtilis system is utilized 
in the pharmaceutical production of hormones such as insulin and human growth hormone.  This 
system is suited to industry due to protein yields being maintained after scale-up, however the 
system does have limitations due to plasmid instability within B. subtilis. 
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An additional downfall when using E. coli as a host expression system is the lack of enzymes 
involved in post-translational modifications, which can often affect the recombinant proteins 
function.  S. cerevisiae, Schizosaccaromyces pombe, Pichia pastoris, and Pichia angusta are 
yeast strains often used protein expression systems, offer an alternative system allowing for 
sufficient expression levels along with most eukaryotic post-translational modifications (Bradley, 
1990).  Proteins that were insoluble in the bacterial system are often soluble in this system due to 
the protein processing within yeast being more efficient and intricate.  Another advantage when 
using yeast expression systems is that proteins can be secreted into the growth media upon 
induction.  This feature is often engineered to prevent toxicity problems and to simplify protein 
purification (Bradley, 1990).  However, one severe drawback in yeast expression systems is the 
reduction of recombinant protein levels due to the presence of active proteases, however this is 
often immaterial when utilizing yeast strains that have had protease-encoding genes eliminated.  
Additionally, when utilizing the His-tag system for protein purification (discussed in section 
2.1.3) yeast cells may pose an additional problem due to their ability to acidify the culture media. 
This results in compounds being present that may interfere with the binding of the His-tag to the 
nickel charged resin, thus interfering with protein purification.   
 
In addition to yeast and bacterial expression systems Baculovirus vectors are useful in the 
expression of recombinant proteins in insect cells.  Recombinant proteins in this system are 
expressed with the majority of mammalian post-translational modifications and can either be 
produced within the insect cell itself or secreted into the media.  This system does have the 
limitation of being rather difficult to set-up and scale-up and that insect cells have a far slower 
growth rate than bacteria and yeast cells (Madigan et al., 1997). 
 
2.1.2 Heterologous Production Problems Encountered for P. falciparum Recombinant 
Proteins 
 
Malarial proteins present protein production difficulties especially when producing large 
quantities necessary for biochemical and biophysical analysis.  Expression within E. coli is 
hampered due to the codon bias with P. falciparum having an AT rich genome.  Codons common 
within parasitic protein coding regions are rare within E. coli and thus protein synthesis is 
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hampered due to translational problems.  Strategies to codon optimise parasitic genes to suite the 
codon usage of E. coli are often costly and lengthy.  Baca and Hol, (2000) have described the 
successful use of the RIG plasmid to overcome translational limitations.  This plasmid is 
designed to encode the genes for tRNA’s that are present at low levels in E. coli, i.e. tRNA`s that 
recognise rare codons for Arg, Ile, and Gly common in parasitic genes.   
 
Parasitic proteins are often toxic to E. coli even with the RIG plasmid present.  This is due to the 
inducible promoter present within the expression vector allowing for the basal transcription of the 
protein to occur prior to induction, resulting in hampered growth of the host expression system.  
Cinquin et al. (2001) have developed a hybrid plasmid, which allows for the expression of toxic 
proteins on an expression vector containing a T7 inducible promoter within E. coli.  The hybrid 
plasmid was constructed from the RIG plasmid and the pLysS plasmid, which allows for low 
levels of T7 lysozyme, a potent natural T7 RNA polymerase inhibitor, to be expressed.  This 
allows for the control of levels of transcription allowing toxic proteins to be accommodated 
within the cell.  Thus the hybrid plasmid contains the properties of both the pLysS and RIG 
plasmids allowing for toxicity and codon bias to be overcome when expressing toxic parasitic 
proteins. 
 
Overall, the expression and subsequent purification of recombinant proteins facilitates the 
production and biochemical characterization of almost any protein.  There are many expression 
systems that have been developed for protein production in E. coli each with their own 
advantages and disadvantages.  Within this research the application of fusion proteins and metal-
chelate affinity chromatography was utilized and will be discussed in detail.  Several methods for 
protein purification are reviewed within Sheibani (1999). 
 
2.1.3 Metal Chelate Affinity Chromatography 
 
Affinity-based techniques for the isolation and purification of proteins have become a common 
practice in protein biochemistry.  Affinity chromatography is the only technique available 
whereby a biomolecule may be purified due to its biological function or individual chemical 
structure.  It allows for the rapid separation of proteins, based on reversible interactions between 
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the protein and a specific ligand, which is attached to a chromatographic matrix.  This technique 
has the advantages of selectivity, thus high resolution, and high capacity (Porath et al., 1975; 
Chaga, 2001).   
 
The coupling of affinity chromatography techniques with the development of epitope tagging of 
recombinant proteins has allowed for rapid affinity-based purification methodology, such as 
immunoprecipitation.  Such techniques have aided studies involving protein production, 
expression, purification and modification and interactions in various biological systems. 
 
The first successful description of the purification of recombinant proteins via a chromatographic 
technique was by Porath et al. (1975).  This study combined Metal-Chelate Affinity 
Chromatography (MCAC) in the purification of human serum proteins.  The basis of MCAC 
involves the binding of metal ions to solid chromatographic matrices, which in turn interact and 
bind to the exposed imidazole and thiol groups of proteins.  The exploitation of this technique has 
been to use tagging systems wherein the protein is tagged, in this case with a poly histidine tag, 
allowing the purification of the tagged protein on a nickel charged column.  The advantage to the 
poly histidine tag system is that, with sufficient levels of protein, one-step purification is 
possible.  In addition to this it is poorly immunogenic, and at a pH of 8.0 the tag is small as well 
as uncharged ((His)6–0.84 kDa vs.Glutathione-S-transferase GST–26 kDa).  These characteristics 
make it unlikely that the tag will interfere with secretion, compartmentalization, or folding of the 
protein nor will it affect the structure or function of the purified protein.  Unfortunately, the size 
of the tag bears its own problems as it can often be ‘buried’ as a consequence of protein folding, 
particularly if it is situated at the C-terminus of the protein (Sheibani, 1999).  Sometimes the 
(His)6
 
 tag itself can interfere with protein solubility and a range of histidine tags are now 
available that are still applicable for protein purification yet confer better solubility characteristics 
to the expressed protein, these include the 6xHN and HAT tags (www.clontech.com). 
The high level production of (His)6 DOXP reductoisomerse was carried out in E. coli XL1 Blue 
using the QIAexpress pQE vector system.  This system is based on the T5 promotor 
transcription-translation system.  The pQE vector plasmids belong to the PDS family of plasmids 
described by Bujard et al. (1987) and were derived from plasmids pDS56/RBSII and 
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PDS781/RBSII-DHFRS (Stüber et al., 1990).  The E. coli and P. falciparum DOXP 
reductoisomerase proteins were purified for use in functional and biochemical characterization. 
 
2.2 Aim 
 
To heterologously over-produce, purify and biochemically characterize E. coli and P. falciparum 
DOXP reductoisomerase. 
 
2.3 Experimental Procedures 
 
2.3.1 Reagents and Chemicals 
 
All reagents and chemicals utilized in the expression and purification of P. falciparum and E. coli 
DOXP reductoisomerase are described in the Appendices (Chapter 6; section 6.1). 
 
2.3.2 Heterologous Protein Production and Purification of DOXP Reductoisomerase 
 
2.3.2.1 Constructs and Host Expression Systems for the Over-Expression and Purification 
of E. coli and P. falciparum DOXP Reductoisomerase 
 
Both plasmid contructs containing the coding regions for P. falciparum and E. coli DOXP 
reductoisomerase were kindly provided by Jomaa Pharmaka GmbH (Germany; pQE9EcDXR and 
pQE31PfDXR).  DOXP reductoisomerase coding sequences were provided within pQE (Qiagen) 
expression constructs incorporating N-terminal (His)6 fusion tags for nickel affinity purification.  
The E. coli DOXP reductoisomerase coding sequence was inserted into the pQE9 vector in frame 
with an N-terminal (His)6 tag.  An ampicillin resistance cassette provides a selectable marker 
(Jomaa et al., 1999).  The malarial parasite P. falciparum has different codon preferences to that 
of the host expression system E. coli and often in such cases codons, which are preferential in P. 
falciparum genes are rare in E. coli genes.  In order to combat this problem the P. falciparum 
DOXP reductoisomerase coding sequence was optimized to the preferential codon usage of E. 
coli.  This coding sequence was then inserted within pQE31 (Jomaa et al., 1999).  The genotype 
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of the host E. coli cells utilized for the expression of the pQE expression vector constructs was E. 
coli XL1Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac[F′ proAB lacl qZΔM15 Tn10 
(Tetr)]c
 
.  
2.3.2.2 Transformation of Competent Host Cells with Expression Constructs 
 
E. coli XL1 Blue cells were made competent using a derivation of the calcium chloride method 
described by Dagert and Ehrlich, (1979).  50 ml of sterile 2xYT broth (1.6% tryptone, 1% yeast 
extract, 0.5% NaCl) was inoculated with 0.25 ml of an E. coli XL1 Blue overnight culture.  The 
culture was then incubated at 37°C with shaking until the culture reached early log phase with an 
absorbance (A600nm) of between 0.3 and 0.6.  The cells were harvested via centrifugation (5000x 
g for 15 minutes at 4°C) and the cell pellet resuspended in one culture volume (50 ml) of sterile 
ice cold 0.1 M MgCl2.  After incubation on ice for 20 minutes the cells were collected as 
previously described via centrifugation and the cell pellet resuspended in half the culture volume 
(25 ml) of sterile ice cold 0.1 M CaCl2.  The cell suspension was incubated for 2 hours on ice and 
the cells subsequently collected following the same centrifugation procedure.  The resulting cell 
pellet was resuspended in one-tenth the culture volume (5 ml) ice cold 0.1 M CaCl2
 
.  Aliquots of 
competent cells were stored as 200 μl fractions (100 μl cell suspension and 100 μl of sterile ice 
cold 30 % glycerol) at –80°C. 
Aliquots (100 μl) of competent E. coli XL1-Blue cells were transformed with aliquots (~200 ng) 
of double stranded plasmid DNA, pUC18 plasmid DNA (1 μl; 0.1 ng/μl) as a transformation 
positive control and sterile deionized milli-Q water as a no DNA control.  Transformation 
reactions were incubated on ice for 30 minutes after which the reactions were heat pulsed for 2 
minutes at 42˚C, followed by incubation on ice for a further 2 minutes.  Sterile 2xYT Broth (900 
μl), preheated to 42˚ C was supplemented to the transformation reactions followed by incubation 
at 37˚ C with shaking at 225 -250 rpm for 1 hour to allow for the expression of the antibiotic 
resistance gene specific to the plasmid construct being transformed.  All reactions, excluding 
pUC18, were micro centrifuged (12 000x g) for 1 minute and 800 μl of the supernatant removed 
from each reaction, and the cell pellet resuspended in the remaining supernatant (100 μl).  All 
transformation reactions were spread plated onto 2xYT broth agar plates containing 1.5 % agar 
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and 0.1 mg/ml ampicillin, except for pUC18.  pUC18 (5 μl) was plated onto 5 % MacConkey 
agar plates (1 % Lactose) containing 0.1 mg/ml ampicillin.  Plates were inverted and incubated at 
37˚C for >16 hours.  The efficiency of transformation was reflected through the number of 
colony forming units obtained from the pUC18 transformation reaction, and the water 
transformation control ensured sterility.  Transformants, colonies containing the plasmid 
construct, were then picked and streaked onto 2xYT broth agar plates containing 0.1 mg/ml 
ampicillin and analyzed to confirm the presence of the plasmid DNA. 
 
2.3.2.3 Isolation of Plasmid DNA from Transformants for Confirmation of Plasmid 
Identity via Diagnostic Restriction Enzyme Analysis 
 
E. coli XL1Blue transformants for each putative plasmid were incubated in sterile 2xYT broth (5 
ml) containing 0.1 mg/ml ampicillin at 37˚C overnight with shaking at 225 -250 rpm.  Cells were 
collected via was centrifugation at 12 000x g for 1 minute and preparation of purified plasmid 
DNA was performed using either the High Pure Plasmid Isolation Kit (Roche) or the QIAprep 
Spin Miniprep Kit (Qiagen).   
 
The High Pure Isolation Kit procedure involved the resuspension of the bacterial cell pellet in 
Suspension Buffer containing RNase (100 μg/ml)(250 μl; 50 mM Tris-HCl, 10 mM EDTA, pH 
8.0, 25˚C).  To the resuspended solution 250 μl of Lysis Buffer (0.2 M NaOH; 1% SDS) was then 
added and the suspension inverted a few times and incubated for 5 minutes at room temperature.  
Chilled Binding Buffer (350 μl; 4 M guanidine hydrochloride; 0.5 M potassium acetate; pH 4.2) 
was added and the tube inverted, followed by incubation on ice for 5 minutes.  The cloudy 
precipitate was collected via centrifugation (12 000x g for 1 minute) and the supernatant 
transferred to a High Pure filter tube reservoir and centrifuged (12 000x g for 1 minute).  The 
flow-through solution was discarded and Wash Buffer II (700 μl; 20 mM NaCl; 2 mM Tris-HCl; 
pH 7.5) added to the upper reservoir and the filter tube centrifuged (12 000x g for 1 minute).  The 
flow-through solution was again discarded and residual wash buffer removed by centrifugation 
(under previous conditions) once more.  The plasmid DNA was eluted into a sterile 1.5 ml 
eppendorf tube with Elution Buffer (100 μl; 10 mM Tris-HCl; pH 8.5) via centrifugation (12 
000x g for 1 minute).   
  51 
 
The QIAprep Spin Miniprep Kit Protocol involved the resuspension of the bacterial cell pellet in 
Buffer P1 containing RNase (100 μg/ml)(250 μl; 50 mM Tris-HCl, 10 mM EDTA, pH 8.0, 25˚ C) 
after which Buffer P2 (250 μl; 200 mM NaOH; 1% SDS) was added and the tube inverted to 
allow for alkaline lysis.  Lysis was followed by the addition of Buffer N3 (350 μl)(buffer 
constituents were not revealed by the manufacturere) and additional inversion of the tube.  The 
resultative cloudy solution was centrifuged (12 000x g for 10 minutes) and the supernatant 
transferred to a QIAprep column and centrifuged for a further minute.  The flow-through was 
discarded and the column washed by adding Buffer PE (750 μl)(buffer constituents were not 
revealed by the manufacturere) and centrifuging for 30-60 seconds.  The resultative flow-through 
was discarded and the plasmid DNA eluted with Buffer EB (50 μl)(buffer constituents were not 
revealed by the manufacturere) into a sterile 1.5 ml eppendorf via centrifugation (12 000x g for 1 
minute).  For sequencing purposes sterile distilled milli-Q water was utilized for elution purposes 
instead of Buffer EB.  Each of the plasmid DNA preparations was then utilized in diagnostic 
restriction enzyme analysis procedures to confirm the presence of the correct plasmid construct. 
 
Restriction Analysis of ~100-500 ng of double stranded plasmid DNA was performed with ~10 
Units of the relevant diagnostic restriction enzyme at the relevant temperature for ~2 hours 
(Amersham; MBI Fermentas; Roche; Promega).  Diagnostic Restriction Enzyme Digests were 
analyzed via agarose gel electrophoresis (AGE).  Agarose gel loading buffer (6x buffer; 30% 
glycerol, 0.25% bromophenol blue) was added to each restriction endonuclease reaction (20 μl) 
and the samples resolved on the required percentage agarose gel containing 0.5 μg/ml ethidium 
bromide in 0.5x TBE Buffer (45 mM Tris, 45 mM borate, 1 mM EDTA, pH 8.3) at 100V for ~1.5 
hours and visualized under ultraviolet (UV) light.  PstI – digested lambda (λ) DNA was resolved 
as a molecular weight marker. 
 
2.3.2.4 Heterologous Production of DOXP Reductoisomerase 
 
Cultures of E. coli [pQE9EcDXR] and E. coli [pQE31PfDXR] were incubated in sterile 2xYT 
broth (25 ml) containing 0.1 mg/ml ampicillin at 37˚C overnight with shaking at 225 -250 rpm.  
Overnight cultures were diluted 1:10 into sterile 2x YT broth (225 ml) containing 0.1 mg/ml 
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ampicillin and incubated at 37˚ C with shaking until the mid -logarithmic stage was reached (A600 
of between 0.6 and 1).  For the production of recombinant protein, cultures were induced with the 
addition of isopropyl-β-D-galactopyranoside (IPTG)(final concentration of 1 mM).  Samples (2 
ml) were taken hourly for a period of 5 hours after induction and overnight: A600 of a 1 ml 
sample was determined and the remainder (1 ml) collected by centrifugation at 12 000x g for 1 
minute.  The cell pellet was resuspended in sterile ice cold Phosphate Buffered Saline (PBS)(137 
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4) to a ratio of 50 μl PBS per 0.5 
A600 
 
unit.  PBS cell suspensions (20 μl) were added to sodium dodecyl sulphate (SDS) 
polyacrylamide gel loading buffer (4 μl of a 5x loading buffer)(62.5 mM Tris-HCl pH 6.8, 10 % 
(v/v) glycerol, 2 % (w/v) sodium dodecyl sulphate (SDS), 5 % (v/v) β-mercaptoethanol, 0.05 % 
(w/v) bromophenol blue) and boiled at 95˚C for 5 minutes for analysis via discontinuous 0.1 % 
SDS  12 % Polyacrylamide Gel Electrophoresis (SDS-PAGE)(12 % acrylamide resolving gel; 4 
% acrylamide stacking gel)(BioRad Minigel Electrophoresis Set) at 200 V for 1 hour (Running 
Buffer: 25 mM Tris-HCl; 250 mM Glycine; pH 8.0; 0.1 % SDS)(Laemmli, 1970).  The gel was 
removed and stained with Coomassie Brilliant Blue stain (0.1 % (w/v) Coomassie Brilliant Blue 
R-250, 40 % (v/v) methanol, 10 % (v/v) glacial acetic acid) for protein visualization, for 1 hour 
with shaking and destained for 3 hours in destain (40 % (v/v) methanol, 10 % (v/v) glacial acetic 
acid).  Gels were dried by equilibrating in 20 % ethanol, 10 % glycerol for at least 30 minutes and 
placing in-between cellophane sheets using the Gel Drying frames supplied by Diversified 
Biotech (Sigma). 
For the solubility analysis cultures of E. coli [pQE9EcDXR] and E. coli [pQE31PfDXR] were 
incubated and harvested as described above.  Cell pellets were resuspended in PBS (5 ml) and 
phenylmethylsulfonylfluoride (PMSF)(100 mM), and aliquoted into 5 x 1 ml fractions in sterile 
eppendorf tubes.  The aliquoted cells were lysed on ice by sonication (60 Amp), for 30 seconds 
pulses to allow for 30 seconds, 60 seconds, 90 seconds, 120 seconds and 150 seconds sonicated 
samples.  The cell debri was removed from the soluble cell extract via centrifugation at 12 000x g 
for 20 minutes at 4˚ C.  Samples (80 μl) of soluble cell extract were added to SDS loading buffer 
(20 μl) for analysis on 0.1 % SDS 12 % PAGE.  The lysed cell pellet was resuspended in PBS (1 
ml) and samples (80 μl) were added to SDS loading buffer (20 μl) for analysis on 0.1 % SDS 
12% PAGE. 
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2.3.2.5 Western Blot Analysis and Chemiluminescence-Based Immunodetection of 6x His-
tagged DOXP Reductoisomerase 
 
The protein samples separated on the SDS-PAGE gel (described in section 2.3.2.4) were 
transferred to a nitrocellulose membrane (Hybond ECL) in chilled transfer buffer (25 mM Tris, 
192 mM glycine, 20 % (v/v) methanol) at 100V for 1 hour utilizing the Biorad Western Transfer 
Apparatus (Towbin et al., 1979).  The transfer was visualized by incubating the membrane in 
Ponceau S stain (0.5 % (w/v) Ponceau S, 1 % (v/v) glacial acetic acid) for 1 minute and rinsing 
with milli-Q water.  The stained membrane was then scanned and rinsed to remove excess 
Ponceau stain and subjected to chemiluminescent immunodetection using either the Boeringer 
Mannheim (BM) Chemiluminescence Western Blotting Kit (Boeringer Mannheim; Germany) or 
the ECL Advance Western Blotting Kit (Amersham Biosciences).  In both cases the 
nitrocellulose membrane was initially washed with Tris-Buffered-Saline (TBS; 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl).  The membrane was then incubated at 4˚C overnight in blocking 
solution (5 % (w/v) non-fat milk powder in TBS) to prevent non-specific binding of the antibody.  
Detection of (His)6 proteins was performed by incubating the membrane with anti-His 
monoclonal mouse antibody (1:5 000 dilution of the antibody within blocking solution) for 1 
hour at room temperature with shaking.  The primary antibody was removed and the membrane 
was washed four times for 20 minutes with TBS-Tween (0.1 % (v/v) Tween-20 in TBS) at room 
temperature with shaking.  At this point either the BM Chemiluminescence Western Blotting Kit 
secondary antibody (anti-mouse IgG-peroxidase labeled [POD]/anti-rabbit IgG-POD) or the ECL 
kit secondary antibody (anti-mouse IgG, peroxidase-linked species-specific whole antibody) was 
diluted 1:10 000 in blocking solution and added to the membrane.  The membrane and secondary 
antibody was then incubated for 2 hours at room temperature with shaking after which the 
antibody was removed and the nitrocellulose membrane washed with TBS-Tween four times for 
20 minutes with shaking at room temperature.  The membrane was incubated with the 
chemiluminescent substrate luminol (BM Chemiluminescence Western Blotting Kit solution A 
(5ml) and solution B (50 μl) or ECL Advance Western Blotting Kit solution A and solution B (in 
a 1:1 ratio) in the dark for 1minute and placed in a HyperFilm Developing Cassette (Agfa, USA) 
and exposed to high performance autoradiography film (Agfa, USA) for various lengths of time 
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(30 seconds – 1 hour) depending on the intensity of the signal emitted due to the oxidation of the 
chemiluminescence substrate by the peroxidase-conjugated secondary antibody used.  The X-ray 
film was developed in developer solution (Agfa, USA) for 1-5 minutes, rinsed in stop solution to 
stop the reaction (2 % glacial acetic acid), and fixed in fixer solution (Agfa, USA), and rinsed in 
water before drying.    
 
2.3.3 Nickel Chelate Affinity Purification of E. coli DOXP Reductoisomerase 
 
2.3.3.1 Preparation of the cleared lysate of E. coli DOXP Reductoisomerase 
 
Cultures of E. coli [pQE9EcDXR] were incubated in sterile 2xYT broth (4 x 25 ml) containing 
0.1 mg/ml ampicillin at 37˚C overnight with shaking at 225 -250 rpm.  Overnight cultures were 
diluted 1:10 into sterile 2x YT broth (225ml) containing 0.1 mg/ml ampicillin and incubated at 
37˚C with shaking until the mid-logarithmic stage was reached (A600
 
 of between 0.6 and 1).  For 
the production of recombinant protein, cultures were induced with the addition of IPTG (final 
concentration of 1 mM).  After 4 hours of recombinant protein induction, the cells were harvested 
via centrifugation (5 000x g; 15 minutes; 4˚ C).  The cell pellet was resuspended in Native Lysis 
Buffer (10 ml per litre culture volume)(20 mM Tris-HCl; 300 mM NaCl; 10 mM Imidazole; pH 
8.0; 4˚ C) and Phenylmethylsulfonyl  fluoride (PMSF)(final concentration of 1 mM) and stored 
overnight at –80˚C.  Cell lysis was achieved by adding the enzyme lysozyme (100μg/ml) for ~2 
hours on ice and sonication for a single 30 second pulse at 4˚C.  The cell debris was removed via 
centrifugation (12 000x g; 25 min; 4˚C) and the lysate containing soluble protein (supernatant) 
utilized in native batch purification via nickel chelate affinity chromatography.   
2.3.3.2 Native Batch Nickel Purification of E. coli DOXP Reductoisomerase 
 
The cleared lysate obtained was added to nickel charged sepharose resin (Pharmacia 
Biotech)(500 μl) and agitated gently overnight at 4˚C.  The resin was collected via centrifugation 
(4 000x g; 5 minutes; 4˚C) and washed, with gentle agitation at 4˚C, three times with Nati ve 
Wash Buffer (5 ml)(20 mM Tris-HCl; 300 mM NaCl; 100 mM Imidazole; pH 8.0; 4˚C).  The 
(His)6 protein was then eluted from the beads using Native Elution Buffer (20 mM Tris-HCl; 300 
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mM NaCl; 1 M Imidazole; pH 8.0; 4˚C) in 4 times the bead volume.  The res in was collected 
between each wash and elution via centrifugation at 4 000x g; 5 minutes; 4˚C and 12 000x g; 1 
minute, 4˚C respectively.  The protein purification profile was monitored by discontinuous SDS-
PAGE (outlined in section 2.3.2.4) of the fractions collected throughout the purification 
procedure.  The eluted protein volume was then buffer exchanged into 100 mM Tris-HCl (pH 
7.5) via size exclusion/gel filtration chromatography at 4˚ C to remove imidazole from the protein 
fraction.  This procedure involved subjecting the pooled eluates to a buffer equilibrated Sephadex 
G-25 (Amersham Biosciences) column (length 10 cm; width 1 cm) and eluted using 100 mM 
Tris-HCl (pH 7.5) to allow for buffer exchange.  Protein and imidazole elution from the column 
was monitored at 280nm (100 μl)(using a flat-bottomed 96-well microtitre UV plate; Corning 
Costar) and via Bradford’s Assay (Bradford, 1976).  A sample/standard (10 μl) was incubated 
with Bradford’s Reagent (200 μl) at room temperature for 5 minutes and the absorbance 
measured at 595 nm using a Powerwave Microtitre Plate Reader (Bio-Tek Instruments).  A 
standard curve of protein concentration (0 – 250 μg/ml) was determined using a standard protein, 
Bovine Serum Albumin (BSA)(Sigma) and was used to monitor elution of protein from the 
column.  The protein fractions eluted from the column were pooled and concentrated on 
Polyethylene glycol 20 000 (PEG) in dialysis tubing at 4˚C.  The protein concentration was then 
determined using the Bradford’s Assay described above and the protein stored as a concentrated 
solution at –80˚C in aliquots.   
 
2.3.3.3  The in vitro Analysis of E. coli DOXP Reductoisomerase Activity 
 
The substrate DOXP was a kind gift from Jomaa Pharmaka GmbH, Germany and the DOXP 
reductoisomerase assay was adapted from Takahashi et al. (1998).  The assay mixture consisted 
of 100 mM Tris-HCl (pH 7.5), 1 mM MnCl2; freshly made 0.3 mM NADPH (Sigma) and 0.3 
mM of DOXP substrate.  The assay was initiated by addition of 20 μl of purified enzyme (8.73 
μM, final concentration in assay 0.873 μM) to the complete assay mixture (final volume 200 μl).  
The oxidation of NADPH was monitored at 340 nm at 37˚C for 5 minutes using a Microtitre 
Plate Reader and a flat-bottomed 96-well microtitre UV plate.  The controls utilized included a 
no DOXP (i.e. no substrate therefore no oxidation of NADPH should be monitored), no NADPH 
(i.e. no cofactor therefore no A340 reading), no enzyme (i.e. no oxidation of NADPH at 340 nm), 
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boiled enzyme (i.e. no oxidation of NADPH should occur), and no DOXP and no NADPH (i.e. 
no DOXP present and no cofactor present therefore no A340nm reading).  This allowed for the 
correction of any basal level of activity to be accounted for as well as validating that any 
oxidation of NADPH monitored at 340 nm was due to the active soluble enzyme within the 
assay.  The extinction coefficient (ε) for NADPH at 340 nm is 6.3 x 103
 
 L/mol/cm.  The 
pathlength for the microtitre plate reader was determined as 0.52 cm.   
2.3.4 Nickel Chelate Affinity Purification of P. falciparum DOXP Reductoisomerase 
 
2.3.4.1 Preparation of the cleared lysate of P. falciparum DOXP Reductoisomerase 
 
Cultures of P. falciparum [pQE31PfDXR] were incubated, as stipulated for the production of E. 
coli [pQE9EcDXR], until the mid-logarithmic stage was reached (A600
 
 of between 0.6 and 1).  
For the production of recombinant protein, cultures were induced with the addition of IPTG (final 
concentration of 1 mM).  After 4 hours of recombinant protein induction, the cells were harvested 
via centrifugation (5 000x g; 15 minutes; 4˚C).  Several methods were utilized during the 
optimization of the purification protocol for P. falciparum DOXP reductoisomerase.  In each case 
the resultant cell pellet was resuspendend in the appropriate Lysis Buffer (detailed in the 
purification protocols below)(10 ml per litre culture volume) and PMSF (final concentration of 1 
mM).  The resuspended pellet was then stored overnight at –80˚C after which lysis was achieved 
through the addition of lysozyme and sonication as for E. coli DOXP reductoisomerase cleared 
lysate preparation.  The cell debris was removed via centrifugation (12 000x g; 25 min; 4˚ C) and 
the resultant cleared lysate (supernatant), containing soluble protein, utilized in the batch 
purification procedures outlined below involving nickel affinity chromatographic techniques.   
2.3.4.2 Denaturing Lysis, Native Wash and Elution Purification of P. falciparum DOXP 
Reductoisomerase 
 
During the preparation of the cleared lysate for P. falciparum DOXP reductoisomerase, the cell 
pellet was resuspended within Denaturing Lysis Buffer (8 M Urea; 20 mM Tris-HCl; 300 mM 
NaCl; 10 mM Imidazole; pH 8.0; 4˚C).  The cleared lysate obtained from the procedure outlined 
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above was then applied to charged nickel sepharose beads (500 μl per litre culture volume) and 
allowed to agitate gently overnight at 4˚C.  The beads were then collected via centrifugation        
(4 000x g; 5 minutes; 4˚C) and washed four times successively with Native Wash Buffer I (20 
mM Tris-HCl; 300 mM NaCl; 4 mM Imidazole; pH 8.0; 4˚C) and Native Wash Buffer II (20 mM 
Tris-HCl; 300 mM NaCl; 50 mM Imidazole; pH 8.0; 4˚C) and collected between each wash step 
as described.  The elution of the (His)6
2.3.2.4
 recombinant protein was achieved using Native Elution 
Buffer (20 mM Tris-HCl; 300 mM NaCl; 1 M Imidazole; pH 8.0; 4˚C).  Collection of the beads 
during elution was via centrifugation (12 000x g; 1 minute; 4˚C).  The protein purification profile 
was monitored via discontinuous SDS-PAGE and protein concentration determined via the 
Bradford Assay (as described in section  and 2.3.3.2). 
 
2.4 Results and Discussion 
 
2.4.1 Heterologous Production and Purification of E. coli DOXP Reductoisomerase 
 
2.4.1.1 Confirmation of the Identity of pQE9EcDXR Plasmid 
 
Previous expression of the recombinant E. coli DOXP reductoisomerase utilizing this plasmid 
has been demonstrated by Jomaa et al. (1999) for inhibitor analysis.  Within this work we were 
interested in producing the recombinant protein as a (His)6
Figure 2.1
 protein from this construct for use in 
biochemical characterization of the enzymes function as well as inhibitor analysis.  Additionally, 
due to the sequence similarity of the E. coli DOXP reductoisomerase protein to its malarial 
homologue, the E. coli protein could allow for a model system for initial inhibitor assay 
screening and biochemical characterization.  This was especially the case due to the problems 
experienced in the purification of the P. falciparum DOXP reductoisomerase in comparison to 
the high levels of pure native protein obtained in the E. coli DOXP reductoisomerase purification.  
In order to confirm the identity of the plasmid construct a series of diagnostic restriction enzyme 
digests were used to confirm the plasmid identity ( ).  The E. coli DOXP 
reductoisomerase coding sequence was inserted into the pQE9 expression vector at the BamHI 
and HindIII sites and upon restriction enzyme digestion with these enzymes the coding sequence 
was released yielding two DNA fragments of 3419 bp and 1203 bp (Figure 2.1; lane 5).  A partial 
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digest of 4622 bp representative of linearized plasmid DNA is also present (Figure 2.1; lane 5).  
Digestion with either of these enzymes individually resulted in the linearization of the plasmid 
construct and a single DNA fragment of 4.622 kbp (Figure 2.1; lanes 3 and 4).  Within lane 4 
partial digestion occurred and uncut conformations of plasmid DNA are seen at ~12 kbp.  
Additionally, to ensure the correct coding sequence for both expression vector as well as 
recombinant E. coli DOXP reductoisomerase protein within the construct, restriction with the 
enzyme NcoI was performed.  This enzyme has single cut sites within both vector and the protein 
coding sequence releasing two DNA fragments of 3599 bp and 1023 bp (Figure 2.1; lane 6). 
 
 
Figure 2.1: Confirmation of the pQE9EcDXR plasmid 
(A) Plasmid Map of pQE9EcDXR showing the diagnostic restriction enzyme sites.  The E. coli DOXP 
reductoisomerase coding region is shown in pink and the ampicillin resistance marker in blue.  (B) 0.8 % Agarose 
gel showing confirmation of the pQE9EcPfDXR plasmid by diagnostic restriction enzyme analysis.  Lane 1 – 
Lambda DNA restricted with PstI as a molecular marker in base pairs (bp); Lane 2 – Uncut pQE9EcPfDXR; Lane 3 
– Linearized plasmid from BamHI restriction resulting in a fragment of 4622 bp; Lane 4 – Linearized plasmid from 
restriction with HindIII resulting in a fragment of 4622 bp and partial digest with an uncut fragment at ~12000 bp; 
Lane 5 – BamHI and HindIII double digest resulting in release of the coding region with two fragments of 34199 bp 
and 1203 bp. A partial digest fragment of 4622 bp is also present; Lane 6 – NcoI restricted pQE9EcDXR resulting in 
two fragments of 3599 bp and 1023 bp. 
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2.4.1.2 Over-Production and Purification of E. coli DOXP reductoisomerase 
 
The over-production of (His)6
Figure 2.2
- E. coli DOXP reductoisomerase in E. coli XL1 Blue 
[pQE9EcDXR] is depicted within (A).  Whole cells were monitored at hourly intervals 
after the induction of the E. coli DOXP reductoisomerase protein with IPTG (1 mM) and the 
protein induction profile analyzed via discontinuous SDS-PAGE and Coomassie Blue Staining.  
The production of the recombinant protein reached its optimal level 4-6 hours after induction 
with IPTG and did not degrade with overnight induction (Figure 2.2(A); lanes 6-8/9).  The 
increase in intensity of the protein fragment of ~ 46 kDa is representative of the (His)6
Figure 2.2
-DXR 
subunit molecular mass.  Low levels of the recombinant protein were present within un-induced 
whole cells ( (A); lane 2) most likely due to basal levels of transcription occurring.  
Solubility analysis of the inducible E. coli DOXP reductoisomerase was performed to determine 
protein stability and to guide protein purification set-up.  A protein corresponding to the subunit 
molecular mass of (His)6
Figure 2.2
-EcDXR was obtained within the soluble fractions after sonication and 
centrifugation of IPTG induced E. coli XL1 Blue[pQE9EcDXR] ( (B).  The soluble 
recombinant protein reaches a maximal level after a 30 second sonication pulse (Figure 2.2(B); 
lane 2).  The presence of the recombinant protein within the insoluble fractions most likely 
represents protein derived from whole unlysed cells that pelleted with the insoluble fraction 
during centrifugation.  Recombinant E. coli DOXP reductoisomerase is present within all 
insoluble fractions due to high levels of over-production and pelleted whole cells during 
centrifugation. 
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Figure 2.2: Heterologous over-production of soluble E. coli DOXP reductoisomerase 
(A) Whole cell extracts of pre-induction and IPTG induced logarithmic phase E. coli XL1Blue[pQE9EcDXR] cells 
were analysed by SDS-PAGE.  Biorad Broad Range SDS Molecular Weight Marker (kDa) was separated in lane 1.  
Whole cell samples were removed before induction (lane 2), hourly after addition of 1 mM IPTG (lanes 3-8) and 
overnight (lane 9).  Over-production of E. coli DOXP reductoisomerase (~46 kDa) is indicated (arrow).  (B) 
Fractionation study of soluble E. coli DOXP reductoisomerase.  Biorad Broad Range SDS Molecular Weight Marker 
(kDa) was separated in lane 1.  Soluble fractions were obtained after sonication, for 30 seconds, 60 seconds, 90 
seconds, 120 seconds and 150 seconds, and centrifugation (lanes 2, 4, 6 and 8 respectively).  A protein of molecular 
size ~46 kDa represents soluble (His)6
 
-EcDXR (indicated with an arrow).  Insoluble fractions containing cell debri 
were separated within lanes 3, 5, 7 and 9.   
From solubility analysis, the protein was regarded both stable and soluble and was successfully 
purified using native batch nickel-chelate affinity chromatography (Figure 2.3(A)).  
Nitrilotriacetic acid (NTA; Qiagen) interacts with four of the six binding sites in the coordination 
sphere of the nickel ion leaving two sites free to bind to the (His)6 protein.  The cleared lysate 
was exposed to the resin overnight at 4˚ C to allow for maximal binding.  The resi n was saturated 
with (His)6
Figure 2.3
-EcDXR representative of the high levels of unbound protein within the flow through 
fraction ( (A); lane 7).  The DOXP reductoisomerase protein was eluted competitively 
in the presence of 1 M imidazole (Figure 2.3(A); lane 11-13) with >95 % purity, in sufficient 
levels for biological assays (~3 mg per litre of culture), however it was also present within the 
wash steps (Figure 2.3(A); lane 8-10).  This is most likely due to weak binding of the 
recombinant protein to the resin due to the effects of over-saturating the resin.  Furthermore, there 
are low levels of DOXP reductoisomerase still bound to the column after elution, possibly as a 
result of non-specific interactions as a consequence of protein misfolding (Figure 2.3(A); lane 
14).  The pooled eluates were buffer exchanged, concentrated and stored in aliquots at -80˚C.  
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Figure 2.3 (B) represents the western analysis and chemiluminescence-based immunodetection of 
the purified recombinant (His)6
 
-EcDXR protein.  The high molecular mass band detected within 
lane 4 possibly represents aggregates that were recalcitrant to the SDS/heat treatment for SDS-
PAGE analysis. 
 
Figure 2.3: Purification of (His)6
(A) Purification of (His)
-EcDXR by nickel affinity chromatography 
6-EcDXR by nickel affinity chromatography was analysed after each purification step using 
SDS-PAGE.  The Biorad Broad Range Molecular Weight Marker (kDa) was separated in lane 1.  The purification 
samples included un-induced whole cell extract (lane 2), induced whole cell extract (lane 3), whole cell lysate (lane 
4), insoluble fraction (lane 5), soluble fraction (lane 6), flow-through (lane 7), native wash (lanes 8-10), native 
elution (lanes 11-13) and Ni-affinity sepharose beads (lane 14).  The EcDXR was purified successfully and is 
indicated with an arrow.  (B) SDS-PAGE and Detection of (His)6-EcDXR by Western Analysis and 
chemiluminescence-based immunodetection.  Biorad Markers are separated within Lane 1.  Lane 2 and 3 represent a 
66 kDa His-tagged protein positive control and E. coli XL1Blue whole cell extract as a negative control respectively.  
The purification samples for the soluble (lane 4), insoluble (lane 5), wash (lane 6-7) and elution fractions (lane 8-10) 
are detected by the anti-His-antibody within lanes 4 – 10 indicative of the (His)6
 
-EcDXR being present within these 
samples (indicated with an arrow). 
2.4.1.3 The in vitro Analysis of E. coli DOXP Reductoisomerase Activity 
 
The kinetic parameters for E. coli DOXP reductoisomerase were determined using the NADPH 
coupled enzyme assay.  A plot of activity (μmol/min) versus enzyme concentration (μM) 
indicated that an enzyme concentration of 8.73 μM was satisfactory to ensure linearity (data not 
shown).  The Michaelis-Menten and Lineweaver-Burk plots for E. coli DOXP reductoisomerase 
are shown in Figure 2.4.  The reciprocal Lineweaver-Burk (Figure 2.4(B)) plot exhibited Km and 
Vmax values of 282 μM and 0.74 μmol/min/mg respectively. A specific activity of 1.77 
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μmol/min/mg ± 0.34 was obtained.  The analyses for the determination of the kinetic parameters 
Km and Vmax were determined using protein with compromised activity and therefore resulted in 
a lower Vmax
 
 value calculated than expected.  A single independent purification of EcDXR was 
used to assay for DOXP activity in duplicate.  The Michaelis-Menten and Lineweaver-Burk plots 
were generated using SigmaPlot 8.0 with each data point representing the average of 2 individual 
experiments on the same purified protein.  Kinetic studies were limited due to the substrate not 
being commercially available and thus a limiting factor.   
 
Figure 2.4: Michaelis-Menten and Lineweaver-Burk Plots for the DOXP reductoisomerase 
activity of EcDXR 
The NADPH DOXP reductoisomerase coupled enzyme assay was monitored by the oxidation of NADPH at 340nm 
and the kinetic parameters were determined using a final enzyme concentration of 0.873 μM and a substrate 
concentration range of 0 – 300 μM.  (A) The Michaelis-Menten plot for E. coli DOXP reductoisomerase (B) The 
reciprocal Lineweaver-Burk plot.  Kinetic parameters, Km of 282 μM and Vmax
 
 of 0.74 μmol/min/mg, were 
calculated.  The Michaelis-Menten and Lineweaver-Burk plots were generated using SigmaPlot 8.0 with each data 
point representing the average of 2 individual experiments on the same purified protein. 
2.4.2 Heterologous Production and Purification of P. falciparum DOXP Reductoisomerase 
 
2.4.2.1 Confirmation of the Identity of pQE31PfDXR Plasmid 
 
Work involving the expression of the P. falciparum DOXP reductoisomerase protein has been 
demonstrated in the preparation of purified parasitic DOXP reductoisomerase for inhibitor 
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analyses, in particular the purification from the plasmid pQE31PfDXR has been reported by 
Jomaa et al. (1999).  Within our work we were interested not only in the inhibitor analysis of the 
parasitic protein in comparison to the E. coli protein, but also the biochemical characterization of 
the parasitic protein as well as the identification of subtle sequence differences between the 
parasitic DOXP reductoisomerase and its homologues in other organisms that could further 
elucidate any unique functions of the parasitic protein.  The P. falciparum coding sequence for 
DOXP reductoisomerase has been codon-optimized for the expression within the E. coli 
expression system and inserted into the pQE31 expression vector Jomaa et al. (1999).  This 
allowed for the production of the (His)6
Figure 2.5
 tagged protein for affinity purification via nickel chelate 
affinity chromatography.  In order to confirm the identity of the pQE31PfDXR plasmid a series 
of restriction enzyme digests were performed ( (B)).  Restriction with BamHI resulted 
in two fragments of 3436 bp and 1279 bp (Figure 2.5; lane 3) due to the release of a fragment 
containing the coding sequence of P. falciparum DOXP reductoisomerase.  To confirm the 
coding sequence of the recombinant protein, restriction with PstI was performed as it has two 
restriction sites within the coding sequence and therefore produces two DNA fragments of 4067 
bp and 648 bp (Figure 2.5; lane 4).  Additionally, the vector sequence was also confirmed 
through SacI and NdeI double restriction digestion yielding two fragments of 2490 bp and 2225 
bp (Figure 2.5; lane 7).  Restriction with either of these enzymes individually resulted in 
linearized pQE31PfDXR of size 4.715 kbp (Figure 2.5; lanes 5 and 6).   
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Figure 2.5: Confirmation of the pQE31PfDXR plasmid 
(A) Plasmid map of pQE31PfDXR showing the diagnostic restriction enzyme sites.  The P. falciparum DOXP 
reductoisomerase coding region is shown in purple and the ampicillin resistance marker in blue.  (B) 0.8 % Agarose 
gel showing confirmation of the pQE31PfDXR plasmid by diagnostic restriction enzyme analysis.  Lane 1 – Lambda 
DNA restricted with PstI as a molecular marker in base pairs (bp); Lane 2 – Uncut pQE31PfDXR; Lane 3 – BamHI 
restricted pQE31PfDXR resulting in two fragments of 3436 bp and 1279 bp; Lane 4 – PstI restricted pQE31PfDXR 
resulting in 2 fragments of 4067 bp and 648 bp; Lane 5 – Linearized pQE31PfDXR by digestion with SacI (4715 
bp); Lane 6 – Linearized pQE31PfDXR by digestion with NdeI; Lane 7 – SacI and NdeI double digest resulting in 
two fragments of 2490 bp and 2225 bp. 
 
2.4.2.2 Over-Production and Purification of P. falciparum DOXP Reductoisomerase 
 
The over-production of (His)6
Figure 2.6
-PfDXR in E. coli XL1 Blue [pQE31PfDXR] is depicted within 
(A).  Whole cells were monitored at hourly intervals after the induction of the 
recombinant DOXP reductoisomerase protein with IPTG (1 mM) and the protein induction 
profile analyzed via discontinuous SDS-PAGE and Coomassie Blue Staining.  The over-
production of the recombinant protein was problematic with very low levels of induction 
occurring with an optimal level being reached at 2 hours after induction with IPTG (Figure 
2.6(A); lane 5).  Degradation did not seem to occur with overnight induction (Figure 2.6(A); lane 
10).  The increase in intensity of the protein fragment of ~ 45 kDa is representative of the (His)6
Figure 2.6
-
tagged P. falciparum DOXP reductoisomerase subunit molecular mass.  Extremely low levels of 
the recombinant protein were present within un-induced and induced whole cells ( (A); 
lane 4) are likely due to basal levels of transcription occurring and the protein being toxic toward 
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the host expression system.  Additionally, the low growth rate of the E. coli host cells was 
indicative of a toxic protein being produced that inhibited cell growth (data not shown).  Figure 
2.6 (B) represents the detection of the recombinant (His)6-tagged protein by western analysis and 
chemiluminescence-based immunodetection.  Solubility analysis of the inducible (His)6-PfDXR 
was performed to determine protein stability and to guide protein purification set-up.  A protein 
corresponding to the subunit molecular mass of (His)6
Figure 2.6
-PfDXR was obtained within the soluble 
fractions after sonication and centrifugation of IPTG induced E. coli XL1 Blue[pQE31PfDXR] 
( (C); lane 7-8).  The soluble recombinant protein reaches a maximal level after 120 
seconds of sonication with 30 second bursts (Figure 2.6(C); lane 6).  Unlike the E. coli DOXP 
reductoisomerase protein, the P. falciparum DOXP reductoisomerase doesn’t seem to be 
appearing in the pellet fraction in large amounts.  This is most likely accountable due to its low 
level of induction and over-production. 
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Figure 2.6: Heterologous production of soluble P. falciparum DOXP reductoisomerase 
(A) Whole cell extracts of pre-induction and IPTG induced logarithmic phase E. coli XL1Blue[pQE31PfDXR] were 
analysed by SDS-PAGE.  Biorad Broad Range SDS Molecular Weight Marker (kDa) was separated in lane 1.  
Whole cell samples were removed before induction (lane 4), hourly after addition of 1 mM IPTG (lanes 5-9) and 
overnight (lane 10).  Over-production of P. falciparum DOXP reductoisomerase (~44 kDa) is indicated (arrow).  
Lane 2 and 3 represent a positive control (His)6 protein of ~66 kDa and a negative control for western analysis.  (B) 
Detection of (His)6 tag on (His)6-PfDXR by western analysis and chemiluminescence-based immunodetection.  
Lane 2 and 3 represent a 66 kDa His-tagged protein positive control and E. coli XL1Blue whole cell extract as a 
negative control respectively.  Un-induced pQE31PfDXR and induced pQE31PfDXR fractions are detected by the 
His-antibody within lanes 4 – 10 indicative of the (His)6-PfDXR being present within these samples.  (C) 
Heterologous over-production of soluble P. falciparum DOXP reductoisomerase.  Biorad Broad Range SDS 
Molecular Weight Marker (kDa) was separated in lane 1.  Soluble fractions were obtained after sonication, for 30 
seconds, 60 seconds, 90 seconds, 120 seconds and 150 seconds, and centrifugation (lanes 2, 4, 6 and 8 respectively).  
A protein of molecular size ~44 kDa represents soluble (His)6
 
-PfDXR (indicated with an arrow).  Insoluble fractions 
containing cell debris were separated within lanes 3, 5, 7 and 9.  Recombinant P. falciparum DOXP 
reductoisomerase is present within the insoluble fractions to a larger extent than in the soluble fractions however, 
solubility increased relative to sonication period.   
From the solubility analysis the recombinant protein was regarded as stable and soluble which 
has also been reported by Jomaa et al. (1999).  However, successful purification of this protein 
proved to be challenging due to the low levels of induction of the recombinant protein.  Initially 
attempts were to purify the protein through native batch purification that proved successful in the 
E. coli DOXP reductoisomerase purification.  This purification strategy failed, however small 
levels of recombinant protein were appearing within the wash steps of the purification (data not 
shown).  From several attempts to purify P. falciparum DOXP reductoisomerase via this strategy 
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it was decided to attempt native purification using sodium phosphate purification buffers.  This 
attempt at native purification resulted in low levels of pure P. falciparum (data not shown).   
 
Buffer composition is important when considering whether the buffer will interact with the 
protein being purified negatively or with other buffering components.  This may in turn impact 
the stability or even solubility of the protein/enzyme being purified.  Many components can be 
added to buffers in order to improve protein stability depending on the purification procedure and 
recombinant protein.  Thiol compounds are often incorporated within nickel affinity purification 
procedures to protect protein thiols from oxidation.  Dithiothreitol is the choice over 2-
mercaptoethanol, due to its higher stability and lower redox potential.  Jomaa et al. (1999) 
reported the purification of P. falciparum using 2-mercaptoethanol within the purification buffers 
as a stabilizing agent.  This purification procedure was attempted however yielded small amounts 
of protein within the wash steps of the purification along with several contaminating proteins.  
No P. falciparum DOXP reductoisomerase protein could be detected in the elution samples upon 
SDS-PAGE analysis (data not shown).   
 
A combination of denaturing and native purification was then attempted (Figure 2.7).  The cell 
lysis was achieved using denaturing conditions in the presence of 8 M Urea followed by native 
wash to remove the urea, allowing the proteins to renaturate.  Elution of P. falciparum DOXP 
reductoisomerase was achieved by competitive elution with imidazole.  This was only partially 
successful with a large majority of protein still bound to the Ni-affinity sepharose beads (Figure 
2.7; lane 14).  A wide range of proteins other than P. falciparum DOXP remained bound to the 
beads as well (Figure 2.7; lane14).  This was only noted to occur under the denaturing 
purification conditions where there were lower levels of expressed recombinant protein.  Under 
such circumstances the matrix would not have been saturated with P. falciparum DOXP 
reductoisomerase and histidine rich denatured proteins would have attempted to bind to the 
matrix through specific interactions.  Furthermore, denatured proteins would also have bound to 
the matrix through hydrophobic and electrostatic interactions and would not have been eluted 
from the Ni-affinity beads easily.  Attempts at improving the concentration of protein 
competitively released from the beads by an increase in the concentration gradient of imidazole 
was unsuccessful. The difficulties experienced in eluting the P. falciparum DOXP 
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reductoisomerase could be as a result of the protein binding non-specifically to the sepharose 
matrix of the column, making it difficult to elute.  Additional attempts at eluting the recombinant 
protein using 0.1% SDS and attempting to regain enzymatic activity by refolding the protein 
could be investigated.  A possible reason for the difficulty in obtaining sufficient P. falciparum 
DOXP reductoisomerase could be due to it being toxic toward the host expression system. One 
solution to this problem could be to express the protein together with the pLysS or pLysE 
plasmids that are engineered to allow the stable production of toxic proteins within E. coli.  
Furthermore, altering the expression strain may also be an alternative. The E. coli M15[pREP4] 
strain allows for the suppression of toxic protein expression prior to induction thus allowing for 
an improvement in the expression of recombinant toxic proteins.  Utilising western analysis the 
(His)6
 
-PfDXR protein could only be detected after overnight exposure using chemiluminescence 
(data not shown).  Insufficient amounts of active enzyme were purified for accurate enzyme 
kinetics analysis to be conducted. 
 
Figure 2.7: Purification of (His)6
(A) Purification of (His)
PfDXR by nickel affinity chromatography 
6
 
-PfDXR by nickel affinity chromatography was analysed after each purification step using 
SDS-PAGE.  The Biorad Broad Range Molecular Weight Marker (kDa) was separated in lane 1.  The purification 
samples included un-induced whole cell extract (lane 2), induced whole cell extract (lane 3), whole cell lysate (lane 
4), insoluble fraction (lane 5), soluble fraction (lane 6), flow-through (lane 7), native wash (lanes 8-10), native 
elution (lanes 11-13) and Ni-affinity sepharose beads (lane 14).   
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2.5 Conclusion 
 
Heterologous production and nickel chelate affinity purification of (His)6 E. coli DOXP 
reductoisomerase was successful.  The native purified EcDXR was shown to be active using 
NADPH coupled enzyme assays with a Km of 282 μM, Vmax
 
 of 0.74 μmol/min/mg, and specific 
activity of 1.77 μmol/min/mg ± 0.340 was obtained. 
The purification of P. falciparum DOXP reductoisomerase was problematic with the combinatory 
denaturing and native purification strategy being the only successful purification yielding low 
amounts of pure protein.  The P. falciparum DOXP reductoisomerase was found to remain bound 
to the Ni-affinity sepharose beads even after treatment with increased imidazole concentrations.  
Due to low levels of pure P. falciparum DOXP reductoisomerase being purified, credible enzyme 
assays were not possible.  It was regarded that the recombinant protein had poor expression levels 
due to it being toxic toward the host cells, which resulted in poor yields within the purification 
strategies attempted.  The low growth rate of the E. coli host cells upon heterologous over-
production of P. falciparum DOXP reductoisomerase further suggested that the P. falciparum 
DOXP reductoisomerase recombinant protein was toxic toward the host cell.  A possible solution 
would be to express the protein in E. coli containing either the pLysS or pLysE plasmids suited 
for expression of toxic proteins within E. coli.  Furthermore, expression within differing strains 
of E. coli may improve the expression level.  This is especially the case for the E. coli 
M15[pREP4] strain, which contains the pREP4 repressor plasmid for suppression of the 
recombinant protein expression prior to induction.  A further consideration may involve the lack 
of correct folding of the P. falciparum DOXP reductoisomerase protein within its “unnatural” 
cellular environment, E. coli.  Co-expression of parasitic partner chaperone proteins may improve 
the folding mechanisms and thus expression of recombinant P. falciparum DOXP 
reductoisomerase.  An additional consideration is that the pQE line of plasmids may be flawed 
for the expression of malarial genes in E. coli due to the absence of the lac repressor gene in the 
plasmid backbone, thus leading to inefficient suppression of the plasmid promoter and high 
background levels of protein expression in the absence of IPTG.  A range of different expression 
plasmids that contain the repressor gene in addition to the Amp resistance gene and expression 
cassette could be used to improve expression levels.  Furthermore, the possibility of using 
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alternative expression and purification strategies could be explored.  This may involve using the 
GST-fusion approach along with attempts at expression within other heterologous systems (e.g. 
insect cells).   
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REDUCTOISOMERASE CATALYTIC ACTIVE SITE BY RATIONAL AMINO 
ACID SUBSTITUTION ANALYSIS 
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3 CHARACTERIZATION OF THE DOXP REDUCTOISOMERASE 
CATALYTIC ACTIVE SITE BY RATIONAL AMINO ACID 
SUBSTITUTION ANALYSIS 
3.1 Introduction 
The function of any protein relies strongly on its primary amino acid sequence.  Engineered 
changes/mutations in the genetic code of the cloned gene can create a method for generating 
structural/functional changes to the protein itself.  Advances within recombinant DNA 
technology have allowed for the ability to manipulate DNA, thereby allowing researchers to 
manipulate regulatory elements and gene products (reviewed in Ling and Robinson, 1998).  The 
modification of the genetic code often encompasses research in the fields of protein structure-
function relationships, gene expression and vector modifications.  Additionally, modifications of 
a specific protein are often beneficial in medical/industrial applications in the improvement of 
specific biochemical properties.   
 
Bioinformatics is at the forefront of modern gene and protein research.  With whole genome 
sequencing a reality, bioinformatics now holds the key to the identification of genes, proteins and 
their secondary structure and functional roles.  Proteins are vital for all biological processes with 
the primary amino acid sequence holding all the necessary structural information for its 
functional conformation.  Several computational methods for nucleic acid and amino acid 
sequence analysis are available from which structural and functional predictions can be made.  
Genomes are being published rapidly and the genomes of several model organisms have been 
sequenced and include the yeast Saccharomyces cerevisiae, the bacterium E. coli, the worm 
Caenorhabditis elegans, the fruit fly Drosophila melanogaster as well as the human genome.  
From these and other sequenced genomes there is an enormous amount of information available 
for biological analysis to uncover ancestry, gene function, and protein identification, secondary 
structure prediction and protein function. 
 
Bioinformatic analysis of DOXP reductoisomerase has been performed by several research 
groups with the most significant being Jomaa et al. (1999), Reuter et al. (2002), Yajima et al. 
(2002) and Steinbacher et al. (2003).  Jomaa et al. (1999) initially analysed the primary protein 
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amino acid sequence to identify the gene encoding DOXP reductoisomerase within P. 
falciparum.  From the multiple sequence alignment they identified an extended N-terminal 
sequence that was present only in the bacterial and blue algae sequences.  This leader sequence 
was found to be 74 amino acids in length with the first 30 amino acids representing an 
endoplasmic reticulum signal peptide and the remainder a plastidal target sequence.  
Additionally, the N-terminal leader sequence was shown to direct localization to the extranuclear 
apicoplast, verifying DOXP reductoisomerase as an apicoplast destined protein.  Reuter et al. 
(2002), Yajima et al. (2002) and Steinbacher et al. (2003) have crystalized the E. coli DOXP 
reductoisomerase.  The protein has been shown to be a homodimer in solution with a predicted 
monomer size of ~43.5 kDa.  In addition to secondary structure predictions, several catalytically 
and structurally significant residues within the protein sequence have been identified, some of 
which have been experimentally tested, and are summarized in Table 3 and will be referred 
to/discussed in further sections. 
 
Residues that occur within the substrate binding domain, and are conserved amongst DOXP 
reductoisomerase homologues, were analysed via site-directed mutagenesis techniques by Reuter 
et al. 2002 and Yajima et al., 2002.  The Gly14 to Asp mutation resulted in insoluble protein and 
was reported as essential in the binding of the NADPH cofactor (Reuter et al., 2002).  The 
residues Glu231, His153, His209, and His257 were found to be strictly conserved and cluster within 
the substrate binding region, within the catalytic domain, and were analysed for their functional 
roles in substrate binding.  It was reported that the Glu231 to Lys mutation resulted in unaffected 
affinity of the protein toward substrate and NADPH.  However, the kcat was significantly 
decreased indicative of this residue mainly involved in catalysis rather than substrate or cofactor 
binding (Reuter et al., 2002).  The kcat decreased substantially on the His153 to Gln mutation 
suggestive of this residue being vital in the catalysis, while substrate binding was shown to be 
mediated by the His209 and His257 residues (Reuter et al., 2002).  Yajima et al. (2002) have also 
previously conducted mutagenesis analyses upon His209, His153, His257 and Glu231 residues and 
reported that these residues were all involved in catalysis.  These residues are located with their 
side chains projecting within the pocket formed by the N-terminal, central domain and C-terminal 
of the protein allowing it to be identified as the catalytic pocket of DOXP reductoisomerase 
(Yajima et al., 2002). 
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Table 3: Predicted critical residues within DOXP reductoisomerase 
Identified 
Amino 
Acid/s 
Predicted Role Experimentally Proven Reference 
Thr Anchors 2` phosphate moiety of 
NADPH through hydrogen bonding 
10  Yajima et al. (2002) 
Gly11 and 
Ser
Co-ordinate the pyrophosphonate 
moiety of NADPH 12 
 Reuter et al. (2002) 
Gly Essential in construction of NADPH 
binding motif 
14 Gly14 Reuter et al. (2002)  to Asp resulted in an 
insoluble protein 
Ala35 and 
Gly
Position to accommodate 2` phosphate 
moiety of NADPH 36 
 Reuter et al. (2002) 
Asp150, 
Glu152, Glu231, 
and Glu
Divalent Cation Binding and form salt 
bridges with acidic residues Lys
234 
125, 
His153, and Lys
 
228 
Reuter et al. (2002); 
Yajima et al. (2002); 
Steinbacher et al. 
(2003) 
Glu Involved in enzyme catalysis and Trans 
to N-formyl oxygen on Fosmidomycin 
binding 
231 Glu231 to Lys resulted in a 
change for kcat but no change in 
K
Yajima et al. (2002); 
Steinbacher et al. 
(2003) m 
Asp Trans to N-hydroxyl oxygen on 
Fosmidomycin binding 
150  Steinbacher et al. 
(2003) 
Lys125, His153, 
and Lys
Acidic residues forming salt bridges 
with basic divalent cation binding 
residues listed above 
228 
 Reuter et al. (2002) 
His153, His209, 
and His
Involved in enzyme catalysis 
257 
His209 and His257 to Gln 
resulted in decreased affinity 
toward substrate.  His153 to Gln 
results in 10 fold decrease in 
k
Reuter et al. (2002); 
Yajima et al. (2002) 
cat 
His Essential residue in catalysis and forms 
a hydrogen bond between itself and the 
phosphonate function of the enzyme 
and in so doing closes the catalytic 
hatch 
209 His209 to Gln resulted in 
kcat/Km
Yajima et al. (2002) 
 decreasing substantially 
His Phosphonate moiety binding mediated 
by catalytic hatch 
257 His257 to Gln resulted in Km for 
NADPH increasing and kcat/Km
Steinbacher et al. 
(2003)  
decreasing 
His257, Trp212 
and Pro
His
274 
257 and Trp212 from a stacking role, 
which is supported by Pro274
 
 thus 
ordering the active site structure only in 
the presence of NADPH.  Also interact 
with carbon backbone of substrate 
Yajima et al. (2002); 
Steinbacher et al. 
(2003) 
Ser186, Ser222, 
Asn227, and 
Lys
Substrate phosphonate moiety 
anchoring via hydrogen bonding 
interactions 228 
 Steinbacher et al. 
(2003) 
Trp212 and 
Met
Stacking functions essential in forming 
hydrophobic contacts with 
nicotinamide moiety of NADPH 
214 
 Steinbacher et al. 
(2003) 
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3.1.1 Homology Modelling of Protein Sequences 
 
Knowledge of the three dimensional (3-D) structure of a protein is essential for rational amino 
acid analysis via site-directed mutagenesis techniques and can be vital for the design of protein-
specific drugs.  Structural information can enhance our understanding of protein function.   
However, many proteins 3-D structures are still not available.  Many proteins fail to crystallize 
and often cannot be obtained or dissolved in large enough quantities for NMR analysis.  In such 
cases model building with known 3-D structural data of a homologous protein is at present the 
only reliable method to obtain structural information.  Homology modelling involves the 
prediction of a protein’s 3-D structure from the primary amino acid sequence of a homologous 
protein for which there is either X-ray or NMR structural information available.  The Protein 
Data Bank (PDB) (Westbrook et al., 2003) is a database of 3-dimensional structural information 
from which the structural information for the template/homologous protein can be obtained.  
Creating a homology model of a target protein is useful in that well-defined secondary structure 
predictions individually do not illustrate the 3-D structure of a protein.  The homology model 
fulfils this role and has several applications within catalytic mechanism analysis, ligand docking 
analysis, the identification of antibody epitopes, rational amino acid site-directed mutagenesis, 
and identification of functional sites (www.cmbi.kun.nl/gvteach/hommod/index.shtml).   
 
Homology modelling proceeds via a multi-step process.  Initially, the template protein must be 
recognized and consequently the primary amino acid sequence for the template and protein to be 
modelled are aligned and optimized through a multiple sequence alignment.  After which, the 
backbone for the model is generated and ab initio building of canonical loops is performed.  
Template side chains are then replaced with model side chains and optimized.  Modelling of 
insertions and deletions is then performed and the model detected for errors and optimized.  
Iterating of the steps to remove errors is conducted after which the model undergoes energy 
minimization and dynamic simulation methods (www.expasy.org/swissmod/SWISS-MODEL 
and www.cmbi.kun.nl/gvteach/hommod/index.shtml).  Homology modelling is dependent on the 
quality of the 3-D structural data of the template protein as well as sequence identity between the 
template and the protein to be modelled.  The choice of the modelling template is crucial and 
high deviations in the model can be the cause of the modelling template.  Additionally the 
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presence or absence of substrate, cofactors or subunits from the template structural information 
can impact the experimental protein model (www.cmbi.kun.nl/gvteach/hommod/index.shtml).  
As differences within the 3-D structure increase with the decrease in sequence identity the 
homology modelling accuracy deteriorates.  With >90 % sequence identity such errors are low 
however, with 50 % sequence identity root mean square (RMS) errors in the modelled co-
ordinates can be as large as 1.5 Å with large local errors.  25 % Sequence identity will introduce 
problems at the alignment level resulting in large errors and homology is undetected with 
sequence identity below 25 % (www.cmbi.kun.nl/gvteach/hommod/index.shtml).   
 
Several assumptions regarding the overall three dimensional structure and residue topology are 
made in the process of creating a homology model.  The main assumption is that the overall 3-D 
structure of the target protein is similar to that of the template with regions of homology having 
similar structure.  Furthermore, when constructing the predicted 3-D model, residues that are 
homologous within a family of proteins are regarded as structurally conserved and those crucial 
in the biological function are thought to be topologically equivalent.  Loop regions are often not 
constructed as conserved regions and are regarded as flexible allowing for deletions and 
insertions to be made within the model.  In so doing one assumes that such deletions and 
insertions do not impact the global structure of the protein and more importantly that the loop 
region is not performing a biological role within the protein (www.cmbi.kun.nl/ 
gvteach/hommod/index.shtml). 
 
3.1.2 Approaches to Rational Protein Engineering/Mutagenesis 
 
Several methods have been employed and optimized to mutate DNA.  Originally, random 
techniques were used for manipulating DNA, often involving the generation of random mutations 
in chromosomal DNA through exposure to X-rays or various chemicals (Ling and Robinson, 
1998).  These techniques were beneficial in past genetic studies, but were limited in their inability 
to target the mutation toward a specific gene.  An additional drawback was the intensive 
screening procedures.  Recombinant DNA technology now allows for the ability to target DNA 
in vitro and make precise changes within a specific gene.   
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3.1.3 Site-Directed Mutagenesis 
 
Site-directed mutagenesis is a versatile technique in rational amino acid substitution and allows 
for a mutation to be engineered at a specific site within a desired gene (Madigan et al., 1997).  
Such methodologies are divided into i) techniques that restructure fragments of DNA, such as 
cassette mutagenesis; ii) localized random mutagenesis; and iii) oligonucleotide-based 
mutagenesis (Cosby and Lesley, 1997).  Oligonucleotide-based mutagenesis is the most common 
for introduction of small specific mutations and includes PCR and Non-PCR based approaches.  
Unlike PCR based approaches in which the product is able to act as a template resulting in 
exponential amplification, in Non-PCR only the parental plasmid can act as template resulting in 
a linear amplification and lower error rates.  This method is preferred over PCR-based methods 
for mutagenesis as incorporation of errors is avoided and was used within this work.   
 
Oligonucleotide mutagenesis can be used to generate point mutations, change amino acids, and 
delete or insert single or several amino acids.  The success of the technique relies on the 
construction of the synthetic oligonucleotide, which is designed to incorporate the desired 
mutation(s).  Parameters such as annealing efficiency and temperature, primer length, and GC 
content must be considered in ensuring that the oligonucleotide anneals to the plasmid DNA and 
initiates DNA synthesis of the mutant strand (Cosby and Lesley, 1997). 
 
Site-directed mutagenesis within this work was achieved using two synthetic complementary 
oligonucleotide primers containing the desired mutation(s) (Jung et al., 1992).  The 
oligonucleotides anneal to the opposite strands of the double-stranded template vector DNA and 
are extended such that successive cycles of annealing and extension results in linear amplification 
of the whole plasmid.  The parental plasmid DNA is removed by restriction with DpnI, which 
digests the template parental DNA as it is specific for methylated DNA.  The resultant mutant 
plasmid product can then be propagated within a suitable host organism and the DNA screened 
for the desired mutation. 
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3.2 Aim 
 
Several amino acid residues have been considered essential in the function and structure of 
DOXP reductoisomerase.  Specifically, the catalytic hatch region within the protein has been 
regarded to enclose the substrate within the catalytic pocket and therefore not only play a role 
within substrate binding but active site architectural orientation.  Reuter et al. (2002), Yajima et 
al. (2002) and Steinbacher et al. (2003) have noted the importance of the conserved Trp212, 
Met214 and Pro274
 
 residues within the catalytic hatch, however they have not been experimentally 
determined.  Upon 3-D inspection of these residues within the E. coli DOXP reductoisomerase 
structure, amino acid substitution experiments were designed to test the functional predictions for 
these amino acids.  
The Met214 residue was replaced with an isoleucine residue to ensure that overall global 
disruption to the protein was avoided along with the removal of the sulphur group and length of 
the Met side chain.  This would remove possible stacking interactions previously mediated by 
Met214 with Pro274 and Trp212 and interaction with NADPH.  The Pro274 was mutated to an 
isoleucine in order to maintain bulk (to an extent), but interrupt any stacking role the cyclic Pro 
residue may perform with Trp212 and Met214.  Trp212 substitution with tyrosine, leucine and 
phenylalanine will allow for the stacking and substrate binding interactions of Trp212 to be 
interrupted.  The tyrosine residue introduced a polar hydroxyl group with potential for hydrogen 
bonding interactions while simultaneously removing the 5-membered ring previously present 
within the Trp side chain.  This would likely affect the stacking role of the residue in the active 
site as well as any substrate binding interactions.  The leucine and phenylalanine residues are 
both hydrophobic with phenylalanine maintaining a degree of aromaticity.  These substitutions 
would be less detrimental to the hydrophobic nature of the active site and would hopefully 
elucidate the precise role of the Trp212 residue in stacking with Met214 and Pro274
 
 and substrate 
binding. 
A multiple sequence alignment was used to determine the differences within the P. falciparum 
DOXP reductoisomerase in comparison to E. coli and other DOXP reductoisomerase homologues 
possibly representative of structural/functional differences in the parasitic protein.  Homology 
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modeling of the P. falciparum DOXP reductoisomerase, using the E. coli DOXP 
reductoisomerase homologue’s primary amino acid sequence and crystal structure data as a 
template, was performed to obtain the 3-D predicted structure for P. falciparum DOXP 
reductoisomerase.  The 3-D predicted structure of P. falciparum DOXP reductoisomerase 
allowed for future biochemical characterization through rational amino acid substitution analysis. 
 
3.3 Experimental Procedures 
 
3.3.1 Reagents and Chemicals 
 
All reagents and chemicals utilized are described in the Appendices (Chapter 6, section 6.1). 
 
3.3.2 Multiple Sequence Alignment Analysis of the Primary Amino Acid Sequences of E. 
coli and P. falciparum DOXP Reductoisomerase 
 
Homologous protein sequences were identified using the Basic Local Alignment Search Tool 
(BLAST)(Altschul et al., 1997) and downloaded from the National Center for Biotechnology 
(NCBI) server (http://ncbi.nlm.nih.gov).  Multiple sequence alignment was performed using the 
software programme ClustalX (Jeanmougin et al., 1998). 
 
3.3.3 Homology Modelling of P. falciparum DOXP Reductoisomerase 
 
Homology modelling was used to generate a predicted 3-D structure for the P. falciparum DOXP 
reductoisomerase and was performed using SWISS-MODEL (Peitsch, 1996) and WHATIF 
(Vriend, 1990).  Energy minimization and dynamic simulation were performed using the 
GROMOS 96 method within SWISS-MODEL and via the programme WHATCHECK within 
WHATIF.  The template protein, i.e. the E. coli DOXP reductoisomerase homologue, primary 
amino acid sequence and structural information, was downloaded from the PDB (Westbrook et 
al., 2003).  Protein models/structures were visualized using Molscript (Kraulis, 1991).  Two 
homology models were created for P. falciparum DOXP reductoisomerase.  The first predicted 
structure was generated with the crystal structure for the E. coli DOXP reductoisomerase 
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obtained by Yajima et al. (2002)(PDB accession code 1JVS) as a template, in the absence of the 
cofactor metal cation and substrate.  The second predicted 3-D structure of P. falciparum DOXP 
reductoisomerase was generated using structural data for the E. coli DOXP reductoisomerase 
with the substrate, cofactor metal cation, and inhibitor bound obtained by Steinbacher et al. 
(2003)(PDB accession codes 1ONO, 1ONP and 1ONN).   
 
3.3.4 Identification of Potentially Critical Residues for the Catalytic Functioning of P. 
falciparum and E. coli DOXP Reductoisomerase 
 
Residues essential in the catalytic functioning of E. coli DOXP reductoisomerase identified from 
crystal structure information and analysed via site-directed mutagenesis techniques by Reuter et 
al. (2002) and Yajima et al. (2002) were discussed in section 3.1.  From Reuter et al. (2002), 
Yajima et al. (2002) and Steinbacher et al. (2003), amino acids that were predicted as crucial in 
the functioning of DOXP reductoisomerase, but not tested experimentally, were noted and chosen 
for functional analysis via site-directed mutagenesis.  A multiple sequence alignment was 
performed amongst DOXP reductoisomerase homologues to identify the level of conservation of 
these residues and to show any differences within the P. falciparum DOXP reductoisomerase 
amino acid sequence that could be of functional/structural importance.  Inspection of the 3-D 
orientation of the residues within the E. coli DOXP reductoisomerase and P. falciparum DOXP 
reductoisomerase was performed to validate their predicted functional/structural roles through 
interaction with the substrate, cofactor or other contacts made within 4 Å.  Protein structure 
visualization was performed using Molscript (Kraulis, 1991). 
 
3.3.5 Site-Directed Mutagenesis of DOXP Reductoisomerase 
 
Plasmids encoding (His)6-EcDXR(W212Y), (His)6-EcDXR(W212L), (His)6-EcDXR(W212F), 
(His)6-EcDXR(M214I), (His)6-EcDXR(P274I), (His)6-EcDXR(N211K, S213K) and (His)6
6.2
-
PfDXR(K295N, K297S) were prepared via site-directed mutagenesis using a double stranded 
whole plasmid amplification technique as described in Jung et al. (1992).  Synthetic 
oligonucleotide primers were designed using Generunner Software (Hastings Software Inc.) and 
are tabulated in the appendices (Chapter 6, refer to section , Table 8). 
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All mutations were generated using the standard procedure outlined in the QuikChange Site-
Directed Mutagenesis Kit supplied by Stratagene (USA) with the respective complementary 
synthetic oligonucleotide primer pairs.  The linear amplification products representative of 
successful mutagenesis were transformed into supercompetent E. coli XL1-Blue cells 
(Stratagene, USA) and the putative mutant plasmid DNA isolated.  Diagnostic restriction enzyme 
analysis was performed on the plasmids and samples resolved upon agarose gel electropheresis, 
as described in section 2.3.2.3.  Table 4 illustrates the respective mutant construct and the 
diagnostic restriction enzyme to validate successful incorporation of the desired codon 
substitutions.   
 
Table 4: Diagnostic restriction enzyme analysis of rational amino acid substitutions within 
DOXP reductoisomerase  
Plasmid Construct Diagnostic Restriction 
Enzyme 
Expected DNA Fragments 
(bp) 
pQE9EcDXR NcoI 3599 & 1023 
pQE9EcDXR(W212Y) 
pQE9EcDXR(W212L) 
pQE9EcDXR(W212F) 
NcoI 3389, 1023, & 210 
pQE9EcDXR XmaIII Uncut DNA conformations 
pQE9EcDXR(M214I) XmaIII 4622 
pQE9EcDXR ClaI Uncut DNA conformations 
pQE9EcDXR(P274I) ClaI 4622 
pQE9EcDXR(N211K) NcoI 3389, 1023, & 210 
pQE9EcDXR(N211K, S213K) NcoI 3599 & 1023 
pQE31PfDXR NcoI 2771 & 1944 
pQE31PfDXR(K297S) NcoI 2771, 1263 &681 
pQE31PfDXR(K295N, K297S) NcoI 2771 & 1944 
 
For the preparation of (His)6
6.2
-EcDXR(N211K, S213K) plasmid DNA, a two-stage mutagenesis 
reaction was used to introduce the N211K mutation followed by the S213K mutation.  For the 
generation of the pQE9EcDXR(N211K) plasmid DNA a complementary 27-mer primer pair 
(refer to the appendices, Chapter 6, section , Table 8) was synthesised to contain the codon for 
the lysine amino acid change as well as a silent mutation to introduce the restriction site for NcoI.  
The parental plasmid DNA restricted with NcoI results in fragments of 3599 bp and 1023 bp.  
Through the introduction of a third NcoI site the pQE9EcDXR(N211K) plasmid DNA results in 
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three fragments of 3389 bp, 1023 bp, and 210 bp upon NcoI restriction.  Samples were resolved 
using agarose gel electrophoresis, as described in section 2.3.2.3, on a 1 % agarose gel containing 
0.5 μg/ml ethidium bromide in 0.5x TBE buffer at 100V.  For the incorporation of the lysine 
residue at 213 a set of complementary primers were synthesised to the pQE9EcDXR(N211K) 
plasmid DNA (refer to the appendices, Chapter 6, section 6.2, Table 8).  Through the introduction 
of the codon for this amino acid substitution the NcoI site engineered through a silent mutation 
during the lysine codon 211 mutagenesis is removed. Thus identification of 
pQE9EcDXR(N211K, S213K) by restriction with NcoI yields two fragments of sizes 3599 bp 
and 1023 bp, indicative of the (His)6
2.3.2.3
-EcDXR(N211K, S213K) plasmid DNA.  Samples were 
resolved using agarose gel electrophoresis, as described in section , on a 1 % and 0.8 % 
agarose gel containing 0.5 μg/ml ethidium bromide. 
 
To prepare the (His)6
6.2
-PfDXR(K295N, K297S) plasmid DNA a two-stage mutagenesis reaction 
was used.  The introduction of a codon for serine at codon 297 was conducted first, and followed 
by the introduction of a codon for an asparagine residue at codon 295. For the K297S mutation a 
complementary primer pair was synthesised (refer to the appendices, Chapter 6, section , 
Table 8) to comprise the required amino acid change and simultaneously introduce an NcoI 
restriction site.  Thus pQE31PfDXR(K297S) could be identified due to three fragments of 2771 
bp, 1263 bp and 681 bp compared to only two fragments appearing (2771 bp and 1944 bp) for the 
parental plasmid DNA upon restriction with NcoI.  Samples were resolved using agarose gel 
electrophoresis, as described in section 2.3.2.3, upon a 0.8 % agarose gel containing 0.5 μg/ml 
ethidium bromide in 0.5x TBE buffer at 100V.  The introduction of the codon for an asparagine 
residue at codon 295 was achieved through the synthesis of a complementary oligonucleotide 
primer pair (refer to the appendices, Chapter 6, section 6.2, Table 8).  Additionally a silent 
mutation was incorporated to remove the NcoI site engineered through the first round of 
mutagenesis.  Upon restriction with NcoI the pQE31PfDXR(K295A, K297S) plasmid DNA 
results in two DNA fragments of 2771 bp and 1944 bp whereas the pQE31PfDXR(K297S) 
plasmid DNA results in three DNA fragments of 2771 bp, 1263 bp and 681 bp.  Samples were 
resolved using agarose gel electrophoresis, as described in section 2.3.2.3, upon a 1 % and 0.8 % 
agarose gel containing 0.5 μg/ml ethidium bromide in 0.5x TBE buffer at 100V. 
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The QuikChange Site-Directed Mutagenesis Kit (Stratagene, USA) was utilized to generate all 
mutant plasmid constructs according to the reaction scheme outlined in Table 5.  A control 
reaction using the pWhitescriptTM 4.5 kb control plasmid is used as a mutagenesis efficiency 
control.  The pWhitescriptTM plasmid contains a stop codon within the β-galactosidase gene 
where a glutamine codon is usually found.  The oligonucleotide control primers contain a point 
mutation that substitutes the T residue within the TAA stop codon to a C residue.  This reverts 
the codon sequence to the wild-type glutamine codon allowing for colonies to be screened after 
transformation for the β-galactosidase phenotype (β-gal+
 
, blue).   
Table 5: Preparation of plasmid DNA site-directed mutagenesis reactions 
Volume (μl) Reagent Reagent Details 
Control Reaction: 
5 10x Reaction Buffer 100 mM KCl, 100 mM (NH2)2SO4, 
200 mM Tris-HCl (pH 8.8), 20 mM 
MgSO4, 1 % Triton X-100, 1 mg/ml 
nuclease free bovine serum albumin 
(BSA) 
2 pWhitescriptTM 5 μg/μl, 10 ng, 4.5 kb  positive control plasmid 
1.25 Forward Primer 100 ng/μl, 125 ng, 34-mer 
1.25 Reverse Primer 100 ng/μl, 125 ng, 34-mer 
1 dNTP mix 200 mM 
38.5 Sterile deionized milli-Q water  
1 PfuTurboTM 2.5 U/μl  DNA polymerase 
  Total Volume = 50 μl 
Sample Reaction: 
5 10x Reaction Buffer 100 mM KCl, 100 mM (NH2)2SO4, 
200 mM Tris-HCl (pH 8.8), 20 mM 
MgSO4, 1 % Triton X-100, 1 mg/ml 
nuclease free bovine serum albumin 
(BSA) 
2 Plasmid Template DNA ~200 ng/μl 
1 Synthesised Forward Primer 200 ng/μl, refer to appendix for 
sequences 
1 Synthesised Reverse Primer 200 ng/μl, refer to appendix for 
sequences 
1 dNTP mix 200 mM 
39 Sterile deionized milli-Q water  
1 PfuTurboTM 2.5 U/μl  DNA polymerase 
  Total Volume = 50 μl 
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3.3.6 Thermal Cycling Parameters utilized in Site-Directed Mutagenesis 
 
The reaction samples were incubated within the GeneAmp PCR System 9700 (Applied 
Biosystems) utilizing the cycle parameters tabulated in Table 6. 
 
Table 6: Thermal cylcing parameters utilized for site-directed mutagenesis reactions 
Segment Cycles Temperature (˚C) Time 
1 1 95 30 seconds 
2 18 95 30 seconds 
  52 1 minute 
  68 9 minutes 
3 1 78 7 minutes 
4 1 4 Holding 
 
After thermal cycling, DpnI (1 μl; 10 U) was added to the mutagenesis reaction products and 
incubated at 37˚C for 2 hours.  Aliquots (10 μl) of the mutagenesis reactions were taken prior to 
and post DpnI digestion and resolved on a 0.8 % agarose gel as described in section 2.3.2.3.   
 
3.3.7 Screening of (His)6-EcDXR(W212Y), (His)6-EcDXR(W212L), (His)6-
EcDXR(W212F), (His)6-EcDXR(M214I), (His)6-EcDXR(P274I), (His)6-
EcDXR(N211K, S213K) and (His)6-PfDXR(K295N, K297S) Plasmid Constructs 
 
Aliquots (50 μl) of competent E. coli XL1-Blue cells were transformed with 2 μl of DpnI treated 
test mutagenesis products, DpnI treated pWhitescriptTM
2.3.2.2
 mutagenesis product (1 μl) as a 
mutagenesis positive control, pUC18 plasmid DNA (1 μl; 0.1 ng/μl) as a transformation control 
and sterile milli-Q water as a no DNA control according to the method described in section 
.  pUC18 and pWhitescriptTM were plated onto 5 % MacConkey Agar plates (10 g/L 
lactose) containing ampicillin (0.1 mg/ml).  The mutagenesis efficiency (ME) for the 
pWhitescriptTM
 
 4.5 kb plasmid positive mutagenesis control transformation reaction was 
calculated with accordance to the following formula: 
ME  = Number of red colony forming units (cfu)      x 100 % 
Total number of cfu 
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The mutagenesis efficiency was assumed to correlate with that of pWhitescriptTM
 
 and the 
efficiency of transformation was reflected through the pUC18 transformation reaction. 
The mutant plasmid DNA constructs were confirmed using diagnostic restriction enzyme 
analysis (discussed in section 3.3.5) and DNA sequencing.  Purified plasmid DNA encoding 
EcDXR(W212Y), EcDXR(W212L), EcDXR(W212F), EcDXR(M214I), and EcDXR(N211K, 
S213K) (~400 ng) was added to 3.2 pmol primer EcDXRSPF (refer to the appendices, Chapter 6, 
section 6.3, Table 8 for details) and purified plasmid DNA encoding PfDXR(K295N, K297S) 
(~400ng) was added to 3.2 pmol primer PfDXRSPF (refer to the appendices, Chapter 6, section 
6.2, Table 8 for details).  The cycle sequencing reactions (final volume 20 μl) were performed 
using the ABI PRISM® BigDyeTM Terminator Cycle Sequencing Ready Reaction Kit according 
to manufacturers conditions.  AmpliTaq®
 
 DNA polymerase, FS, and nucleotide terminators 
labelled with fluoroscein donor dyes linked to dRhodomine acceptor dye were used to generate 
DNA sequences.    
3.3.8 Over-Production and Purification of (His)6-EcDXR(W212Y), (His)6-
EcDXR(W212L), (His)6-EcDXR(W212F), (His)6-EcDXR(M214I), (His)6-
EcDXR(N211K, S213K) and (His)6-PfDXR(K295N, K297S) 
 
The over-production of the mutant proteins was performed according to the methodology 
described in section 2.3.2.4.  Purification was achieved through nickel affinity chromatography 
according to section 2.3.3 for the E. coli DOXP reductoisomerase mutant proteins and section 
2.3.4 for the P. falciparum DOXP reductoisomerase mutant protein.   
 
3.3.9 The in vitro Analysis of EcDXR(W212Y), EcDXR(W212L), EcDXR(W212F), and 
EcDXR(M214I) DOXP Reductoisomerase Activity 
 
DOXP reductoisomerase activity assays were performed using purified EcDXR(W212Y), 
EcDXR(W212L), EcDXR(W212F), and EcDXR(M214I) according to the procedure outlined 
within section 2.3.3.3.  In some cases the stability of the purified protein was transient possibly 
due to the mutations themselves and assays were therefore performed directly after purification.  
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The EcDXR(N211K, S213K) and PfDXR(K295N, K297S) proteins were not characterized 
further as insufficient amounts of active protein were obtained after buffer exchange. 
 
3.4 Results and Discussion 
 
3.4.1 Multiple Sequence Alignment Analysis of the Primary Amino Acid Sequences of E. 
coli and P. falciparum DOXP Reductoisomerase 
 
DOXP reductoisomerase comprises three domains that define the V-shaped structure of the 
monomer (refer to Figure 1.4).  This includes an NADPH binding N-terminal domain, a 
catalytic/connective domain and the C-terminal domain.  The protein has been confirmed to exist 
as a homodimer within solution with the monomer being ~43.5 kDa (Steinbacher et al., 2003; 
Reuter et al., 2002).   
 
The multiple sequence alignment of the DOXP reductoisomerase homologues are depicted in 
Figure 3.1.  An N-terminal leader sequence is present within the P. falciparum (residues 1-77) 
and Artemisia annua (residues 1-77) homologues.  Jomaa et al. (1999) have previously identified 
this leader sequence within P. falciparum and shown it’s functioning in targeting the protein to 
the apicoplast.  It is not surprising that a leader sequence is present within the plant homologue 
due to isoprenoids being synthesized within the plant plastid via the DOXP/non-mevalonate 
pathway and sterols being synthesized within the cytosol by the classical mevalonate pathway.  A 
high degree of conservation and sequence similarity amongst the various homologues of DOXP 
reductoisomerase can be observed (refer to Figure 3.1; total sequence conservation is represented 
by a ‘*’ in the consensus sequence).  For general discussion purposes the amino acid numbering 
will reflect that of the E. coli DOXP reductoisomerase primary amino acid sequence. 
 
The cleft within the protein is as a result of two main stretches of strictly conserved residues or 
similar residues amongst all homologues, His251 to Ser258 and Pro274 to Arg277 Steinbacher et al. 
(2003).  The NADPH binding domain spans residues 1-149 within the E. coli homologue with 
residues Thr10, Gly11, Ser12, Gly14, Ala35, Gly36, and Lys37
Table 3
 being proposed essential for NADPH 
binding (refer to ; Reuter et al., 2002; Yajima et al., 2002; Steinbacher et al., 2003).  Of 
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the strictly conserved residues Thr10 and Gly14
Figure 3.1
 are thought to be vital in the binding of NADPH 
(refer to ) with Gly14
Table 3
 experimentally shown to be essential in NADPH binding upon 
mutation to an Asp residue ( ; Reuter et al., 2002).  Gly11 and Ser12 co-ordinate the 
phosphonate of NADPH and are therefore strictly conserved.  The residues Ala35 and Gly36 are 
not strictly conserved with Ala35 substituted as valine within P. falciparum and as a glycine 
within H. influenzae, and Gly36
 
 substituted for asparagine within P. falciparum.  This may be due 
to these residues being positioned slightly differently between homologues to accommodate the 
2` phosphate on NADPH binding.   
The catalytic domain spans residues 150-285 within the E. coli homologue with the catalytic loop 
comprising residues His209 to Met214 (Yajima et al., 2002).  The acidic residues Asp150, Glu152, 
Glu231, and Glu234
Figure 3.2
 are conserved and play a role in the binding of the divalent cation essential for 
catalysis ( (A)).  They additionally form a network of salt bridges with the basic 
residues Lys125, His153, and Lys228 (Reuter et al., 2002).  Residues His209, His153, Glu231, and 
His257
Figure 3.2
 have been shown to perform a catalytic function and are conserved amongst all 
homologues within the sequence alignment (Reuter et al., 2003; Yajima. et al., 2002)( ), 
with Glu231 the most critical catalytic residue (Yajima et al., 2002).  Residues that have been 
experimentally shown to be involved within catalysis include His153 and Glu231, whereas His257 
and His209
3.1
 have been experimentally shown to play a role in substrate binding (refer to section 
 and Table 3; Reuter et al., 2002, Yajima et al., 2002).  His257
Figure 3.2
 seems to perform a catalytic as 
well as substrate binding role within DOXP reductoisomerase activity.  These residues side 
chains protrude into the active site (as shown within ) and were defined as those which 
constitute the catalytic pocket formed by the N-terminal, catalytic and C-terminal domains of the 
protein by Yajima et al. (2002). 
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Figure 3.1: Multiple sequence alignment of DOXP reductoisomerase homologues 
The multiple sequence alignment of DOXP reductoisomerase homologues was generated via the software 
programme ClustalX (Jeanmougin et al., 1998).  The consensus sequence represents identical residues as ‘*’ and 
similar residues as ‘:’ or ‘.’.  Residues are colour co-ordinated according to their biochemical properties.  Both P. 
falciparum and A. annua share the amino terminal leader sequence, which harbours the endoplasmic reticulum and 
apicoplast signal peptides.   
Key: Nostoc = Nostocaceae sp.PCC 7120 (Genbank accession number AP003596); Artemisia = Artemisia annua 
(Genbank accession number AAD56391.1); Haemophilus = Haemophilus influenzae Rd (Genbank accession number 
NP_438967); Escherichia = E. coli (GenBank accession number EDL933); Bacillus = Bacillus halodurans 
(Q9KA69.1) and Plasmodium = P. falciparum (GenBank accession number AF111813.1). 
 
  89 
 
Figure 3.2: Ribbon representation of E. coli DOXP reductoisomerase illustrating residues 
involved in catalysis 
The ribbon representation of E. coli DOXP reductoisomerase was generated using Molscript (Kraulis, 1991).  The N-
terminal domain is coloured blue, the catalytic domain green and the C-terminal red.  (A) E. coli DOXP 
reductoisomerase with the acidic catalytic residues Asp150, Glu152, Glu231, and Glu234 highlighted in stick 
conformation.  (B) E. coli DOXP reductoisomerase with the basic catalytic residues His153, His209, and His257
 
 
highlighted in stick conformation.   
The residues Ser186, Ser222, Asn227 and Lys228
Figure 3.3
 are strictly conserved within the catalytic domain 
and form hydrogen bonds with the phosphonate moiety of the substrate/inhibitor thus performing 
an anchoring role (refer to ).  Since the catalytic loop performs the essential role of 
locking the substrate within the active site pocket, and securing it within a hydrophobic 
environment, residues within this region of the multiple sequence alignment are crucial in protein 
function and are expected to be strictly conserved to maintain structural and functional integrity 
within the active site pocket.  The residues Met214 and Trp212
Figure 3.3
 have been predicted from structural 
data to interact with the nicotinamide moiety of NADPH allowing for the catalytic hatch to close 
over the substrate once it has bound (Steinbacher et al., 2003).  These residues perform an 
essential hydrophobic function, which allows them not only to interact with the NADPH but also 
the hydrophobic backbone of the substrate or the inhibitor fosmidomycin (Yajima et al., 2002).  
 illustrates the essential contacts that are made upon binding of the inhibitor.  His 257 
and Trp212, together with Pro274, seem to perform the stacking role vital for the formation of the 
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structure of the active site and are therefore strictly conserved amongst all homologues 
(Steinbacher et al., 2003).  Upon binding of fosmidomycin Steinbacher et al. (2003) reported that 
the catalytic loop became disordered possibly suggesting that it can form more than one 
conformation.  Pro210
Table 3
 represents another residue that is conserved amongst all homologues within 
the catalytic loop region.  The residues predicted to perform the stacking roles essential in the 
orientation of the active site as well as within substrate binding have not been verified through 
experimental work and functional predictions regarding these residues have relied upon 3-D 
analysis of the crystal structure ( ).  The Trp212 residue is closely associated with the bound 
inhibitor possibly making it essential in substrate/inhibitor binding through interactions with the 
substrate/inhibitor carbon backbone.  Additionally, the Met214 does not seem to be in close 
proximity to the bound inhibitor, as in the case for Trp212 Figure 3.3( ).  Rather it is in close 
proximity to the cofactor NADPH and is possibly vital within NADPH binding and the structural 
orientation of the active site once it has interacted with the cofactor NADPH.  
 
 
Figure 3.3: Ribbon representation of E. coli DOXP reductoisomerase illustrating residues 
critical for fosmidomycin binding 
(A) Fosmidomycin bound to E. coli DOXP reductoisomerase with the interacting amino acids highlighted.  (B) 
Close-up view of contacts made between E. coli DOXP reductoisomerase and fosmidomycin.  The N-formyl oxygen 
on fosmidomycin is positioned trans to Glu231 while the N-hydroxyl oxygen is positioned trans to Asp150.  Pro274 
orders the active site allowing Trp212 and Met214 to perform a stacking role and thus securing the cofactor NADPH.  
The phosphonate moiety of fosmidomycin is anchored via hydrogen bonding with Ser186, Ser222, Asn227 and Lys228.  
The ribbon representations were generated via Molscript (Kraulis, 1991) using the crystal structure data generated 
via Steinbacher et al. (2003)(Protein Data Bank accession codes 1ONO, 1ONN and 1ONP). 
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3.4.2 Homology Modelling of the P. falciparum DOXP Reductoisomerase 
 
P. falciparum DOXP reductoisomerase has an amino acid sequence identity of 43.5 % to that of 
the E. coli homologue sequence.  Due to the high sequence similarity the E. coli DOXP 
reductoisomerase homologue it may be used as a template and model for P. falciparum DOXP 
reductoisomerase, from which structural, functional and catalytic predictions regarding the 
parasitic protein’s mechanism can be made.  Utilizing the known structural information for E. 
coli DOXP reductoisomerase as a template, homology models for the P. falciparum were created 
(refer to Figure 3.4).  Two homology models were created based on crystal structure data 
available from Reuter et al. (2002), Yajima et al. (2002) and Steinbacher et al. (2003).  The first 
utilized the structure co-ordinates from the unbound protein (Reuter et al., 2002; Yajima et al., 
2002) and the second from structural co-ordinates of the protein with bound substrate/inhibitor 
and the divalent cation (Steinbacher et al., 2003). 
 
Figure 3.4(C) and (D) represent the predicted structure of the P. falciparum DOXP 
reductoisomerase monomer modelled using the ligand-free E. coli DOXP reductoisomerase as 
the template via SWISS-MODEL and the substrate/inhibitor bound and divalent cation-bound E. 
coli DOXP reductoisomerase template via WHATIF respectively.  Each monomer forms the V-
shaped cleft and contains the 3 domains previously described.   
 
The P. falciparum DOXP reductoisomerase homology model closely resembles the 3D structure 
of the E. coli homologue when the substrate/inhibitor bound and divalent cation and NADPH 
bound template was used and the homology model generated with WHATIF.  Variation in the 
predicted 3-D structure for P. falciparum DOXP reductoisomerase is likely due to the differences 
within the primary amino acid alignment generated in the homology modelling process.  Since 
there is ~56.5 % amino acid difference between E. coli and P. falciparum DOXP 
reductoisomerase, with some key differences in the catalytic lid region, one would expect 
variation within the modelled structure for P. falciparum DOXP reductoisomerase to occur.  This 
is especially noted for the NADPH-binding N-terminal domain and catalytic domain in the 
sequence alignment.  In specific, the catalytic hatch region for P. falciparum DOXP 
reductoisomerase contains a Lys295 and Lys297 amino acid in comparison to the respective 
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conserved Asn and Ser residues amongst DOXP reductoisomerase homologues.  This would 
suggest a different 3-D orientation of theses residues within the predicted P. falciparum DOXP 
reductoisomerase protein than that of Asn211 and Ser213
 
 in the 3-D structure of E. coli DOXP 
reductoisomerase. The 3-D predicted structure for P. falciparum DOXP reductoisomerase 
generated by SWISS-MODEL utilizing unbound template differs significantly in the N-terminal 
and catalytic domains.  This is most likely due to the X-ray crystal information for E. coli DOXP 
reductoisomerase being impaired due to the absence of the cofactor NADPH, the metal cation 
and substrate.  In this case, structural conformational changes that occur upon the binding of the 
cofactor NADPH and the substrate within the active site of the protein are therefore not taken 
into consideration on generation of the predicted 3-D structure for P. falciparum DOXP.   
3.4.3 Identification of Potentially Critical Residues for the Catalytic Functioning of P. 
falciparum and E. coli DOXP Reductoisomerase 
 
Bioinformatic analysis of the DOXP reductoisomerase protein sequences were performed using 
the multiple sequence alignment (Figure 3.1) and analyses of the structures of the E. coli DOXP 
reductoisomerase and the predicted structure of the P. falciparum DOXP reductoisomerase.  
Residues that have been reported as critical in the biochemical functioning of DOXP 
reductoisomerase from crystallographic studies were identified within the multiple sequence 
alignment and monitored for degree of conservation.   
 
In specific the residues Trp212, Met214 and Pro274 of the catalytic hatch region of E. coli DOXP 
reductoisomerase were inspected.  These residues have been previously identified as critical in 
the orientation of the active site and binding of NADPH.  Trp212 has also been considered to 
interact with the carbon backbone of the substrate/inhibitor (Reuter et al., 2002, Yajima et al., 
2002 and Steinbacher et al., 2003).  The function of these residues has not been experimentally 
confirmed and Trp212, Met214 and Pro274 were therefore considered for site-directed amino acid 
analysis in this investigation. 
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Figure 3.4: Ribbon representation of the structure of E. coli DOXP reductoisomerase and 
the predicted structure of P. falciparum DOXP reductoisomerase 
(A) E. coli DOXP reductoisomerase homodimer.  (B) E. coli DOXP reductoisomerase monomer.  The enzyme 
comprises three domains, which form the overall V-shape of the molecule.  The N-terminal NADPH binding domain 
is shown in violet.  The central connective/catalytic domain shown in crimson binds the divalent cation (magnesium, 
manganese or cobalt) and the phosphate moiety of the substrate.  The carboxy terminal provides structural integrity 
for the active site pocket and is shown in turquoise.  (C) Predicted structure of the P. falciparum DOXP 
reductoisomerase monomer homology modeled using the unbound E. coli homologue crystal structure data as a 
template.  (D) Predicted structure of P. falciparum DOXP reductoisomerase monomer homology modeled using the 
substrate/inhibitor and divalent cation-bound E. coli homologue crystal structure data as a template.  Ribbon 
representations were generated using Molscript (Kraulis, 1991) using the crystal structure data generated via Reuter 
et al. (2002)(PDB accession code 1K5H), Yajima et al. (2002)(PDB accession code 1JVS) and Steinbacher et al. 
(2003)(PDB accession codes 1ONO, 1ONN and 1ONP). 
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Strictly conserved residues are likely to be essential within the catalytic mechanism or structural 
integrity within the protein, especially with regards to the catalytic site and hatch of DOXP 
reductoisomerase.  Pro274, Trp212, Met214
Figure 3.5
 were found to be conserved within all homologues and 
due to their potential roles within the binding to the nicotinamide moiety of NADPH and 
structural integrity of the active site, this is not surprising.  The orientation of these residues 
within the 3-D topology of DOXP reductoisomerase were assessed ( ).  Trp212
 
 is a vital 
residue for interaction with the substrate/inhibitor as well as NADPH.  The formation of the 
hydrophobic pocket into which the substrate binds in the presence of NADPH is an essential 
factor in the catalysis process.  The residues, which ensure this hydrophobic nature and structural 
architecture of the active site, are stacked together in a closely associated cluster and form 
essential contacts with residues on the catalytic hatch, NADPH and the substrate.  These residues 
were chosen for biochemical analysis via site-directed mutagenesis to potentially unravel the 
biochemical roles essential in the functioning of DOXP reductoisomerase. 
Small sequence changes affect the biochemical properties of the protein with regard to structure 
or function.  From the analysis of the multiple sequence alignment of the catalytic hatch region 
the residues Asn211 and Ser213 were found not to be conserved within the P. falciparum DOXP 
reductoisomerase sequence in comparison to the E. coli and other homologues within the 
catalytic loop.  In P. falciparum DOXP reductoisomerase both Asn211 and Ser213
Figure 3.5
 are replaced by 
a lysine and represent non-conservative substitutions making it intriguing that both residues are 
substituted for a lysine in the case of P. falciparum DOXP reductoisomerase.  This could result in 
the catalytic hatch of P. falciparum DOXP reductoisomerase behaving in a slightly modified 
manner to that of other species.  The orientation of these residues were analysed using the E. coli 
DOXP reductoisomerase model and the P. falciparum DOXP reductoisomerase homology 
models (refer to ).  The side chains of the Lys295 and Lys297
Figure 3.5
 residues protrude into the 
catalytic pocket of P. falciparum DOXP reductoisomerase ( (C)).  These residues are 
polar and charged and are likely to perform essential contacts with the substrate backbone.  The 
topologically equivalent Asn211 and Ser213 in E. coli DOXP reductoisomerase are however 
orientated differently.  Both Asn and Ser are polar yet carry no charge and upon inspection of the 
3-D E. coli DOXP reductoisomerase Ser213 was found to protrude into the active site whereas 
Asn211 Figure 3.5 seems to protrude outward ( (F)).  This is suggestive of Asn211 being involved 
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within other structural contacts.  The differences in the orientation of the topologically equivalent 
residues within P. falciparum and E. coli DOXP reductoisomerase homologues is suggestive of a 
variation in the role that the catalytic hatch provides in securing the substrate and the mode in 
which it performs this function within the parasitic system.   
 
To determine whether the activity of DOXP reductoisomerase and its affinity to substrate are 
mediated differently between the P. falciparum and E. coli DOXP reductoisomerase proteins site-
directed mutagenesis of the Lys295 and Lys297
 
 within P. falciparum DOXP reductoisomerase to an 
asparagine and serine respectively and vice versa for the E. coli DOXP reductoisomerase were 
prepared.   
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Figure 3.5: Ribbon representation of the E. coli DOXP reductoisomerase and the predicted 
structure of P. falciparum DOXP reductoisomerase 
(A-C) depict the predicted structure of the P. falciparum DOXP reductoisomerase homology model using ligand-
bound E. coli DOXP reductoisomerase crystal data co-ordinates as a template.  (D-F) depict the E. coli DOXP 
reductoisomerase.  A and D represent the individual subunit domains with blue representing the N terminal NADPH 
binding domain, red the catalytic domain and green the C terminal domain.  Residues identified as being potentially 
critical in the function of the enzyme are highlighted in B and E.  C and F show these residues magnified.  Whatif 
was used to generate the homology model (Vriend, 1990) and Molscript to generate the ribbon representations 
(Kraulis, 1991).  The E. coli DOXP reductoisomerase crystal structure co-ordinates were determined by Steinbacher 
et al. (2003)(PDB accession code 1ONO, 1ONN and 1ONP). 
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3.4.4 Screening and Purification of DOXP Reductoisomerase Mutant Plasmid Constructs  
 
Apart from the mutagenesis reaction for plasmid construct pQE9EcDXR(P274I), all mutagenesis 
reactions were successful.  
 
3.4.4.1 Screening of pQE9EcDXR(W212Y), pQE9EcDXR(W212L), and 
pQE9EcDXR(W212F) and Purification of (His)6-EcDXR(W212Y), (His)6-
EcDXR(W212L) and (His)6-EcDXR(W212F) 
 
The mutagenesis reaction products for were resolved on 0.8 % agarose gel according to the 
method described in 2.3.2.3 (data not shown).  Mutagenic amplification products were screened 
via diagnostic restriction enzyme analysis according to sections 3.3.5 and 3.3.7.  Figure 3.6 (A) 
indicates the successful NcoI restriction digests of the pQE9EcDXR(W212Y) and 
pQE9EcDXR(W212L) plasmid constructs.  Upon NcoI restriction the putative 
pQE9EcDXR(W212Y) and pQE9EcDXR(W212L) mutant plasmid constructs resulted in three 
DNA fragments of 3389 bp, 1023 bp, and 210 bp (Figure 3.6(A); lanes 5 and 7 respectively) thus 
confirming the presence of mutagenic DNA.  The parental/template DNA resulted in only two 
DNA fragments of 3599 bp and 1023 bp as expected (refer to Figure 3.6(A); lane 3).  The 
presence of the desired mutation on plasmids pQE9EcDXR(W212Y) and pQE9EcDXR(W212L) 
was further validated through DNA sequencing (data not shown).  The desired mutation on 
plasmid pQE9EcDXR(W212F) could not be confirmed through restriction digest with NcoI but 
was confirmed through DNA sequencing (data not shown).  DNA sequencing revealed the 
incorporation of the required mutation however the silent mutation required for the insertion of 
the restriction enzyme site for NcoI was not achieved possibly due to a fault in the synthesis of 
the oligonuceotide primer pair.  
 
Over-production and solubility analysis was performed for each mutant construct according to 
section 2.3.2.4.  All mutant DOXP reductoisomerase proteins showed profiles corresponding to 
that of the wild type protein (E. coli DOXP reductoisomerase) with regard to optimal induction 
period and solubility (data not shown).  Purification of the (His)6-tagged EcDXR(W212Y), 
EcDXR(W212L) and EcDXR(W212F) proteins was via nickel chelate affinity chromatography 
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under native conditions described in section 2.3.3 (refer to Figure 3.6 B, C, and D respectively).  
The cleared lysate of the respective mutant DOXP reductoisomerase protein was exposed to the 
resin overnight at 4˚C to allow for maximal bindi ng.  The (His)6-tagged E. coli DOXP 
reductoisomerase mutant proteins saturated the nickel sepharose beads representative of the high 
levels of unbound protein within the flow through fractions (Figure 3.6 (B, C and D); lane 7).  
The respective EcDXR(W212Y), EcDXR(W212L) and EcDXR(W212F) protein was eluted 
competitively in the presence of 1 M imidazole (Figure 3.6 B, C, and D respectively; lane 11-13); 
however it was also present within the wash steps (Figure 3.6 (B, C and D); lane 8-10) possibly 
due to weak interaction of the recombinant protein to the resin due to the effects of over-
saturating the resin.  Buffer exchange to remove the imidazole from the protein fractions was 
performed and the protein concentrated and utilized in subsequent DOXP reductoisomerase 
activity assays (refer to Figure 3.6 (B, C, and D); lane 15).  All proteins were purified to >95 % 
purity with yields of 2.5 mg, 2.7 mg and 5.4 mg per litre of culture for EcDXR(W212L), 
EcDXR(W212Y), and EcDXR(W212F) respectively.  
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Figure 3.6: Screening of pQE9EcDXR(W212Y) and pQE9EcDXR(W212L) DOXP 
reductoisomerase mutant plasmid constructs and purification of the (His)6-
EcDXR(W212Y), (His)6-EcDXR(W212L) and (His)6-EcDXR(W212F) DOXP 
reductoisomerase proteins 
(A) 1.6 % Agarose gel electrophoresis of the diagnostic restriction enzyme analysis of putative 
pQE9EcDXR(W212Y) and pQE9EcDXR(W212L) plasmid DNA.  Lambda DNA restricted with PstI was separated 
within lane 1 as a marker (sizes are in bp).  The uncut no enzyme pQE9EcDXR parental plasmid DNA products can 
be seen within lane 2.  Within lane 3 the template DNA restricted with NcoI results in two DNA fragments of 3599 
bp and 1023 bp as expected.  Lanes 4 and 6 represent the uncut putative pQE9EcDXR(W212Y) and 
pQE9EcDXR(W212L) plasmid DNA.  pQE9EcDXR(W212Y) restricted with the diagnostic enzyme NcoI results in 
three DNA fragments of sizes 3389 bp, 1023 bp, and 210 bp as expected within lane 5.  pQE9EcDXR(W212L) DNA 
is represented within lane 7 as upon restriction with NcoI the resultative DNA fragments of 3389 bp, 1023 bp, and 
210 bp can be seen.  (B, C and D) Native batch nickel affinity purification of (His)6-EcDXR(W212Y), (His)6-
EcDXR(W212L) and (His)6-EcDXR(W212F) respectively.  Each purification step was analysed using SDS-PAGE.  
The Biorad Broad Range Molecular Weight Marker (kDa) was separated in lane 1.  The purification samples 
included un-induced whole cell extract (lane 2), induced whole cell extract (lane 3), whole cell lysate (lane 4), 
soluble fraction (lane 5), insoluble fraction (lane 6), flow-through (lane 7), native wash (lanes 8-10), native elution 
(lanes 11-13), Ni-affinity sepharose beads (lane 14) and imidazole buffer exchanged concentrated protein (lane 15).  
The mutant EcDXR proteins were purified successfully and are indicated with an arrow.   
 
3.4.4.2 Screening of pQE9EcDXR(M214I) and Purification of (His)6-EcDXR(M214I) 
 
The mutagenesis reaction product for the putative mutant pQE9EcDXR(M214I) plasmid DNA 
was transformed into E. coli XL1Blue and screened via diagnostic restriction enzyme digestion 
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according to section 3.3.5 and 3.3.7 (Figure 3.7(A)).  From the digestion with XmaIII a linearized 
fragment was obtained representative of mutant plasmid DNA (Figure 3.7(A); lane 7).  A further 
digest with BamHI and XmaIII was performed to confirm the mutant plasmid DNA and resulted 
in two bands of 3975 bp and 647 bp as expected (Figure 3.7(A); lane 8). The parental template 
DNA restricted with XmaIII resulted in the conformations of uncut DNA being separated, within 
Figure 3.7(A) lane 2, as expected.  Upon digestion with BamHI individually or together with 
XmaIII the parental plasmid was expected to be linearized and resolve as a single DNA fragment 
of 4622 bp (as seen in Figure 3.7(A); lane 4 and 5 respectively).  The desired mutation was 
identified on plasmid pQE9EcDXR(M214I) and validated through DNA sequencing (data not 
shown). 
 
Over-production and solubility analysis was performed according to the procedure outlined 
within section 2.3.2.4.  The (His)6-EcDXR(M214I) protein was found to have similar induction 
and solubility characteristics as that of the wild-type protein (data not shown) and was purified 
through native batch nickel chelate affinity chromatography (section 2.3.3; Figure 3.7(B)).  The 
cleared lysate was bound to the resin maximally overnight representative of little protein of 
DOXP reductoisomerase monomer mass (~45 kDa) in the flow-through sample (Figure 3.7(B); 
lane 7).  The protein appears within the wash samples possibly as a cause of weak interactions 
between the resin and protein due to saturation levels of protein present (Figure 3.7(B); lane 8-
10).  The EcDXR(M214I) protein was successfully purified to >95 % purity at levels sufficient 
for biological analysis (2 mg per litre of culture) through competitive release with 1 M imidazole 
(Figure 3.7(B); lane 11-13, 15).  A large proportion of pure recombinant protein remains attached 
to the Ni2+
Figure 3.7
 charged resin possibly due to strong interactions and maximal binding having 
occurred ( (B); lane 14).  Additional protein may be eluted from the column by 
increasing the imidazole concentration further.  The EcDXR(M214I) protein was buffer 
exchanged and concentrated for activity analysis (Figure 3.7(B); lane 15). 
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Figure 3.7: Screening of pQE9EcDXR(M214I) and purification of (His)6-EcDXR(M214I) 
DOXP reductoisomerase 
(A) 1.6 % Agarose gel electrophoresis of diagnostic restriction enzyme analysis of putative pQE9EcDXR(M214I).  
Lambda DNA restricted with PstI was separated within lane 1 as a marker (sizes are in bp).  Parental plasmid DNA 
uncut DNA conformations are separated within lane 2.  As no XmaIII restriction site is present within the template 
plasmid DNA uncut conformations of plasmid DNA are present (lane 3).  Parental plasmid DNA restricted with 
BamHI results in linearized plasmid DNA and a single fragment of 4622 bp can be seen within lane 4.  BamHI and 
XmaIII double digest of parental plasmid DNA yields a single DNA fragment representing linearized plasmid DNA 
(4622 bp) due to BamHI restriction and no XmaIII nuclease restriction site present in parental plasmid DNA (lane 5).  
Lane 6 represents the uncut DNA for pQE9EcDXR(M214I).  Linearized pQE9EcDXR(M214I) of size 4622 bp is 
present within lane 7 and 8 due to restriction with XmaIII and BamHI respectively.  Upon the double digest with 
XmaIII and BamHI the putative mutant DNA is confirmed through the separation of two DNA fragments of 3975 bp 
and 647 bp.  (B) Native batch nickel chelate affinity purification of EcDXR(M214I).  Biorad Broad Range SDS-
PAGE Molecular Markers are separated in lane 1 and sizes shown in kDa.  Native purification samples were taken 
after each purification step and analysed on SDS-PAGE these included uninduced and induced E. coli 
XL1Blue[pQE9EcDXR(M214I)] whole cell extracts separated within lane 2 and 3 respectively, cleared lysate (lane 
4), insoluble fraction (lane 5), soluble fraction (lane 6), flow-through (lane 7), native wash fractions (lane 8- 10), 
native elution fractions (lane 11 – 13), nickel sepharose beads (lane 14) and concentrated imidazole buffer-
exchanged protein eluate fraction (lane 15).  (His)6-EcDXR(M214I) was successfully purified for biological analysis 
(indicated with an arrow). 
 
3.4.4.3 Screening of pQE9EcDXR(N211K, S213K) and pQE31PfDXR(K295N, K297S) and 
Purification of (His)6-EcDXR(N211K, S213K) and (His)6-PfDXR(K295N, K297S) 
 
The mutagenesis reaction products for the putative pQE9EcDXR(N211K, S213K) and 
pQE31PfDXR(K295N, K297S) were transformed into E. coli XL1Blue and diagnostic restriction 
enzyme analysis to confirm the putative mutant DOXP reductoisomerase DNA was performed 
according to section 3.3.7. 
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The replacement of the Asn211 and Ser213
Figure 3.8
 residues within the E. coli DOXP reductoisomerase 
protein with lysine residues was successful.  This was achieved through first introducing the 
codon for lysine at codon 211, confirming this mutation, and then utilizing the 
pQE9EcDXR(N211K) DNA as a template to incorporate the codon for lysine at codon 213.  
Verification of the pQE9EcDXR(N211K) DNA is shown within  (A).  Upon the 
substitution of the Asn211
Figure 3.8
 with lysine the restriction endonuclease site for NcoI was introduced 
through a silent mutation.  Upon NcoI digestion of template DNA only two fragments of 3599 bp 
and 1023 bp were resolved however are not clear within  (A), lane 3.  For the 
incorporation of the lysine residue at codon 211 three DNA fragments were obtained (Figure 
3.8(A); lane 5 and 7) of 3389 bp, 1023 bp and 210 bp upon NcoI digestion as expected indicating 
the presence of pQE9EcDXR(N213K) DNA.  The pQE9EcDXR(N211K) DNA was then used as 
the template for the introduction of the codon for lysine at codon 213.  Confirmation of putative 
pQE9EcDXR(N211K, S213K) DNA was through NcoI restriction analysis.  The removal of the 
previously incorporated NcoI site upon substitution of the Ser213
2.3.2.3
 to a lysine residue resulted in 
only two DNA fragments of 3599 bp and 1023 bp as expected (data not shown).  Samples were 
resolved using agarose gel electrophoresis, as described in section , upon a 1 % agarose 
gel, 0.5 μg/ml ethidium bromide in 0.5x TBE buffer at 100V. Additionally the desired mutations 
in pQE9EcDXR(N211K, S213K) were verified through DNA sequencing (data not shown). 
 
The over-production and solubility analyses for the (His)6-EcDXR(N211K, S213K) protein were 
performed according to the methodology described in section 2.3.2.4 (data not shown).  The 
over-production for this protein was equivalent with the wild type enzyme upon SDS-PAGE 
analysis and the protein was found to be soluble.  The EcDXR(N211K, S213K) cleared lysate 
was allowed to bind to the resin overnight for maximal binding.  This is apparent due to residual 
levels of protein present within the flow-through fraction (Figure 3.8(B); lane 7).  Elution was 
achieved through competition with 1 M imidazole (Figure 3.8(B); lane 11-13) and resulted in 
pure protein being released from the nickel charged resin.  Protein was still bound to the resin 
after purification as can be seen for Figure 3.8 (B) lane 14.  Native batch purification of the 
(His)6-tagged protein was successful (Figure 3.8(B)) however; levels of active protein were not 
sufficient for activity assays 
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Figure 3.8: Screening of pQE9EcDXR(N211K, S213K) and purification of (His)6-
EcDXR(N211K, S213K) DOXP reductoisomerase 
(A) 1 % Agarose gel electrophoresis of diagnostic restriction enzyme analysis of putative pQE9EcDXR(N211K, 
S213K).  Lambda DNA restricted with PstI was separated within lane 1 as a marker (sizes are in bp).  Parental 
plasmid DNA uncut DNA conformations are separated within lane 2.  Lane 3 represents the restriction of parental 
plasmid DNA with NcoI, which should have resulted in two DNA fragments of 3599 bp and 1023 bp.  Lanes 4 and 6 
represent uncut pQE9EcDXR(N211K) DNA.  Lanes 5 and 7 represent NcoI restricted mutant DNA resulting in three 
DNA fragments of 3389 bp, 1023 bp, and 210 bp as expected.  NcoI restriction of pQE9EcDXR(N211K, S213K) 
DNA did not allow for visualization of the mutant DNA clearly and therefore was confirmed by DNA sequencing.  
(B) Native batch nickel-chelate affinity purification of EcDXR(N211K, S213K).  Biorad Broad Range SDS-PAGE 
Molecular Markers are separated in lane 1 and sizes shown in kDa.  Native purification samples were taken after 
each purification step and analysed on SDS-PAGE these included uninduced and induced E. coli 
XL1Blue[pQE9EcDXR(N211K, S213K)] whole cell extracts separated within lane 2 and 3 respectively, cleared 
lysate (lane 4), insoluble fraction (lane 5), soluble fraction (lane 6), flow-through (lane 7), native wash fractions (lane 
8- 10), native elution fractions (lane 11 – 13), and nickel sepharose beads (lane 14).  Purified (His)6-EcDXR(N211K, 
S213K) is indicated with an arrow. 
 
The mutagenesis reaction product for pQE31PfDXR(K295N, K297S) was transformed into E. 
coli XL1Blue and screened for the putative mutant DNA via restriction enzyme analysis 
described in section 3.3.7.  A similar approach to that of the pQE9EcDXR(N211K, S213K) 
mutagenesis construction was used.  The codon for lysine at codon 297 was replaced by the 
codon for serine in the first mutagenesis reaction followed by the introduction of the codon for 
asparagine at codon 295.  The confirmation of the pQE31PfDXR(K297S) mutation was achieved 
through NcoI restriction (Figure 3.9(A)).  The restriction site was engineered through a silent 
mutation to allow for three fragments of 2771 bp, 1263 bp and 681 bp to be resolved on agarose 
gel electrophoresis representing successful mutagenesis (Figure 3.9(A); lane 5).  The parental 
plasmid has two restriction sites for NcoI thus resulting in two DNA fragments of 2771 bp and 
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1944 bp (Figure 3.9(A); lane 3).  The pQE31PfDXR(K297S) DNA was then used as the template 
for the introduction of the codon change for the K295N amino acid substitution.  Upon successful 
replacement of the codon for lysine at codon 295 with a codon for asparagines, the NcoI 
restriction site introduced within the K297S substitution was removed.  Thus upon restriction 
with NcoI two fragments of 2771 bp and 1944 bp are present representing pQE31PfDXR(K295N, 
K297S) DNA (Figure 3.9(B); lane 5).   
 
Over-production and solubility analysis (data not shown) indicated that the same problems were 
still apparent as experienced for the PfDXR protein, but to a lesser degree.  The over-production 
of the PfDXR(K295N, K297S) protein improved compared to PfDXR (refer to Figure 3.9(C), 
lane 2 and 3) and the protein seemed to be mainly soluble.  Native batch purification was not 
successful even though the protein is soluble under native conditions (data not shown).  For 
purification purposes the combination of denaturing and native batch purification was then 
attempted (Figure 3.9(C)).  The lysate was prepared under denaturing conditions and the protein 
allowed to bind maximally to the resin overnight, apparent due to the low levels of P. falciparum 
DOXP reductoisomerase present within the flow-through sample (Figure 3.9(C); lane 7).  The 
protein bound resin was then washed under native conditions allowing for renaturation (Figure 
3.9 (C); lane 8-10).  The protein was then removed from the column through competitive elution 
with increasing imidazole concentrations (Figure 3.9(C); lane 11-17).  A 31 kDa protein within 
the protein elution can be seen in Figure 3.9 (C); lane 12 – 17 and is possibly an E. coli protein 
contamination as a result of non-specific proteins that have bound to the nickel charged resin and 
eluted off in the presence of the imidazole.  Additionally, the recombinant protein was found to 
remain associated with the nickel sepharose beads after purification (Figure 3.9(C); lane 18).  
Attempted removal of the protein using increasing concentrations of imidazole was attempted but 
unsuccessful (data not shown).  Due to the low concentration and low purity of the 
PfDXR(K295N, K297S) protein obtained, biological assays were not performed. 
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Figure 3.9: Screening of pQE31PfDXR(K295N, K297S) and purification of (His)6-
PfDXR(K295N, K297S) DOXP reductoisomerase 
(A) 0.8 % Agarose gel electrophoresis of pQE31PfDXR(K297S).  Lambda DNA restricted with PstI was separated 
in lane 1 with sizes depicted in bp.  Lane 2 represents the conformations of uncut parental DNA.  NcoI restricted 
parental DNA resulted in two fragments of 2771 bp and 1944 bp within lane 3.  Lane 4 and 5 constitute the uncut 
and NcoI restricted pQE31PfDXR(K297S) DNA respectively.  Three fragments of 2771 bp, 1263 bp and 681 bp are 
present within lane 5 indicative of the pQE31PfDXR(K297S) DNA.  (B) 0.8 % Agarose gel electrophoresis of 
pQE31PfDXR(K295N, K297S).  PstI restricted Lambda DNA in bp was separated in lane 1.  Lane 2 and 3 represent 
the pQE31PfDXR(K297S) DNA as for (A) lane 4 and 5.  pQE31PfDXR(K295N, K297S) DNA was present within 
lane 4 and 5.  Lane 4 represents the uncut DNA conformations and lane 5 the NcoI restricted putative mutant DNA.  
Upon NcoI restriction the disappearance of the 681 bp fragment was noted and two DNA fragments of 2771 bp and 
1944 bp are present indicative of pQE31PfDXR(K295N, K297S) DNA.  (C)  Denaturing/Native batch purification of 
(His)6-PfDXR(K295N, K297S) reductoisomerase.  Samples were analysed using SDS-PAGE at each step of the 
purification procedure.  Biorad Broad Range Molecular Markers (kDa) are separated in lane 1.  Uninduced and 
induced E. coli XL1Blue[pQE31PfDXR(K295N, K297S)] whole cell extracts separated within lane 2 and 3 
respectively, cleared lysate (lane 4), insoluble fraction (lane 5), soluble fraction (lane 6), flow-through (lane 7), 
native wash fractions (lane 8- 10), duplicate native elution fractions with 100mM (lane 11), 150 mM (lane 12-13), 
200 mM (lane 14-15), and 250 mM imidazole (lane 16-17), and nickel sepharose beads (lane 18) are shown.  
Purified (His)6-PfDXR(K295N, K297S) is indicated with an arrow. 
 
  106 
3.4.5 The in vitro Analysis of the Rational Amino Acid Substituted E. coli DOXP 
Reductoisomerase Proteins 
 
The Trp212 and the Met214 residues present within the catalytic hatch have been considered 
essential for the DOXP reductoisomerase catalysis based on predictions from structural data.  
They are considered to provide a stacking role, together with Pro274
Figure 3.1
, essential in ordering of the 
active site and association with NADPH.  Both residues were shown to be conserved amongst 
DOXP homologues ( ) and are thought to be involved in hydrophobic interactions with 
the NADPH cofactor as well as with the carbon backbone of the substrate, making them essential 
in DOXP reductoisomerase activity.  These residues were targeted for rational amino acid 
substitution to further elucidate the role they provide in association with the substrate, cofactor 
and the active site structural residues in ensuring DOXP reductoisomerase activity. 
 
Proteins that contained rational amino acid substitutions were analysed for the effect of the 
substitution upon the activity of DOXP reductoisomerase according to the NADPH coupled 
enzyme assay described in section 2.3.3.3 (Figure 3.10).  Specific activities were determined for 
the modified proteins according to the published assay which, uses substrate concentrations that 
are saturating (excess relative to enzyme), but which are not necessarily steady state conditions.  
To further characterize the effects of the mutations, Michaelis-Menten and Lineweaver-Burk 
plots were generated to determine Km values.  While the specific enzyme activities for EcDXR 
and its derivatives was determined from three independent batches of purified protein, the Km 
values for the EcDXR derivatives were determined for only one batch of purified protein.  
Therefore, the Km values for the EcDXR derivatives were considered to be preliminary data.  
However, the Km values were used as an indicator of any effect on substrate (DOXP) binding 
affinity.  The enzyme kinetic data and specific enzyme activities are illustrated within Table 7 
and discussed in the following section. 
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Figure 3.10: DOXP reductoisomerase specific activity for EcDXR and its derivatives 
The NADPH coupled DOXP Assay was monitored at 340 nm for the oxidation of NADPH.  Final substrate and 
NADPH concentrations of 0.3 mM were used.  Three independent purifications for the EcDXR and its derivatives 
were used to assay for DOXP activity in triplicate with the bars representative of standard deviation.  Bar graphs are 
representative of the specific activity obtained for EcDXR (blue), EcDXR(W212Y) (dark pink), EcDXR(W212L) 
(yellow), EcDXR(W212F) (light blue) and EcDXR(M214I) (purple) and are labelled below accordingly.  All 
derivatives of EcDXR resulted in the decline of specific activity with the EcDXRW212Y and EcDXRM214I 
derivatives causing a significant decrease of specific activity on comparison with the wild-type EcDXR.  The 
specific activities and standard deviations calculated are depicted in Table 7. 
 
Trp212 was substituted with three residues; tyrosine, leucine and phenylalanine and Met214
5.2
 with an 
isoleucine.  All purifications of the EcDXR derivatives were successful with the proteins being 
both soluble and active.  There is the assumption that the protein is folded and functional on a 
gross level and that any perturbations have occurred at a local level at the active site.  However, 
we are aware that thorough characterization of the folded protein is ideally required e.g. circular 
dichroism (CD) for secondary structure analysis and 3-D crystal structure analysis for tertiary 
structure analysis.  Additionally, validation of the substitutions on substrate affinity, inferred 
indirectly here from Km analysis, is still required through the determination of direct binding 
affinities (KD) using non-hydrolysable substrates/inhibitors (discussed in Chapter 5, section ). 
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Upon introduction of a tyrosine residue in EcDXR(W212Y) the specific activity and affinity for 
the substrate were affected (refer to Figure 3.10 and Table 7).  EcDXR(W212Y) had a 7 fold 
lower specific activity compared to EcDXR (0.25 μmol/min/mg ± 0.04; Figure 3.10), possibly as 
a result of the tyrosine being unable to engage in contacts that the tryptophan residue was 
previously involved in.  Interaction of the indole ring of His257 with Trp212 was possibly 
eliminated, preventing the correct orientation of these residues.  It is also possible that the polar 
hydroxyl group of the tyrosine could not be accommodated within the active site resulting in the 
loss of structural packing of the active site and the decrease in enzyme activity.  In particular, the 
hydrophobic stacking interactions that Trp212 had with the Met214 and Pro274 were possibly not 
accommodated by a tyrosine at position 212.  The hydroxyl moiety of tyrosine may seek to 
hydrogen bond with other residues either within the catalytic pocket or elsewhere in the protein.  
The hydroxyl group could potentially form hydrogen bonds with catalytic residues (e.g. Ser222) 
thereby competing with the substrate leading to the loss of affinity of enzyme to substrate along 
with loss of activity.  Therefore, the hydrophobic interactions between Trp212, Met214 and Pro274
 
 
which are necessary for the correct active site architecture and binding of substrate, as well as 
activity, are affected by the W212Y substitution creating a protein no longer as efficient in the 
catalysis reaction and secure binding of the substrate 
When Trp212
Figure 3.10
 was substituted with leucine the specific activity of the resultant protein 
EcDXR(W212L) was lower than that of EcDXR, but higher than that of EcDXR(W212Y)(0.52 
μmol/min/mg ± 0.4;  and Table 7).  The EcDXR(W212L) DOXP reductoisomerase 
activity was determined to have a Km value of ~8 μM.  The leucine may be accommodated within 
the catalytic pocket more effectively than a tyrosine resulting in a higher specific activity for 
EcDXR(W212L) compared to EcDXR(W212Y).  The affinity for the substrate was found to be 
increased relative to EcDXR (Km of ~8 μM).  The leucine may be able to maintain the 
hydrophobic interactions between the residues essential for structural integrity of the active site 
and DOXP binding.  More specifically, the leucine may be able to interact with the Met214 and 
Pro274 sufficiently enough to maintain the structural integrity of the active site despite the loss of 
the tryptophan residue.  The interaction between His257 and Ser151 and interaction between Trp212 
and His257, through hydrogen bonding would have been removed by introducing the leucine at 
position 212 and non-polar interactions between the leucine and other residues would be favoured 
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in EcDXR(W212L).  This suggests that while the substrate binding affinity was improved for 
EcDXR(W212L), possible due to increased hydrophobic interactions within the active site, the 
orientation of the His257, Ser151, Met214 and Pro274
 
 may have been disrupted sufficiently to perturb 
catalytic activity slightly compared to EcDXR. 
Trp212
Figure 3.10
 was substituted with a phenylalanine residue in EcDXR(W212F) affecting specific activity 
and substrate affinity (refer to  and Table 7).  EcDXR(W212F) had a 2 fold reduction 
in specific activity (0.74 μmol/min/mg) compared to EcDXR, but higher than that of 
EcDXR(W212Y) and EcDXR(W212L).  The phenylalanine residue may be accommodated 
within the active site more effectively than a tyrosine or leucine.  Phenylalanine may maintain the 
hydrophobic interactions within the active site and still interact with Met214 and Pro274 
sufficiently enough to maintain the structural integrity of the active site despite the loss of the 
tryptophan residue.  The interaction between His257 and Trp212 was possibly interrupted on the 
phenylalanine substitution and the stacking of the active site slightly altered causing the decrease 
in enzyme activity in EcDXR(W212F).  The affinity for substrate was found to be decreased 
relative to EcDXR, possibly due to the phenylalanine residue not being able to interact with the 
carbon backbone of the substrate.  Any potential interactions between the Trp212 and the substrate 
backbone are affected by the altered orientation of the active site residues on phenylalanine 
substitution, thus lowering the affinity for substrate.  Therefore, Trp212
 
 may make essential 
contacts with the carbon backbone of the substrate allowing for the secure binding as well as 
providing a stacking role essential for the correct architecture of the active site. 
The Met214
Figure 3.10
 residue is closely associated with NADPH and was substituted with an isoleucine 
residue.  This substitution resulted in a specific activity of 0.049 ± 0.02 μmol/min/mg and a Km 
value of ~8 μM ( , Table 7).  The EcDXR(M214I) specific activity was significantly 
reduced (36 fold) compared to EcDXR, whereas the Km value of ~8 μM is suggestive of an 
increase in affinity of EcDXR(M214I) to the substrate (DOXP).  The Met214 residue is suggested 
to interact with Pro274 and Trp212 and in the presence of NADPH allow for the structural 
architecture of the active site to be correctly orientated.  The isoleucine may be able to maintain 
the hydrophobic interactions and hydrogen bonding interactions made between the substrate and 
the structural and catalytic residues.  The possible increase in substrate affinity suggests that it is 
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the interference of the contact made between Met214 and NADPH, which has resulted in the loss 
of enzyme activity.  To elucidate if indeed the interaction between Met214
 
 and NADPH has been 
interrupted, calculation of the Km with regard to NADPH is necessary. 
Table 7: DOXP reductoisomerase kinetic parameters for EcDXR and its derivatives 
 Specific Activity 
(μmol/min/mg) ± Std. Dev. 
Km
(μM) 
a 
EcDXR 1.77 ± 0.39 282 
EcDXRW212Y 0.25 ± 0.04 N.D. 
EcDXRW212L 0.52 ± 0.4 8 
EcDXRW212F 0.74 ± 0.18 N.D. 
EcDXRM214I 0.05 ±0.02 8 
a = The Km values were determined from Michaelis-Menten and Lineweaver-Burk plots using a substrate 
concentration range of 0 – 300 μM 
N.D. = Km could not be determined accurately using the standard substrate concentration range most likely due to 
greatly reduced substrate affinity (Km in millimolar range). 
 
3.5 Conclusion 
 
The analysis of the sequence identity of E. coli and P. falciparum DOXP reductoisomerase 
revealed a relatively high level of identity at the protein level.  The construction of a predicted 
structure for P. falciparum DOXP reductoisomerase using the E. coli DOXP reductoisomerase as 
a template was performed.  The predicted 3-D structure of P. falciparum DOXP 
reductoisomerase may be used for structural, functional and catalytic predictions regarding the 
parasitic protein’s mechanism.  Two homology models were generated based on crystal structure 
data available (Reuter et al., 2002, Yajima et al., 2002 and Steinbacher et al., 2003).  The first 
predicted 3-D structure for P. falciparum DOXP reductoisomerase was generated from crystal 
structure data from the ligand-free E. coli DOXP reductoisomerase (Reuter et al., 2002; Yajima 
et al., 2002) whereas the second utilized X-ray crystal structure co-ordinates of the substrate 
bound, cofactor bound and metal cation bound E. coli DOXP reductoisomerase.   
 
The 3-D predicted structure for P. falciparum DOXP reductoisomerase, when utilizing the ligand 
bound template, closely resembled the 3-D structure of E. coli DOXP reductoisomerase.  The 3-D 
predicted structure for P. falciparum DOXP reductoisomerase based upon unbound template 
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varied from E. coli DOXP reductoisomerase`s 3-D structure greatly.  This is possibly as a result 
of the X-ray crystal structure of E. coli DOXP reductoisomerase used being impaired due to the 
absence of the NADPH, substrate and metal cation.   
 
Bioinformatic analysis of the primary amino acid sequences of E. coli and P. falciparum DOXP 
reductoisomerase was via multiple sequence alignment and analyses of their 3-D structures.  
Residues that have been previously identified as critical in DOXP reductoisomerase activity were 
identified within the multiple sequence alignment for degree of conservation.  In particular, 
residues within the catalytic hatch of P. falciparum and E. coli DOXP reductoisomerase were 
analysed for conservation and 3-D orientation.   
 
From previous analysis of the 3-D structure of E. coli DOXP reductoisomerase, amino acids 
essential in the functioning of the enzyme have been identified.  Trp212, Met214 and Pro274 have 
been previously identified as critical in the orientation of the architecture of the active site in the 
presence of NADPH, and interaction with the carbon backbone of the substrate (Reuter et al., 
2002, Yajima et al., 2002 and Steinbacher et al., 2003), however this has not been experimentally 
verified.  In this investigation Trp212, Met214 and Pro274
 
 were analysed by site-directed 
mutagenesis and the substitution effect on the enzyme monitored via DOXP reductoisomerase 
activity assays.   
Upon introduction of a tyrosine in EcDXR(W212Y) the specific activity decreased 7-fold upon 
comparison with EcDXR possibly as a result of the tyrosine no longer able to provide the 
essential contacts that the tryptophan was previously involved in.  The hydroxyl group of tyrosine 
was possibly not accommodated within the active site resulting in loss of interaction with Met214 
and Pro274
 
 and therefore a decrease in enzyme activity.  The decrease in affinity in 
EcDXR(W212Y)  to substrate relative to EcDXR could potentially be the result of the hydroxyl 
group competing with the substrate for hydrogen bonding interactions with the active site 
residues.   
On substitution with leucine in EcDXR(W212L) the leucine may be accommodated within the 
catalytic pocket more effectively than a tyrosine resulting in a higher specific activity relative to 
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EcDXR(W212Y).  In particular, the leucine may manage to maintain some of the hydrophobic 
interactions between residues essential for structural integrity of the active site.  Additionally, 
leucine may be able to interact with Met214 and Pro274 sufficiently enough to maintain the active 
site structure.  However, the Met214 and Pro274
 
 residues must be disrupted sufficiently to perturb 
catalytic activity in comparison to EcDXR.   
EcDXR(W212F) had a 2-fold lower specific activity compared to EcDXR, but its activity was 
higher than that of EcDXR(W212Y) and EcDXR(W212L).  The W212F substitution may 
maintain some of the hydrophobic interaction within the active site pocket and still interact to 
some extent with Met214 and Pro274.  The affinity of EcDXR(W212F) for DOXP was reduced 
relative to EcDXR.  The phenylalanine residue can likely no longer associate with the carbon 
backbone of the substrate.  Therefore, for EcDXR(W212F) the Phe residue may maintain a 
degree of structural integrity by interaction with Met214 and Pro274
 
 but can no longer secure the 
substrate as effectively within the catalytic pocket.   
The Met214 substitution with isoleucine resulted in an enzyme with 36-fold lower specific activity 
and increased affinity for DOXP compared to EcDXR.  Since Met214 is closely associated with 
NADPH it is likely that the isoleucine can no longer harbour this interaction causing the decrease 
in enzyme activity observed.  Furthermore, the isoleucine residue may no longer engage in 
interactions with Trp212 and Pro274 to allow for the correct architecture of the active site.  The 
increase in substrate affinity observed for EcDXR(M214I) may be due to isoleucine maintaining 
hydrophobic interactions necessary between active site residues and DOXP.  To validate whether 
the NADPH and Met214 
 
interaction has been disrupted, calculation of the Km with respect to 
NADPH is required. 
The P. falciparum and E. coli DOXP reductoisomerase primary amino acid sequences were 
analysed, for any variation in sequence conservation.  Variations in the amino acid sequence may 
affect biochemical properties of the protein and thus its structure and function.  Specifically, 
analysis of the catalytic hatch region revealed residues Asn211 and Ser213 to be conserved amongst 
E. coli DOXP reductoisomerase and other DOXP reductoisomerase homologues except P. 
falciparum DOXP reductoisomerase where both are replaced with lysine residues.  The different 
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3-D orientation of these topologically equivalent residues within P. falciparum and E. coli DOXP 
reductoisomerase is suggestive of a variation in the role of the catalytic hatch in securing the 
substrate and the mode in which it performs this function in P. falciparum DOXP 
reductoisomerase. 
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4 STRUCTURE-BASED DRUG DESIGN: THE RATIONAL DESIGN OF 
NOVEL ANTI-MALARIAL DRUGS 
4.1 Introduction 
Computational structure-based drug design first made its appearance in the early 1980`s (Joseph-
McCarthy, 1999).  Apart from the development of the HIV-1 protease inhibitors, there have, thus 
far, been few success stories based on this approach.  This apparent lack of progress will 
probably undergo a drastic change in the near future due to the development of functional 
genomics, enhanced computer speed and continuing improvements in structural and sequence 
information (Joseph-Mc
 
Carthy, 1999).  In addition, the coupling of structure-based drug design, 
also referred to as rational drug design, with combinatorial chemistry has allowed for a revolution 
in drug discovery.  On its own, combinatorial chemistry had the disadvantage of producing huge 
numbers of compounds, many of which were irrelevant and ineffective.  Now, with structure-
based drug design, specific knowledge of the drug target can guide combinatorial chemistry to 
produce relevant compounds rapidly and in relatively large numbers. 
4.1.1 Methods and Tools in Structure-Based Drug Design 
 
Structure-based drug design methods can be grouped into two categories, namely, ligand-based 
(analogue-based) or target-based (structure-based) drug design; these can be used as separate 
strategies or together in the process of drug discovery (Bourne and Weissig, 2003).  Ligand-based 
drug design is applicable to all drug discovery strategies as it is dependent upon a group of 
ligands that are known to bind to the drug target even if the structure of the target has not been 
established.  On the other hand, target-based drug design is dependent on the structure of the drug 
target or receptor site of a protein being determined. 
 
In cases where no 3-D receptor information is available, analogue-based drug design may permit 
a 3-D receptor model to be generated from a set of known, active ligands.  Analogue-based drug 
design thus involves the generation of a pharmocophore or quantitative structure-activity 
relationship (QSAR) from which a lead molecule can be identified based on its ability to interact 
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efficiently with the generated receptor model relative to the known set of active ligands (Bourne 
and Weissig, 2003).   
 
Target-based drug design depends on known structural information regarding the target protein 
and receptor site obtained by X-ray crystallography or NMR spectroscopy.  The identification of 
the active site is therefore based upon known ligand-receptor interactions.  In silico docking 
methods then permit an assessment of the binding potential of novel ligands.  Docking methods 
involve the generation of reactivity maps of the ligand docked within the active site of the target 
protein, and have the advantage of allowing for high-throughput screening.  The different binding 
modes or reactivity maps for each ligand can be used to assess the potential of a ligand in terms 
of geometry, conformational space and energy.  De novo synthesis involves the construction of a 
compound within the active site by joining atoms or chemical fragments together that have been 
specifically chosen for their ability to interact with the active site.  The main disadvantage of this 
method is that the compounds are often difficult to synthesize (Bourne and Weissig, 2003). 
 
4.2 Aim 
 
The present investigation has aimed to use DOXP, fosmidomycin and FR900098 as lead 
molecules for the design of novel DOXP reductoisomerase inhibitors.  The binding modes and 
reactivity maps of the lead molecules were assessed and potential DOXP inhibitors designed 
accordingly.  In silico docking studies of novel DOXP reductoisomerase inhibitors were 
performed to permit assessment of the binding potential of the drugs.  DOXP reductoisomerase 
inhibitors, which showed a promising binding affinity, were synthesized and tested using DOXP 
reductoisomerase inhibition assays.  
 
4.3 Experimental Procedures 
 
4.3.1 Ligand Docking and Rational Drug Design 
 
Computer modelling was effected using the ACCELRYS Cerius2TM Drug Discovery Workbench 
modelling platform on a Silicon Graphics O2 computer; the module, LigandFit, was used for the 
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in silico docking experiments.  Structural information regarding the target protein DOXP 
reductoisomerase was downloaded from the PDB (accession codes 1K5H, 1JVS, 1ONN, 1ONO 
and 1ONP).  All ligands were subjected to energy minimization and dynamic simulation routines 
prior to docking.   
 
4.3.2 General Organic Synthesis Procedures 
 
NMR spectra were recorded on a Bruker Avance 400 MHz spectrometer at 303K in deuterated 
chloroform (CDCl3) or deuterated dimethyl sulphoxide (DMSO-d6).  Spectra recorded in CDCl3 
were calibrated on the solvent signals at 7.25 ppm and 77.0 ppm in the 1H and 13C spectra, 
respectively.  Spectra recorded in deuterated DMSO-d6 were calibrated on the solvent signals at 
2.5 ppm in the 1H spectrum and 39.4 ppm in the 13C spectrum.  For 31
 
P NMR, H3PO4 was used as 
an internal standard at δ 0 ppm.   
Normal phase HPLC was performed using a Whatman Partisil 10 Magnum 6 normal phase 
column, a Spectra-Physics P100 Isocratic pump and a Waters RI210 differential refractometer 
detector.  Flash chromatography was adapted from the procedure described by Pederson and 
Rosenbohm (2001) using Merck Silica gel 60 (particle size 0.040 – 0.063 mm).  
 
All solvents were dried according to standard procedures outlined by Perrin and Armarego 
(1988).  Diethyl ether (Et2O) and tetrahydrofuran (THF) were pre-dried over CaH2 and then 
distilled from sodium wire and benzophenone under N2, while N,N-dimethylformamide (DMF) 
was pre-dried with MgSO4 and distilled from 3Å molecular sieves under reduced pressure. 
 
4.3.3 Preparation of Phosphorylated Furan Derivatives 
 
The two experimental approaches explored for the synthesis of the phosphorylated furan 
derivatives were adapted from a method reported by Li and Ganeson (1998).  
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Preparation of 3-trityloxyfuran (2) 
A mixture of triphenylmethyl chloride (8.36 g, 0.03 mol), 3-furanmethanol (1) (3 g, 0.03 mol), 
triethylamine (8 ml; 5.808 g, 0.06 mol) and 4-dimethylaminopyridine (DMAP; 291 mg, 0.002 
mol) was stirred under N2 for 15 hours at 80˚C.  Evaporation of the triethylamine in vacuo gave 
the crude 3-trityloxyfuran (2) (7.084 g, 62 %) as a yellow gum [δH (400 MHz; CDCl3) 3.41 (2H, 
s, CH2) and 7.13 – 7.91 (18H, series of multiplets, Ar-H); δC (100MHz; CDCl3) 40.6 (CH2), 82.0 
(Ph3C), 106.8, 127.2, 127.88, 127.90, 129.6, 139.5 and 146.9 (Ar-C)], which was used without 
further purification. 
 
Preparation of 5-trityloxyfuran-2-carbaldehyde (3) and 3-trityloxyfuran-2-carbaldehyde (4) 
In a dry, round-bottomed flask fitted with a septum seal, a solution of crude 3-trityloxyfuran 
(2)(1g, 0.003mol) in dry THF under N2 was cooled to –30˚C.  Butyllithium (1.5 M in hexane; 4 
ml, 0.006 mol) was then added drop wise from a syringe and the reaction mixture stirred for 4 
hours at -30˚C.  DMF (0.46 ml, 6.0 mmol) was added to the resulting red solution.  The reaction 
mixture was allowed to warm to room temperature, and then stirred for a further 2 hours.  The 
mixture was poured into a slurry of 10 % aqueous NaHCO3 and ice and then extracted using Et2O 
(2 x 25 ml).  Vacuum flash chromatography (elution with hexane-ethyl acetate) afforded a 
residue (2.04 g), shown by 1
 
H NMR analysis to comprise a 0.77:1 mixture of the isomeric 
aldehydes (3) and (4).  Semi-preparative HPLC (elution with MeOH) afforded 5-trityloxyfuran-2-
carbaldehyde (4) as a dark yellow oil; δH (400 MHz; CDCl3) 4.06 (2H, s, CH2), 7.1-7.6 (17H, 
series of signals, Ar-H), and 9.59 (1H, s, CHO); δC (100MHz; CDCl3) 57.8 (CH2), 87.3 (Ph3C), 
126.4, 127.2, 127.9, 128.0, 128.5, 143.6, 145.2 and 153.0 (Ar-C) and 178.0 (CHO). 
Deprotection and phosphorylation of compounds (3) and (4) 
A 0.77:1 mixture of the isomeric aldehydes (3) and (4) (9.0 g in 10 ml dry THF; 24 mmol) was 
stirred together with H3PO4-THF (1:1 v/v; 10 ml) for 2 days at room temperature.  EtOAc (20 ml) 
and 10 % aqueous NaHCO3 (20 ml) were then added.  Effervescence was noted to occur upon 
addition of the NaHCO3 and the aqueous fraction was collected (pH 9.0).  The aqueous fraction 
was acidified to pH 2.0 with 10 % aqueous HCl and then extracted with EtOAc (3 x 10 ml).  The 
organic extract was dried over anhydrous MgSO4 to afford an oil indicated by NMR analysis to 
  119 
contain the isomeric phosphorylated aldehydes (5) and (6).  Annotated NMR spectra of the 
mixture of products are provided in the Appendix (Chapter 6, section 6.3). 
 
Preparation of polymer-bound 3-furanmethanol 
A mixture of polymer bound 2-chlorotrityl chloride (~1.9 mmol Cl/g resin; 4 g), 3-furanmethanol 
(1) (0.157 g; 0.0016 mol) and DMAP (0.003g; 0.025 mmol) in dry DMF was stirred under N2 at 
80˚C for 15 hours.  Evaporation of the solvent in vacuo gave the polymer-bound product (7) as 
pale yellow granules.   
 
Formylation of the polymer-bound substrate (7) 
The yellow product (7) was suspended in anhydrous THF in a dry, round-bottomed flask fitted 
with a septum seal under N2, and the temperature was lowered to -30˚C.  Butyllithium (1.5 M in 
hexane; 5.87 ml, 0.009 mol) was then added drop wise using a syringe and the reaction mixture 
stirred at -30˚C for 4 hours.  The electrophile, DMF (1.17 g; 0.016 mol), was added to the red 
mixture, which was allowed to warm to room temperature and then stirred for a further 2 hours.  
Methanol (40 ml) was added and the resin washed with aqueous methanol (20 ml) and THF (20 
ml) successively to give the polymer-bond aldehyde (8).   
 
Cleavage of 5-(hydroxymethyl)furan-2-carbaldehyde (9) from the polymer support 
A mixture of the polymer-bound aldehyde (8) (3.82 g), trifluoroacetic acid (1 ml), triethylsilane 
(1 ml), and dichloromethane (18 ml) was stirred for 20 minutes at room temperature under N2.  
Evaporation of the filtrate in vacuo afforded a solution of 5-(hydroxymethyl)furan-2-
carbaldehyde (9) in trifluoroacetic acid. 
 
4.4 Results and Discussion 
 
4.4.1 Ligand Docking and Rational Drug Design 
 
To identify and characterize the binding site within DOXP reductoisomerase, previous X-ray 
crystal structure data and residues known to be involved in the catalysis were used. The detailed 
3-D information gave an indication of where the binding pocket is located.  Using a Molecular 
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Mechanics (MM) approach and the LigandFit module, small molecule binding sites on the 
protein surface were identified. Overlap of the known catalytic residues with the putative binding 
pockets on the protein surface permitted the binding site within DOXP reductoisomerase to be 
identified (Figure 4.1).   
 
 
Figure 4.1: The E. coli DOXP reductoisomerase monomer with the site model identifying 
the active site 
Ribbon representation of the E. coli DOXP reductoisomerase with α-helices shown in purple and the β-sheets shown 
in yellow.  The known catalytic residues (shown in solid stick) are situated within the catalytic domain.  The 
identified binding pocket of DOXP reductoisomerase is indicated by yellow dots and fills the groove within the V-
shaped monomer. 
 
For docking purposes, the unbound protein templates were used (1K5H and 1JVS)(Reuter et al., 
2002, Yajima et al., 2002). This was to rule out any fine structural variations within the active 
site that occur on binding to different ligands, such as fosmidomycin in this case, which can 
interfere with the docking method.  Such details are often not detected within docking strategies 
(Fradera et al., 2002).  Initially, the substrate and known inhibitors (fosmidomycin and 
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FR900098) were flexibly docked into the defined active site of DOXP reductoisomerase to 
analyse interactions between the respective ligands and the active site residues.  Examination of 
these known ligands was expected to yield valuable information on the capacity of the active site 
to bind a drug molecule.  The binding modes of these ligands were then compared, and Figure 4.2 
shows the conformational space occupied by DOXP (A and B), fosmidomycin (B and C) and 
FR900098 (D and E).  The receptor model of the bound ligand was coloured according to the 
electrostatic potential (EP) [blue (+ve) to red (-ve)].  The change in the electrostatic potential 
following the introduction of nitrogen within the inhibitor molecule is apparent when compared 
with the natural substrate DOXP.  In previous DFT studies, the nitrogen atoms within the 
inhibitory molecules FOSM and FR-900098 were reported as having calculated charges of –
0.149 and 0.195 respectively, whereas the carbon atom within DOXP was found to be almost 
neutral with a charge of –0.011 (Zubrzycki and Blatch, 2001).  The increase in negative charge 
permits the drug to bind with increased affinity to the active site. 
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Figure 4.2: Binding of DOXP, fosmidomycin and FR900098 to the identified active site 
within DOXP reductoisomerase 
(A, B) The natural substrate (DOXP) flexibly fitted into the catalytic active site of DOXP reductoisomerase.  The 
electrostatic potential surrounding the ligand is indicated from blue (+ve) to red (-ve).  (C, D) The inhibitor 
fosmidomycin flexibly docked within DOXP reductoisomerase.  The electrostatic potential of the receptor model 
indicates an increase in the negative charge surrounding the N atom.  (D, F) The derivative FR900098 docked 
flexibly within the DOXP reductoisomerase active site.  B, D, and F all reflect the same orientation with respect to 
NADPH in the bottom left corner. 
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For the rational design of novel DOXP reductoisomerase inhibitors, a combination of activity, 
specificity and binding stability characteristics were considered.  In terms of specificity and 
activity the conversion of DOXP to MEP mediated by DOXP reductoisomerase was analysed 
(see Chapter 1; Figure 1.5).  DOXP reductoisomerase catalyzes the conversion of DOXP to MEP 
through an intramolecular rearrangement.  Through the introduction of a ring structure within the 
carbon backbone of a drug mimicking DOXP, it was hypothesised that the conformational 
flexibility would be decreased and that the resulting entropic advantage would enhance binding to 
DOXP reductoisomerase.  A set of compounds were designed to mimic the carbon backbone of 
DOXP and the inhibitors FOSM and FR900098, but contain the furan ring (Figure 4.3).   
 
 
Figure 4.3: Chemical Structures of DOXP, fosmidomycin, FR900098 and the furan 
derivatives targeted for synthesis (R= H, Me, Et etc.) 
 
The furan, dihydrofuran and tetrahydrofuran derivatives were fitted into the identified active site 
of DOXP reductoisomerase and scored using LIGSCORE to determine the ranking order of each 
fitted conformation of the ligand.  The ligand that was best conformationally suited to the active 
site was then aligned with the fitted conformations of the substrate, fosmidomycin and FR900098 
(Figure 4.4).  Alignment methods allow for the superposition of molecules using least squares 
fitting, with atom equivalencies specified (in this case manually).  The alignment data (Figure 
4.4) indicates the structural similarity of the fitted conformations of the different ligands.  The 
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rationally designed furan derivatives align with a high level of confidence suggesting they could 
adopt the conformational geometry required for binding to the active site of DOXP 
reductoisomerase.  By improving the specificity of the furan derivatives one could generate a 
novel inhibitor with a higher affinity for the active site.  Improving the specificity could involve 
the introduction of a negative nitrogen within the ring structure or carbon backbone of the furan 
derivatives to increase the affinity of the drug toward the active site.  Furthermore, by altering the 
R-substituent (R=H, Me, Et etc.) one could monitor the effect of different substituents on the 
binding affinity of the drug.   
 
 
Figure 4.4: Alignment of the fitted conformations of the furan, dihydrofuran and 
tetrahydrofuran derivatives upon DOXP and FR900098 
(A) The alignment of the fitted conformations of DOXP and the furan, dihydrofuran and tetrahydrofuran derivatives 
(R=H, Me and Et).  The main carbon backbone aligns with a high degree of confidence with the DOXP substrate.  
(B) The fitted conformation of FR900098 aligned with the furan, dihydrofuran and tetrahydrofuran derivatives 
(R=H, Me and Et).  The alignment suggests that the furan ring might orientate in a different conformation within the 
active site; however, it can still be accommodated by the active site, as the overall conformational space remains 
largely unaffected. 
 
4.4.2 Synthesis of the Phosphorylated Furan Derivatives 
 
The synthesis of the furan derivatives was based upon the procedure described by Li and 
Ganeson (1998) for the preparation of 2,4-disubstituted furans and thiophenes.  The method 
involves lithiation of polymer-bound 3-furanmethanol, reaction with a suitable electrophile and 
subsequent removal from the resin.  It was therefore a promising procedure for the production of 
the furan, dihydrofuran and tetrahydrofuran derivatives outlined in Figure 4.3.  The polymer 
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bound 2-chlorotrityl chloride resin allows for C5 lithiation to occur selectively due to the steric 
bulk of the 2-chlorotrityl moiety preventing electrophilic attack at C2.  In addition to using the 
polymer bound 2-chlorotrityl chloride resin, we decided to “protect” the alcohol function using 
triphenylmethyl chloride, assuming that the bulky trityl moiety would have the same steric effect 
as the polymeric system (Figure 4.5).   
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Figure 4.5: Synthesis of the furan derivative 
 
Initially, 3-furanmethanol was reacted with triphenylmethyl chloride and with the 2-chlorotrityl 
chloride polymer resin.  Direct lithiation of the resulting ethers (2) and (7) generated red 
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mixtures.  Addition of the electrophile, DMF, yielded the formylated furan derivatives (3, 4 and 
8).  The presence of the isomeric formylated derivatives (3 and 4) was indicated by 1H and 13
Figure 
4.6
C 
NMR analysis.  Lithiation at both centres, C2 and C5, is attributed to the failure of the trityl group 
to provide as much steric hindrance at C2 as the polymeric matrix, which only exhibits C5 
lithiation.  Separation of the isomers (3 and 4) was achieved using normal phase HPLC.  
 and Figure 4.7 illustrate the 1H and 13
 
C NMR spectra obtained for compound (4). 
 
10 9 8 7 6 5 4 3 2 1 ppm  
Figure 4.6: δ 400 MHz 1
The aldehyde proton peak (a) can be seen at ~9.5 ppm and the CH2 signal (c) at 4 ppm.  The aromatic phenyl (e) and 
furan protons (b) are present in the region 7.0 ppm to 7.5 ppm. 
H NMR spectrum for compound 4 (separated by normal phase 
HPLC) in CDCl3 
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180 160 140 120 100 80 60 40 20 ppm  
Figure 4.7: 100 MHz 13
 
C NMR spectrum of compound 4 (separated by normal phase 
HPLC) in CDCl3 
Cleavage of trityl ethers has been achieved under mild acid hydrolysis conditions with TFA and 
through catalytic hydrogenation (Barton and Ollis, 1979).  Cleavage of the 5-
(hydroxymethyl)furan-2-carbaldehyde (9) from the polymer support using TFA was achieved 
successfully in low yield.  Thus, phosphorylation was not attempted within this synthetic route.  
The deprotection and phosphorylation of the isomeric tritylated ethers (3) and (4) to afford 
compounds (5) and (6) using phosphoric acid appeared to be successful.  The presence of the 
phosphorylated isomeric aldehydes (5) and (6) was detected using 31 Figure 4.8P NMR ( ). A 
single signal at 4 ppm is indicative of the phosphorylated products (phosphoric acid was used as 
an internal standard at δ 0 ppm). 
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-3-2-110 9 8 7 6 5 4 3 2 1 0 ppm  
Figure 4.8: δ 31P NMR of compounds 5 and 6 in DMSO-d6 
31
 
P NMR spectrum of the isomeric phosphorylated aldehydes (5) and (6). 
Since the tritylated isomers (3) and (4) could be separated using normal phase HPLC, it was 
anticipated that the analogues (5) and (6) could be separated similarly.   
 
4.5 Conclusion 
 
The aim of the structure-based drug design was twofold. Firstly, detailed knowledge of the 
biochemically important features of the protein active site would aid in the development of 
inhibitors that would interact strongly with DOXP reductoisomerase with the added benefit of 
minimizing secondary interactions with other proteins.  Secondly, to rationally design novel 
inhibitors through ligand docking strategies.  The introduction of a ring structure within the 
carbon backbone of a drug mimicking DOXP, was expected to decrease conformational 
flexibility and thus enhance binding to DOXP reductoisomerase.  A set of furan derivatives, 
designed to mimic the carbon backbone of DOXP and the inhibitors FOSM and FR900098, 
demonstrated efficient in silico binding modes, and a synthetic route to a phosphorylated target 
was developed. 
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5 CONCLUSIONS AND FUTURE WORK 
5.1 Conclusions 
5.1.1 Heterologous Protein Production and Purification of DOXP reductoisomerase 
 
The over-production and nickel-chelate affinity purification of E. coli DOXP reductoisomerase in 
a native state was successfully achieved.  The recombinant E. coli DOXP reductoisomerase had a 
specific activity of 1.77 ± 0.34 μmol/min/mg and a Km and Vmax of 282 μM and 0.74 μmoles/min 
respectively.  The Km value determined was in close proximity to the published value of 171 μM 
(Wungsintaweekul, 2001). 
 
The difficulties in the over-production of P. falciparum DOXP reductoisomerase and consequent 
problems in the purification of the recombinant protein made functional analysis of the protein 
not possible.  Different methods of purification were attempted, as well as alteration of the 
growth parameters, to attempt to purify sufficient levels of native P. falciparum DOXP 
reductoisomerase.  The low levels of the protein prior to and upon IPTG induction suggest that 
the recombinant protein was toxic toward the host expression system.   
 
5.1.2 Characterization of the DOXP reductoisomerase Catalytic Site by Rational Amino 
Acid Substitution Analysis 
 
The bioinformatics analysis of the multiple sequence alignment of the DOXP reductoisomerase 
homologues contained conserved residues known to be critical in the functioning of the DOXP 
reductoisomerase protein.  The Trp212, Met214 and Pro274
 
 residues have been previously predicted, 
from crystal structure data, to perform a stacking role essential in the orientation of the active site 
architecture in the presence of NADPH.  These residues have not been tested experimentally and 
were therefore analysed by site-directed mutagenesis and DOXP reductoisomerase activity assays 
to further elucidate their roles within DOXP reductoisomerase activity.   
The Trp212 residue mutations were indicative of this residue performing a vital role in the correct 
orientation of the active site architecture as previously predicted.  Mutations of this residue to a 
Leu, Phe and Tyr residue respectively, resulted in the decrease of DOXP reductoisomerase 
  131 
activity.  This was possibly as a result of a loss of structural integrity within the active site likely 
affected due to the interaction of Met214 and Pro274 being altered on substitution of the Trp212
 
 
residue.  The EcDXR(W212Y) protein had a lower specific activity and reduced affinity for 
substrate relative to EcDXR, possibly due to the hydrophobic nature of the active site being 
affected as well as possible competing hydrogen bonding interactions occurring between the 
hydroxyl of the tyrosine residue and the residues normally involved within substrate binding.  
The EcDXR(W212F) also had a decreased affinity for substrate possibly due to the Phe residue 
no longer being able to interact with the carbon backbone of the substrate.  The EcDXR(W212L) 
protein had a Km value of ~8 μM indicative of an increase in substrate affinity.  This is most 
likely due to the hydrophobic nature of the active site being improved and allowing for improved 
substrate binding.   
The EcDXR(M214I) protein had a reduced enzyme activity however, substrate affinity was 
improved (Km of ~8 μM).  The M214I substitution resulted in the possible disruption of the 
binding of NADPH essential for catalysis and the significant decrease in enzyme activity 
observed relative to EcDXR.  The substrate affinity is not likely to be affected negatively due to 
the interaction with Trp212 and Pro274 being sufficiently maintained by the Ile residue.  The 
improved substrate affinity is possibly due to the hydrophobic interactions being favoured within 
the active site pocket.  The possible increase in substrate affinity suggests that it is the 
interference of the interaction between Met214
 
 and NADPH that has caused the decrease in 
enzyme activity. 
The bioinformatics analysis of the primary amino acid sequence of P. falciparum DOXP 
reductoisomerase with its homologues revealed a deviation in the consensus sequence within the 
catalytic hatch of the protein.  Two lysine residues occur at position 295 and 297 in the P. 
falciparum sequence compared to conserved Asn and Ser residues respectively within other 
DOXP reductoisomerase homologues.  The orientation of the Lys295 and Lys297 Figure 3.5 ( (C)) 
residues were shown to protrude into the catalytic pocket within the predicted 3-D structure of P. 
falciparum DOXP reductoisomerase generated through homology modelling.  The topologically 
equivalent Asn211 and Ser213 in E. coli DOXP reductoisomerase are however orientated 
differently.  In particular, the Asn211 was found to protrude outward suggestive of it not being 
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involved in direct association with the substrate.  These differences in the orientation of the 
topologically equivalent residues within P. falciparum and E. coli DOXP reductoisomerase 
suggests a variation in the role that the catalytic hatch provides in securing the substrate and the 
mode in which it performs this function within the parasitic system.   
 
To determine whether the activity of DOXP reductoisomerase and its affinity to substrate are 
mediated differently between the P. falciparum and E. coli DOXP reductoisomerase proteins site-
directed mutagenesis of the Lys295 and Lys297
 
 within P. falciparum DOXP reductoisomerase to an 
asparagine and serine respectively and vice versa for the E. coli DOXP reductoisomerase were 
prepared.  The purification of these recombinant proteins was successful however not in 
sufficient levels for functional analysis. 
Much of this investigation centres on the residues within the catalytic lid region of DOXP 
reductoisomerase. The Asn211, Trp212 and Ser213 motif is the most predominant consensus 
sequence at this position with regard to the bacterial enzyme, and Lys295, Trp296 and Lys297
Figure 3.1
 
present in the P. falciparum DOXP reductoisomerase sequence (refer to ).  These 
amino acids may differ in other field isolates and laboratory strains for example mouse P. yoelii 
and P. berghei have a Lys295, Trp296 and Asn297 motif and for plant species an Asn274, Trp275 and 
Ser/Asn276
 
 motif occurs.  These variations, at the catalytic lid region of the protein, further 
substantiate the importance of the catalytic hatch within the active site of the enzyme and 
reinforces the need to determine whether the activity of DOXP reductoisomerase and its affinity 
for the substrate are mediated differently amongst different species.    
5.1.3 Structure-Based Drug Design – The Rational Design of Novel Anti-Malarial Drugs 
 
The rational design of novel DOXP reductoisomerase inhibitors was based upon the lead 
molecules DOXP, fosmidomycin and FR900098 and in silico docking studies.  The proposed 
furan derivatives were designed to mimic the carbon backbone of the natural substrate DOXP 
upon binding to the active site.  Through the introduction of a ring structure within the carbon 
backbone of the drug mimicking DOXP, it was hypothesised that the conformational flexibility 
would be reduced and thus enhancing binding to DOXP reductoisomerase relative to the 
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substrate.  This was demonstrated utilizing in silico alignment tools to compare the receptor 
model and binding modes of the furan, dihydrofuran and tetrahydrofuran derivatives to identify 
possible drugs.  A synthetic route for the synthesis of phosphorylated furan derivatives was 
identified and used to synthesise possible DOXP reductoisomerase inhibitors. 
 
5.2 Future Work 
 
The low levels of over-expression of P. falciparum DOXP reductoisomerase suggest that this 
protein is toxic toward the host expression system, E. coli.  Further optimization of the over-
expression and purification of P. falciparum DOXP reductoisomerase is necessary to perform 
functional and inhibitory studies on the parasitic protein.  This could involve the introduction of 
the pLysS plasmid to improve toxic protein expression in E. coli, as well as expression in 
different strains of E. coli, which are suited toward toxic protein production.  The co-expression 
of P. falciparum chaperone proteins may additionally improve expression levels of the P. 
falciparum DOXP reductoisomerase recombinant protein as they may aid in protein folding.  
Additionally, moving into a yeast or baculovirus expression system for the expression of P. 
falciparum DOXP reductoisomerase is worth considering due to the benefits of post-translational 
modification within these expression systems.   
 
Kinetic parameters for E. coli DOXP reductoisomerase were determined on purified protein that 
had a low activity.  In subsequent DOXP reductoisomerase enzyme assays from independent 
purifications of E. coli DOXP reductoisomerase the specific activity has been notably 
consistently higher.  This is suggestive of the purified E. coli DOXP reductoisomerase protein 
utilized within the determination of Km and Vmax was less active.  Therefore, the Km and Vmax 
parameters for E. coli DOXP reductoisomerase need to be verified using several batches of 
independently purified recombinant E. coli DOXP reductoisomerase for which the amount of 
active enzyme is known.  
 
Preliminary kinetic studies of the E. coli mutant DOXP reductoisomerase proteins needs to be 
repeated but suggest a critical role of Met214 and Trp212 in the functioning of DOXP 
reductoisomerase.  The Met214 to Ile mutation specifically indicated a role in the binding of 
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NADPH mediated by this residue essential in DOXP reductoisomerase activity.  Analysis of the 
Km and Vmax of the DOXP reductoisomerase protein and Met214 to Ile derivative with respect to 
NADPH, would further elucidate the Met214
 
 NADPH interaction.   
All purifications of the EcDXR derivatives were successful with the proteins being soluble and 
active.  This assumes that the protein is folded and functional on a gross level and that any 
perturbations occur at a local level within the active site architecture rather than gross misfolding.  
The latter would result in a completely inactive enzyme.  Additional characterization of the 
folded protein is ideally required through either circular dichroism (CD) for secondary structure 
analysis and X-ray crystal structure analysis for tertiary structure determination.   
 
Determination of the amount of active protein within the DOXP reductoisomerase activity assay 
system with an inhibitor (e.g. fosmidomycin) would allow for the kinetic parameters kcat and 
kcat/Km to be calculated to further analyse the effect of the mutation on the DOXP 
reductoisomerase functional mechanism.  This would be achieved by titrating EcDXR and its 
derivatives with an inhibitor to determine at what concentration 100 % inhibition is achieved.  
This in turn is representative of the amount of active enzyme present in an assay.   
 
The Km values determined for EcDXR and its derivatives are not representative of binding 
studies and therefore need to be validated.  The determination of KD through binding studies of 
DOXP reductoisomerase with a non-hydrolysable substrate is necessary to validate the Km values 
and calculate KD.  The natural substrate DOXP cannot be utilized in such studies as it is 
converted to MEP, however the inhibitor fosmidomycin can serve as the non-hydrolysable 
substrate analogue.   
 
Additional rational amino acid substitutions within the active site of DOXP reductoisomerase 
would allow for further biochemical characterization of the protein.  Ultimately, studies within 
the P. falciparum DOXP reductoisomerase need to be performed to determine if the role of the 
residues within the E. coli DOXP reductoisomerase homologue hold true for the parasitic protein.   
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The analysis of the catalytic hatch primary amino acid sequence of P. falciparum DOXP 
reductoisomerase revealed a Lys295 and Lys297
 
 in comparison to asparagine and serine residues in 
other DOXP reductoisomerase homologues.  To examine whether these sequence differences 
noted on bioinformatics analysis are indeed indicative of different functioning of the catalytic 
hatch in the P. falciparum DOXP reductoisomerase, kinetic analysis of the PfDXR(K295A, 
K297S) and EcDXR(A211K, S213K) is required. 
Information from biochemical characterization and further rational amino acid analysis of the E. 
coli and P. falciparum DOXP reductoisomerase active site’s will aid in the development of novel 
DOXP reductoisomerase inhibitors. 
 
In vivo complementation systems could be used to further analyse the ability of the mutant 
DOXP reductoisomerase proteins to complement the wild-type protein (Takahashi et al., 1998).  
This system would also demonstrate whether the P. falciparum DOXP reductoisomerase could 
complement for the E. coli/prokaryotic homologue. 
 
Further optimization of the procedure for the preparation of the furan derivatives is required as 
well as complete chemical characterization of the compounds synthesised.  Enzyme inhibition 
assays of the phosphorylated aldehydes (5) and (6) with purified recombinant E. coli and P. 
falciparum DOXP reductoisomerase will demonstrate their inhibitory effect.  Further 
improvement of the furan derivatives may also be considered through the introduction of a 
negative nitrogen within the heterocyclic system and alteration of the R-group substituents.  
Further structure-based drug design strategies could also involve the screening of structural 
databases to identify a consortium of possible DOXP reductoisomerase inhibitors, which can be 
docked, synthesised and tested for inhibitory effects. 
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6 APPENDICES 
 
6.1 Chemicals and Reagents 
All general buffer components and reagents were from Saarchem, RSA or Sigma-Aldrich, USA.  
Growth media was supplied by Biolab, UK or Difco, USA.  Tabulated below are specialized 
reagents used within this work. 
 
REAGENT       SUPPLIER 
Agar        Oxoid 
Agarose       Whitehead Scientific 
Ammonium persulphate     Saarchem 
Ampicillin       Sigma 
Anti-His Antibody (mouse)     Sigma 
Biorad Minigel Electrophoresis Set    Biorad 
BM Chemiluminescence Western Blotting Kit  Roche 
Bromophenol blue      Sigma 
Chelating Sepharose      Amersham 
2-Chlorotrityl chloride polymer bound   Chemika, Fluka 
Coomassie brilliant blue R250    Saarchem 
DNA Miniprep Kit      Qiagen 
ECL Advance Western Blotting Kit    Amersham Pharmacia Biotech 
Ethanol       Merck 
Ethidium bromide      Sigma 
3-Furanmethanol      Sigma-Aldrich 
High Pure Plasmid Isolation Kit    Roche 
HybondTM
HyperfilmTM MP Autoradiography Film   Amersham 
 –c extra Nitrocellulose Membrane  Sigma 
Imidazole       Sigma 
IPTG        Promega 
Magnesium chloride      Merck 
β-mercaptoethanol      Merck 
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Methanol       Merck 
Nickel sulphate      Sigma 
PMSF        Roche 
Polyethylene glycol 12 000     Merck 
Ponceau S       Sigma 
Restriction endonucleases     Amersham Pharmacia Biotech 
Site-directed Mutagenesis Kit    Stratagene 
SDS-PAGE Molecular Weight Standards Broad Range Biorad 
SDS        Saarchem 
TEMED       Merck 
Triphenylmethylchloride     Sigma-Aldrich 
Tween 20       Saarchem 
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6.2 Oligonucleotide Primers 
Oligonucleotides were synthesized by Integrated DNA Technologies Inc. (IDT).  
 
Table 8: DNA Oligonucleotides and their parameters 
Name Tm at 50 nm 
NaCl (˚C) 
% GC 
content 
Sequence 
pQE9EcDXR 
sequencing primer 
56.5 50 5`-GTT TAC CGC AAC CTA TCC-3` 
pQE31PfDXR 
sequencing primer 
42.1 54.5 5`-CTG GAT AAC AAC AAA GTG C-3` 
pQE9EcDXRW212YF 75.4 55.6 5`-CGT CAT CCG AAC TAT TCC ATG GGG CGT-3` 
pQE9EcDXRW212YR 75.4 55.6 5`-ACG CCC CAT GGA ATA GTT CGG ATG ACG-3` 
pQE9EcDXRW212LF 77.4 61.5 5`-CGC CCC ATG GAC AAG TTC GGA TGA CG-3` 
pQE9EcDXRW212LR 77.4 61.5 5`-CGT CAT CCG AAC TTG TCC ATG GGG CG-3` 
pQE9EcDXRW212FF 77.1 55.6 5`-CGT CAT CCG AAC TTT TCC ATG GGG CGT-3` 
pQE9EcDXRW212FR 77.1 55.6 5`-ACG CCC CAT GGA AAA GTT CGG ATG ACG-3` 
pQE9EcDXRM214IF 78.6 50 5`-CTG GTC GAT CGG CCG TAA AAT TTC TG-3` 
pQE9EcDXRM214IR 78.6 50 5`-CAG AAA TTT TAC GGC CGA TCG ACC AG-3` 
pQE9EcDXRP274IF 79 58.6 5`-CAG CTG GGG GAA ATC GAT ATG CGT ACG CC-3` 
pQE9EcDXRP274IR 79 58.6 5`-GGC GTA CGC ATA TCG ATT TCC CCC AGC TG-3` 
pQE9EcDXRN211KF 76.2 59.3 5`-GTC ATC CGA AGT GGT CCA TGG GGC GTA-3` 
pQE9EcDXRN211KR 76.2 59.3 5`-TAC GCC CCA TGG ACC ACT TCG GAT GAC-3` 
pQE9EcDXRN211K, 
S213KF 
71.8 56 5`-CAT CCG AAG TGG AAG ATG GGG CGT A-3` 
pQE9EcDXRN211K, 
S213KR 
71.8 56 5`-TAC GCC CCA TCT TCC ACT TCG GAT G-3` 
pQE31PfDXRK297SF 72.3 48 5`-CAT CCG AAA TGG TCC ATG GGC AAA A-3` 
pQE31PfDXRK297SR 72.3 48 5`-TTT TGC CCA TGG ACC ATT TCG GAT G-3` 
pQE31PfDXRK295N, 
K297SF 
74.6 41.4 5`-GAA ACA TCC GAA TTG GTC AAT GGG CAA AA-3` 
pQE31PfDXRK295N, 
K297SR 
74.6 41.4 5`-TTT TGC CCA TTG ACC AAT TCG GAT GTT TC-3` 
 
6.3 NMR Spectra 
The NMR Spectra were recorded on a Bruker AMX400 spectrometer and are given below: 
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